On this page
Quick Reference
Overview and Recommendations
Background
- •Hyperlipidemia, elevation of LDL-C, triglycerides, or both, affects approximately 73% of US adults with hypertension and accounts for roughly half the population-attributable risk of myocardial infarction. Lifetime risk of cardiovascular disease at age 50 with all major risk factors present is 38% in men and 24% in women, underscoring the profound prognostic stakes.
- •The four pillars of guideline-directed medical therapy, high-intensity , , , and , have replaced the older statin-alone paradigm following landmark trials such as IMPROVE-IT (ezetimibe add-on), FOURIER (PCSK9i), and CLEAR-Outcomes (bempedoic acid). Combined LDL-C reduction can exceed 80% with statin plus a PCSK9 inhibitor.
- •Subendothelial retention of apolipoprotein B-containing lipoproteins (chiefly LDL and VLDL remnants) is the initiating event in atherogenesis. Oxidative modification of retained LDL triggers endothelial activation, monocyte recruitment, and foam-cell formation, the core pathophysiological cascade that progresses to plaque formation and rupture.
- •Primary (genetic) hyperlipidemia includes familial hypercholesterolemia (FH; prevalence 1:250 for heterozygotes), familial combined hyperlipidemia (1:100), and severe hypertriglyceridemia syndromes. Secondary causes, diabetes, hypothyroidism, nephrotic syndrome, cholestasis, and medications (thiazides, retinoids, protease inhibitors), must be excluded before labeling a patient with a primary disorder.
- •Untreated hyperlipidemia accelerates atherosclerotic progression: premature ASCVD (MI or stroke before age 55 in men, 60 in women) is a hallmark of FH. Primary prevention with statins reduces all-cause mortality by 14% (RR 0.86) and major cardiovascular events by approximately 30%, with consistent benefit across age and sex subgroups.
Evaluation
- •Suspect hyperlipidemia in any patient with exertional dyspnea, unexplained fatigue, or a family history of premature ASCVD, especially when combined with stigmata such as xanthomas or xanthelasma on physical exam.
- •Ask about prior lipid values, personal history of coronary artery disease, stroke, or peripheral artery disease, and any history of acute pancreatitis (marker of severe hypertriglyceridemia). Thoroughly review medications: thiazides, non-selective beta-blockers, retinoids, anabolic steroids, and protease inhibitors can all elevate lipids.
- •Examine for tendon xanthomas, palpate the Achilles tendon while the foot is dorsiflexed; nodular thickening is pathognomonic for (FH). Also check for xanthelasma palpebrarum, arcus corneae before age 45, and eruptive xanthomas (yellow papules on extensor surfaces) that indicate severe hypertriglyceridemia.
- •Order a fasting lipid panel as the gold-standard initial test: measure total cholesterol, LDL-C, HDL-C, and triglycerides. A non-fasting panel is acceptable for initial screening; if total cholesterol ≥200 mg/dL or HDL-C <40 mg/dL, repeat with fasting to confirm.
- •Assess for secondary causes of hyperlipidemia with laboratory studies: TSH (hypothyroidism), HbA1c or fasting glucose (diabetes), urine protein or albumin-creatinine ratio (nephrotic syndrome), and hepatic transaminases (cholestasis, non-alcoholic fatty liver disease).
- •Calculate 10-year ASCVD risk using the (ACC/AHA) or SCORE (ESC) for all adults aged 40-75 years without established ASCVD. Categories: low (<5%), borderline (5-7.5%), intermediate (7.5-20%), and high (≥20%).
- •When LDL-C is ≥190 mg/dL, apply the (DLCN) criteria: assign points based on LDL-C level, family history, personal ASCVD, and physical signs. A score >8 defines definite FH, while 6-8 indicates probable FH. Genetic testing for LDLR, APOB, and PCSK9 mutations is recommended for patients with DLCN score ≥6.
- •Measure [Lp(a)] once in adults; a level ≥50 mg/dL (or ≥125 nmol/L) is an independent risk-enhancing factor that warrants more intensive lipid lowering even if LDL-C appears well controlled.
- •In patients with triglycerides ≥500 mg/dL, rule out familial chylomicronemia syndrome (genetic testing for LPL, APOC2, APOA5) and consider urgent therapy to prevent pancreatitis. Also check for contributory factors such as uncontrolled diabetes, excess alcohol intake, and estrogen therapy.
- •For intermediate-risk patients (7.5-20% 10-year risk), refine risk assessment with coronary artery calcium scoring or high-sensitivity CRP (hsCRP ≥2 mg/L indicates residual inflammatory risk). A CAC score of zero can reclassify many to low risk, potentially deferring statin therapy.
Management
- •Initiate high-intensity statin therapy immediately for all patients with established ASCVD: 40-80 mg daily or 20-40 mg daily, regardless of baseline LDL-C level. For primary prevention with LDL-C ≥190 mg/dL or 10-year risk ≥20%, start a high-intensity statin as first-line.
- •Begin statin therapy at moderate intensity (atorvastatin 10-20 mg or rosuvastatin 5-10 mg) for primary prevention patients with intermediate risk (7.5-20%). Titrate every 4-12 weeks to achieve ≥50% LDL-C reduction.
- •Add 10 mg daily if LDL-C remains ≥70 mg/dL (or ≥55 mg/dL in very high risk, defined as ASCVD with major risk factors or recurrent events) after 12 weeks of maximally tolerated statin. Ezetimibe provides an additional ~15-20% LDL-C reduction.
- •For very high risk patients not at goal on statin plus ezetimibe, advance to a : 140 mg subcutaneously every 2 weeks or 420 mg monthly; or 300 mg subcutaneously at day 1, month 3, then every 6 months. These agents reduce LDL-C by approximately 50-60% on top of background therapy.
- •For patients with statin intolerance (confirmed myalgia or CK elevation not due to other causes), consider 180 mg daily. In CLEAR-Outcomes, it reduced LDL-C by 21% and hsCRP by 22% with no excess muscle symptoms, even in patients aged ≥75 years.
- •For severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL), start 160 mg daily to reduce pancreatitis risk. Add 2 g twice daily if triglycerides remain elevated or for residual cardiovascular risk. Do not use gemfibrozil with statins due to rhabdomyolysis risk; fenofibrate is the preferred fibrate for combination therapy.
- •Monitor hepatic transaminases and creatine kinase at baseline and 4-12 weeks after starting or dose-escalating any statin. Do not discontinue statins for mild, non-progressive myalgias without a dechallenge-rechallenge trial; the absolute excess risk of myalgia in double-blind trials is only 2.7 per 1000 patients.
- •Avoid ineffective or harmful therapies: policosanol, guggulipid, and red yeast rice have no proven LDL-C reduction beyond placebo. Niacin extended-release is no longer recommended due to lack of cardiovascular benefit and poor tolerability (25% discontinuation from flushing).
- •Refer to cardiology or a lipid specialist when FH is suspected (especially in young adults or children with LDL-C ≥190 mg/dL), triglycerides remain ≥1000 mg/dL despite fibrate therapy, or when statin intolerance requires advanced therapies like PCSK9 inhibitors or bempedoic acid.
- •For homozygous FH (HoFH) with LDL-C >100 mg/dL despite maximal pharmacotherapy, consider every 1-2 weeks; it acutely reduces LDL-C by 60-70% and, in registry data, reduces cardiovascular events by approximately 70%. Ensure cascade screening of all first-degree relatives of FH probands.
Board Review — High Yield
- •Tendon xanthomas, Pathognomonic for familial hypercholesterolemia (FH); palpate Achilles tendon with foot dorsiflexed; indicates need for genetic testing.
- •Dutch Lipid Clinic Network score, Definite FH: score >8 (uses LDL-C, family history, personal ASCVD, physical findings); >6 points suggests probable FH.
- •PCSK9 inhibitors, Evolocumab 140 mg SC q2w or 420 mg monthly; achieves ~60% LDL-C reduction; inclisiran 300 mg SC at day 1, month 3, then q6mo offers siRNA-based sustained reduction.
- •Bempedoic acid, Alternative for statin intolerance; reduces LDL-C by ~21% and hsCRP by ~22% without muscle toxicity (CLEAR-Outcomes).
- •Lp(a), Independent risk factor measured once in adults; ≥50 mg/dL (or ≥125 nmol/L) intensifies risk; no specific approved therapy yet, but it justifies more aggressive LDL-C lowering.
- •Severe hypertriglyceridemia, Triglycerides ≥500 mg/dL → risk of acute pancreatitis; first-line fibrate (fenofibrate 160 mg daily) plus lifestyle modification.
- •ASCVD risk scores, Pooled Cohort Equations for 10-year risk: high (≥20%), intermediate (7.5-20%), borderline (5-7.5%), low (<5%). Consider CAC scoring for intermediate risk.
- •Lipoprotein apheresis, For homozygous FH with LDL-C >100 mg/dL despite maximal drug therapy; reduces LDL-C by 60-70% per session every 1-2 weeks.
- •Statins in primary prevention, JUPITER: rosuvastatin 20 mg reduced major CV events by 44% (NNT ~95) in healthy individuals with hsCRP ≥2 and LDL-C <130 mg/dL.
- •Cascade screening, All first-degree relatives of FH probands should be screened with lipid panel and genetic testing if possible; identifies at least one affected relative in ~50% of families.
Deep Dive — Evidence Details
Definition, Classification and Nomenclature
- ▸The supplied evidence uses hyperlipidemia and dyslipidemia as related terms but does not provide a universal biochemical threshold. [220][236][243][248]
- ▸Primary or familial dyslipidemia is represented by the familial dyslipidemia category studied in children. [243]
- ▸Secondary hyperlipidemia is explicitly used as a distinct label in patients with depressive disorders. [236]
- ▸An LDL-C target of **<70 mg/dL** was used for vascular risk-factor control after stroke, but this target is not a definition of hyperlipidemia. [245]
- ▸The references support context-specific classification but do not establish formal numerical criteria for hypercholesterolemia, hypertriglyceridemia, or mixed dyslipidemia. [22][220][236][243][248]
Scope and terminology
Hyperlipidemia is used in the cited literature as a clinical diagnosis or phenotype indicating increased circulating lipid concentrations, but the supplied studies do not provide a universal biochemical threshold for the term. Accordingly, this section distinguishes the broad clinical term from the more specific term dyslipidemia, which may refer to an abnormal lipid pattern involving low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, or combinations of these abnormalities. The references use “hyperlipidemia,” “hyperlipidaemia,” “dyslipidemia,” “familial dyslipidemia,” and “secondary hyperlipidemia” as related but not completely interchangeable labels. [220]C4[236][243][248]
The term should not be confused with an isolated cardiovascular risk measurement. LDL-C is one component of the lipid phenotype and is used as a treatment or risk-control target in some studies; for example, adults with prior stroke were assessed against an LDL-C target of <70 mg/dL, whereas a mobile screening program reported a median LDL-C of 103 mg/dL without defining that value as hyperlipidemia. [245][246] A lipid value should therefore be interpreted in clinical context rather than classified solely from the median values reported in observational cohorts. [245][246]
Practical classification
1. Primary or familial hyperlipidemia
Primary hyperlipidemia refers to lipid abnormalities attributable predominantly to inherited or intrinsic disorders rather than an identified acquired condition. The supplied evidence specifically describes children with “familial dyslipidemia,” indicating a familial category, and evaluated them against age-, sex-, and body-mass-index-matched controls. [243] The cited study does not establish diagnostic lipid cutoffs or a molecular subtype, so familial dyslipidemia should not be equated automatically with a particular genetic diagnosis on the basis of this reference alone. [243]
2. Secondary hyperlipidemia
Secondary hyperlipidemia denotes hyperlipidemia occurring in association with another condition, exposure, or clinical context. In the supplied literature, it is explicitly examined among patients with clinically diagnosed depressive disorders, and a prediction model was developed to identify patients at increased risk. [236] The study supports use of “secondary hyperlipidemia” as a distinct clinical label but does not, in the supplied abstract, enumerate a definitive causal checklist or establish that depression itself is a sufficient cause. [236]
Secondary hyperlipidemia should also be considered within broader metabolic assessment. Hyperlipidemia cohorts have been analyzed in relation to insulin resistance, estimated glucose disposal rate (eGDR), renal function, glycemic status, and mortality, but these associations do not by themselves define secondary causes. [220]C4[248] Similarly, a prospective study defined metabolically healthy non-obese participants partly by the absence of hyperlipidemia, diabetes, and concurrent hypertension, demonstrating that the term is used operationally in cohort eligibility criteria rather than as a standardized phenotype with one threshold. [22]B2b
3. Mixed or combined dyslipidemia
Mixed or combined dyslipidemia describes concurrent abnormalities in more than one lipid fraction, although the supplied references do not specify formal diagnostic criteria. This terminology is preferable when the abnormality cannot be accurately represented by LDL-C alone, particularly in populations characterized by obesity-related adiposity, insulin resistance, diabetes, or cardiometabolic disease. [22]B2b[244][248] HDL-C has been studied in relation to diabetic retinopathy and body roundness index, but the reported association does not establish that either HDL-C or body shape independently defines hyperlipidemia. [244]
4. Context-specific usage
The word “hyperlipidemia” may identify a study population without indicating severity, mechanism, or lipid fraction. A MIMIC-IV cohort consisted of critically ill patients diagnosed with hyperlipidemia and examined hemoglobin glycation index in relation to short-term mortality. [220]C4 Another NHANES analysis included 9,283 adults diagnosed with hyperlipidemia and evaluated eGDR, mortality, and mediation by estimated glomerular filtration rate. [248] These studies support the prognostic relevance of the diagnosis but do not establish a new nomenclature or severity classification. [220]C4[248]
Related terms and exclusions
“Dyslipidemia” is the broader and often preferred term when any lipid abnormality is present, including abnormalities not limited to elevated total cholesterol. “Hypercholesterolemia” should be reserved for cholesterol-predominant elevation, and “hypertriglyceridemia” for triglyceride-predominant elevation; however, the supplied references do not provide numerical thresholds for either term. The evidence also uses cardiometabolic risk terminology without redefining hyperlipidemia: adverse pregnancy outcomes, sleep apnea, fatty liver disease, hypertension, myocardial infarction, peripheral artery disease, and stroke are studied as associated conditions or outcomes rather than as nomenclatural subtypes. [234][235][237][238][239]C[242][245][247]
Several cited reports are unrelated to lipid classification, including studies of carotid web, coronary imaging, Alzheimer disease treatment, venous ulcers, and diabetic neuropathic pain; they provide no evidence for defining or classifying hyperlipidemia. [232][233][187]C4[240][241] Thus, the current evidence supports a mechanism- and context-based vocabulary—primary/familial, secondary, and mixed dyslipidemia—while leaving exact biochemical thresholds to externally established laboratory and guideline standards not included among the permitted references. [22]B2b[220]C4[236][243][245][248]
| Term | Use supported by the supplied references | Limitation |
|---|---|---|
| Hyperlipidemia/hyperlipidaemia | Broad clinical diagnosis or cohort phenotype involving abnormal lipid status [220]C4[245][248] | No universal threshold supplied [220]C4[248] |
| Dyslipidemia | General term used for lipid abnormalities, including familial disease [243][244] | Specific lipid-fraction criteria are not provided [243][244] |
| Familial dyslipidemia | Primary/inherited category described in children [243] | Molecular subtype and diagnostic cutoff are not established [243] |
| Secondary hyperlipidemia | Acquired or associated phenotype explicitly modeled in depressive disorders [236] | Causal criteria are not fully enumerated in the abstract [236] |
| LDL-C target | <70 mg/dL used for prior-stroke risk-factor control [245] | A management target, not a disease definition [245] |
Epidemiology and Risk Factors
- ▸The supplied evidence does not provide a general-population prevalence estimate for hyperlipidemia; most studies examine cardiometabolic comorbidity or use hyperlipidemia as a covariate. [22][58][250][257]
- ▸Older people living with HIV and adults with schizophrenia are specifically represented as populations in which hyperlipidemia is an important metabolic comorbidity requiring surveillance. [58][259]
- ▸Metabolically healthy non-obese status was defined as **BMI <30 kg/m²** with no diabetes, hypertension, or hyperlipidemia; visceral adiposity may identify risk not captured by BMI or waist circumference. [22]
- ▸One study defined metabolic syndrome as type 2 diabetes plus at least **two** of **BMI >30 kg/m²**, hypertension, or hyperlipidemia. [251]
- ▸Gestational diabetes, obesity-related disease, bariatric-surgery status, and selected medication exposures represent clinically relevant contexts for evaluating future or recurrent cardiometabolic disease, but the supplied abstracts do not provide hyperlipidemia-specific estimates. [252][254][261]
Scope of the available evidence
The supplied literature does not provide a population-wide estimate of hyperlipidemia prevalence or a contemporary global incidence trend. Instead, it describes hyperlipidemia as a component of broader cardiometabolic disease, a comorbidity in selected clinical populations, or a covariate in studies whose primary outcomes were unrelated to lipid disorders. [22]B2b[58]A1a[250][257] Accordingly, the evidence supports identification of high-risk groups but does not justify a single prevalence estimate applicable to the general population. [22]B2b[58]A1a[250]
Demographic and clinical epidemiology
Hyperlipidemia is specifically included among the cardiometabolic comorbidities studied in older people living with HIV, for whom a systematic review and meta-analysis synthesized worldwide evidence from studies published between 2013 and December 2023. [58]A1a The abstract supplied here does not report the pooled prevalence estimate, so no numerical prevalence should be assigned from this reference. [58]A1a
A Korean nationwide retrospective cohort followed 60,591 adults aged 20–65 years newly diagnosed with schizophrenia between 2012 and 2014 to quantify incident hyperlipidemia, hypertension, and type 2 diabetes after schizophrenia diagnosis. [259] The study therefore identifies schizophrenia as a population requiring longitudinal cardiometabolic surveillance, although the supplied abstract does not provide the incidence estimates or hazard ratios for hyperlipidemia. [259] Evidence from a Taiwanese nationwide cohort similarly examined physical illnesses during the 5 years after autism diagnosis in children diagnosed at ≤5 years, but the supplied abstract does not report hyperlipidemia-specific findings. [262]
The Guangdong Pharmaceutical University Occupational Health Cohort was established among Chinese coal-mining employees to characterize noncommunicable disease burden and identify occupationally vulnerable groups; its retrospective component covered 2009–2022, and its prospective component began in May 2023. [250] Of 36,577 workers with routine examinations in 2023, 25,597 were eligible employees, but the supplied abstract does not state the cohort’s hyperlipidemia prevalence. [250]
Obesity, adiposity, and metabolic syndrome
Hyperlipidemia commonly appears as part of a clustered cardiometabolic phenotype rather than as an isolated exposure in the supplied studies. [22]B2b[251][258] In a prospective UK Biobank study of 22,040 metabolically healthy non-obese participants, metabolically healthy non-obese status was defined using BMI <30 kg/m², absence of diabetes, and absence of concurrent hypertension or hyperlipidemia. [22]B2b The study assessed visceral and subcutaneous adipose-tissue volumes by whole-body MRI and specifically investigated whether unfavorable visceral adiposity could identify risk not captured by BMI or waist circumference. [22]B2b Thus, apparently normal anthropometric status does not necessarily exclude adverse adipose distribution as a cardiometabolic risk marker, although the supplied abstract does not provide hyperlipidemia-specific effect estimates. [22]B2b
In a claims-based arthroplasty study, metabolic syndrome was operationalized as type 2 diabetes plus at least two of the following: BMI >30 kg/m², hypertension, or hyperlipidemia. [251] A separate real-world cohort evaluated cardiometabolic disease as a modifier of outcomes among patients with knee osteoarthritis receiving intra-articular hyaluronic acid, but the supplied abstract does not provide lipid-specific risk estimates. [258] After metabolic and bariatric surgery, hyperlipidemia was one of the obesity-related medical conditions assessed for initial remission and subsequent recurrence; the study included patients with at least 36 months of follow-up and at least 20% total weight loss, but the supplied abstract does not report recurrence estimates specific to hyperlipidemia. [261]
Disease-associated and treatment-associated risk contexts
Pregnancy-related metabolic disease may identify later cardiometabolic vulnerability. [252] A retrospective MarketScan cohort examined incident postpartum cardiovascular, kidney, and metabolic disorders after gestational diabetes among commercially insured females aged 12–55 years with no preexisting cardiovascular-kidney-metabolic disorder before delivery; the supplied abstract does not specify the incidence of postpartum hyperlipidemia. [252] Adverse pregnancy outcomes were also studied in relation to long-term peripheral artery disease in 2,201,446 women delivering singleton infants in Sweden from 1973–2015, but that study addresses vascular disease rather than hyperlipidemia directly. [235]
Medication and disease-specific contexts may alter lipid-related risk. [254] Bexarotene is described as having predictable but substantial metabolic toxicity in patients with mycosis fungoides; in a propensity-matched real-world cohort of 2,242 patients per group, exposure was not associated with a significant increase in the composite adapted major adverse cardiovascular event endpoint over a median 4.0-year follow-up, although this does not establish absence of dyslipidemia. [254] Hyperlipidemia was also included among candidate predictors of second cancer in a cohort of 1,968 patients with polycythemia vera or essential thrombocythemia followed for a median 11.2 years, but the supplied abstract does not report its adjusted effect estimate. [260]
Cardiovascular and comorbidity relevance
Several studies reinforce that hyperlipidemia is clinically relevant because it is embedded within cardiovascular-risk assessment. [233][256]C[257] A Jordanian electronic-health-record study used approximately 600,000 individuals to develop pharmacotherapy-informed cardiovascular-risk prediction models incorporating demographics, blood pressure, laboratory data, and medications; the supplied abstract does not provide hyperlipidemia-specific model performance. [257] Studies of emergency-department chest-pain imaging, complex aortoiliac occlusive disease, and cardiometabolic disease in osteoarthritis address cardiovascular or vascular outcomes but do not provide hyperlipidemia prevalence estimates. [233][256]C[258]
The remaining supplied studies concern systemic-lupus-associated osteonecrosis, pregnancy-associated acute kidney injury, occupational stress after the Deepwater Horizon spill, cataract-surgery complications, adverse pregnancy outcomes, and physical illness after autism diagnosis; their abstracts do not provide direct epidemiologic estimates or validated risk-factor effect sizes for hyperlipidemia. [249][253][255][158]B2b[235][262] These evidence gaps should be made explicit when applying the available literature to routine hyperlipidemia risk assessment.
| Risk context or population | Evidence relevant to hyperlipidemia | Limitation |
|---|---|---|
| Older people living with HIV | Systematic review and meta-analysis assessed worldwide prevalence of high cholesterol among older people living with HIV. [58]A1a | Pooled estimate not provided in the supplied abstract. [58]A1a |
| Schizophrenia | Nationwide Korean cohort quantified incident cardiometabolic comorbidities, including hyperlipidemia, after diagnosis. [259] | Incidence estimates not provided in the supplied abstract. [259] |
| Visceral adiposity | UK Biobank study assessed MRI-derived visceral and subcutaneous fat among 22,040 metabolically healthy non-obese adults. [22]B2b | No hyperlipidemia-specific effect estimate supplied. [22]B2b |
| Metabolic syndrome | Defined as type 2 diabetes plus at least two of BMI >30 kg/m², hypertension, or hyperlipidemia. [251] | Definition was used for an arthroplasty cohort, not population surveillance. [251] |
| Bexarotene exposure | Described as having predictable metabolic toxicity in mycosis fungoides. [254] | Cardiovascular safety outcome did not establish dyslipidemia risk. [254] |
| Bariatric surgery | Hyperlipidemia was assessed for remission and recurrence after substantial weight loss. [261] | Hyperlipidemia-specific recurrence results not supplied. [261] |
Pathophysiology and Mechanism
- ▸Hyperlipidemia contributes to vascular disease through endothelial activation and adhesion-molecule expression, particularly E-selectin, ICAM-1, P-selectin, and VCAM-1. [332]
- ▸The secondary-prevention LDL-C target cited for adults with prior stroke is **<70 mg/dL**. [245]
- ▸High-cholesterol feeding was associated with myocardial remodeling markers involving galectin-3, TGF-β1, and BNP in miniswine. [265]
- ▸Chronic pain amplified high-fat-diet-associated cardiac injury through a proposed JNK1/SIRT1-related mechanism in apolipoprotein E-deficient mice. [263]
- ▸Visceral adiposity may confer cardiometabolic risk despite **BMI <30 kg/m²** and apparent metabolic health. [22]
- ▸Palmitic-acid lipotoxicity can induce mesangial-cell apoptosis and endoplasmic-reticulum stress, with FGF21–SIRT1 investigated as a protective pathway. [267]
- ▸Genetic and inflammatory pathways, including QDPR and cytokine polymorphisms, may modify lipid-associated diabetic or nephrotic kidney disease. [266,337]
- ▸Evidence for cataract, cancer-related lipid remodeling, and microvascular effects is associative and should not be interpreted as proof of causation. [121,269,278,335]
Overview
Hyperlipidemia is a systemic disorder of lipid transport and handling in which excess circulating cholesterol, triglyceride-rich particles, or both contribute to vascular, cardiac, renal, ocular, and metabolic injury. The available evidence supports a model in which lipid excess interacts with hyperglycemia, hypertension, adipose-tissue distribution, inflammation, oxidative stress, and genetic susceptibility rather than acting as an isolated biochemical abnormality. In type 2 diabetes, hyperglycemia, hypertension, and hyperlipidemia impose cumulative endothelial stress that may promote atherosclerosis and cardiovascular disease. [332]
Endothelial injury and atherogenesis
Lipid excess is mechanistically linked to endothelial activation and impaired vascular homeostasis. Endothelial dysfunction involves reduced vasodilatory capacity and increased expression of endothelial-derived adhesion molecules, including E-selectin, ICAM-1, P-selectin, and VCAM-1; these molecules facilitate leukocyte–endothelial interactions and provide a biologically plausible bridge between dyslipidemia, vascular inflammation, and atherosclerosis. [332] The clinical importance of this pathway is reflected in secondary-prevention targets: among adults with prior stroke, guideline-defined low-density lipoprotein cholesterol (LDL-C) control was specified as <70 mg/dL, alongside blood-pressure and glycemic targets. [245]
The vascular consequences extend beyond coronary disease. Hyperlipidemia was present in 79% of patients undergoing paravisceral transaortic endarterectomy for complex aortic occlusive disease, although this retrospective finding demonstrates clinical association rather than causation. [296]C Similarly, hyperlipidemia was evaluated as a cardiometabolic comorbidity in studies of peripheral arterial disease and revascularization outcomes, supporting its role within the broader atherosclerotic-risk phenotype. [319][336]
Cardiac remodeling and injury
Experimental evidence indicates that lipid excess can directly affect myocardium in addition to promoting epicardial and arterial atherosclerosis. In Yucatan miniswine exposed to a high-cholesterol diet for 8 weeks, hyperlipidemia induced cardiac remodeling-associated changes involving galectin-3, transforming growth factor-β1, and brain natriuretic peptide; these mediators represent overlapping pathways of fibrosis, extracellular-matrix remodeling, and myocardial stress. [265]C The study also compared hyperlipidemia with hyperglycemia, emphasizing that distinct metabolic stresses may produce partially different profibrotic and early stress-response patterns. [265]C
Apolipoprotein E-deficient mice fed a high-fat diet developed a model in which chronic pain and lipid excess interacted to worsen cardiac injury. Spared-nerve-injury-induced chronic pain was associated with assessment of cardiac function, anxiety-like behavior, and a c-Jun N-terminal kinase 1/silent information regulator 1 signaling axis, indicating that neuroendocrine or stress signaling may amplify lipid-associated myocardial damage. [263] Because this evidence derives from a small murine experiment, it supports a mechanistic hypothesis rather than a directly established human pathway. [263]
Adipose tissue, lipotoxicity, and metabolic-organ injury
Visceral adiposity may identify metabolic risk that is missed by BMI or waist circumference alone. In a prospective UK Biobank analysis of metabolically healthy non-obese adults—defined in part by BMI <30 kg/m² and absence of diabetes, hypertension, and hyperlipidemia—whole-body MRI-derived visceral-to-subcutaneous adipose-tissue ratios were used to detect unfavorable fat distribution. [22]B2b This supports the concept that adipose location and biology, not simply total body size, influence subsequent cardiometabolic risk. [22]B2b
Free-fatty-acid excess can produce tissue-specific lipotoxicity. In diabetic-nephropathy research, palmitic acid induced mesangial-cell injury, apoptosis, and endoplasmic-reticulum stress; the FGF21–SIRT1 axis was investigated as a protective metabolic and stress-response pathway. [267] These findings provide a cellular mechanism by which dyslipidemia and insulin resistance may contribute to glomerular injury. Genetic variation may modify this vulnerability: QDPR, a gene involved in tetrahydrobiopterin homeostasis, was examined in relation to type 2 diabetes and diabetic kidney disease accompanied by hyperlipidemia. [266]
Inflammation, immune mechanisms, and systemic lipid remodeling
Inflammatory susceptibility may influence lipid-associated disease. In children with primary nephrotic syndrome, a condition characterized by proteinuria, hypoalbuminemia, edema, and hyperlipidemia, polymorphisms in TNF-α, IL-2, and IL-10 were evaluated across steroid-sensitive and steroid-resistant phenotypes, supporting investigation of cytokine genetics in lipid-associated renal disease. [337] In generalized granuloma annulare, emerging evidence implicates JAK–STAT signaling in inflammatory lesion biology, although this dermatologic literature does not establish hyperlipidemia as a cause. [92]B2a
Circulating lipid composition is also disease-specific. Targeted plasma lipidomics distinguished healthy controls, non-metastatic colorectal cancer, and metastatic colorectal cancer in a small matched-triplet exploratory study, indicating that systemic lipid remodeling accompanies cancer and may vary with disease extent. [335] This observation should not be interpreted as proof that hyperlipidemia causes colorectal cancer progression. [335]
Microvascular and end-organ effects
Metabolic lipid abnormalities may contribute to microvascular dysfunction. In type 2 diabetes without clinically apparent retinopathy, multidomain optical-coherence-tomography angiography biomarkers were investigated to identify preclinical retinal microvasculopathy. [278] Retinal vascular measurements have also been studied as markers of cerebral small-vessel-disease burden, linking systemic vascular injury with cerebral and retinal microcirculatory abnormalities. [269] Hyperlipidemia has additionally been associated with specific age-related cataract subtypes in a clinic-based cross-sectional study, although the relationship remains controversial and differs by cataract morphology. [121]C4
Clinical interpretation
Current evidence supports hyperlipidemia as a mediator and marker of endothelial activation, atherosclerotic vascular disease, myocardial remodeling, adipose-driven metabolic stress, renal lipotoxicity, and microvascular injury. However, several cited studies are cross-sectional, retrospective, exploratory, or preclinical; therefore, they establish biological plausibility and associations more strongly than temporal causation. [22]B2b[92]B2a[121]C4[245][263][265]C[266][267][269][278][296]C[319][332][335][336][337]
| Domain | Proposed mechanism or finding | Evidence |
|---|---|---|
| Endothelium | Endothelial dysfunction and adhesion-molecule activation | [332] |
| Atherosclerosis | Association with coronary, aortic, and peripheral occlusive disease | [245][296]C[319][336] |
| Myocardium | Fibrotic remodeling, myocardial stress, and interaction with chronic pain signaling | [263][265]C |
| Kidney | Free-fatty-acid lipotoxicity, apoptosis, endoplasmic-reticulum stress, and genetic susceptibility | [266][267][337] |
| Microvasculature | Retinal and cerebral small-vessel abnormalities in metabolic disease | [269][278] |
| Other organs | Cataract associations and disease-related plasma lipid remodeling | [121]C4[335] |
Clinical Presentation
- ▸One cited cohort defined hyperlipidemia as LDL cholesterol ≥130 mg/dL and total cholesterol ≥220 mg/dL; these were study inclusion thresholds, not a universal diagnostic standard [324].
- ▸Clinical evaluation should assess obesity, visceral adiposity, diabetes, hypertension, fatty liver disease, and other cardiometabolic features [22,340].
- ▸Atherosclerotic presentations include coronary, carotid, peripheral, cerebrovascular, and retinal vascular disease, although the cited studies do not prove that hyperlipidemia alone caused each event [232,324,338,339,343].
- ▸Hyperlipidemic acute pancreatitis is a clinically important triglyceride-related presentation; severity was classified using the Revised Atlanta Classification in one cohort [294].
- ▸The supplied references do not establish a characteristic symptom pattern or validated lipid-storage findings for uncomplicated hyperlipidemia [341,339,167,334,267,342,109,255,262].
Overview
Hyperlipidemia is frequently identified through laboratory testing or during evaluation of cardiometabolic disease rather than through a lipid-specific symptom pattern. In the available evidence, hyperlipidemia was operationally defined in one clinical cohort as LDL cholesterol ≥130 mg/dL and total cholesterol ≥220 mg/dL; these thresholds were used to identify patients receiving lipid-lowering treatment, not necessarily to establish a universal diagnostic definition [324]. The clinical presentation therefore depends primarily on the associated metabolic phenotype, the severity and duration of lipid exposure, and the presence of atherosclerotic or triglyceride-related complications [324][340]C[343].
Cardiometabolic and metabolic presentation
Hyperlipidemia may coexist with obesity, insulin resistance, diabetes, hypertension, fatty liver disease, or unfavorable visceral adiposity. In a large UK Biobank cohort of 22,040 individuals classified as metabolically healthy and non-obese—defined by BMI <30 kg/m², absence of diabetes and hypertension, and absence of hyperlipidemia—whole-body MRI was used to quantify visceral and subcutaneous adipose tissue; the study specifically addressed the possibility that clinically “healthy” non-obese individuals may harbor adverse visceral adiposity not captured by BMI or waist circumference [22]B2b.
Metabolic dysfunction-associated fatty liver disease was studied in relation to coronary heart disease using a cohort of 1,515 patients and an artificial-intelligence model integrating clinical variables, deep-learning image segmentation, and radiomics [340]C. These data support assessment of hepatic steatosis and broader cardiometabolic abnormalities when hyperlipidemia occurs in a patient with obesity, abnormal liver tests, or suspected fatty liver disease, although the study evaluated risk identification rather than a specific symptom complex [340]C. In kidney-transplant recipients without pre-transplant hepatic steatosis, de novo hepatic steatosis developed in 30.1% of 127 patients, illustrating that steatosis can emerge in medically complex patients in whom dyslipidemia and metabolic risk require assessment [275].
Atherosclerotic vascular presentation
The clinically important presentation of hyperlipidemia is often established atherosclerotic disease. Patients may present with coronary, carotid, peripheral, or retinal vascular disease, although the cited studies do not establish that hyperlipidemia alone caused each manifestation [324][339][343]. In 165 patients undergoing lower-extremity endovascular revascularization for peripheral artery disease, residual lipid-related proteomic and metabolomic signatures were investigated because conventional lipid measurements and the clinical label of hyperlipidemia may incompletely capture ongoing major adverse cardiovascular-event risk after revascularization [343].
Peripheral vascular disease may also occur in association with adverse pregnancy outcomes. A Swedish cohort of 2,201,446 women with singleton deliveries evaluated long-term peripheral artery disease risk after five major adverse pregnancy outcomes and used co-sibling analyses to assess familial confounding [235]. This evidence supports documenting reproductive history when evaluating vascular disease in women, but it does not define a lipid-specific presentation [235]. Similarly, a cohort of 349 patients undergoing CT venography examined lower-extremity venous thrombosis and stenosis in relation to BMI, sex, hypertension, diabetes, and hyperlipidemia; the study evaluated associations with venous abnormalities rather than proving that hyperlipidemia produces venous disease [344].
Cerebrovascular and retinal manifestations
Stroke or transient ischemic attack may be the presenting context in which dyslipidemia is discovered or reassessed. In a cohort of 1,897 patients with acute ischemic stroke, the ZJU index combined fasting plasma glucose, BMI, alanine aminotransferase/aspartate aminotransferase ratio, sex, and triglycerides to evaluate short-term functional prognosis [338]. This composite reflects metabolic burden but should not be interpreted as a diagnostic test for hyperlipidemia [338]. Among 263 patients with ischemic stroke who were in sinus rhythm without prior or current atrial fibrillation, post-stroke ECG-derived periodic repolarization dynamics were studied as a predictor of newly detected atrial fibrillation [333]. Carotid web was separately characterized in 48 patients diagnosed by digital subtraction angiography, with ischemic stroke, transient ischemic attack, and recurrent ipsilateral ischemic events used as clinical outcomes; carotid web is a distinct vascular lesion and should not be attributed automatically to hyperlipidemia [232].
Retinal artery or vein occlusion can be encountered in patients labeled as having hyperlipidemia. A comparative cohort evaluated patients meeting the LDL cholesterol ≥130 mg/dL and total cholesterol ≥220 mg/dL criteria who received either a PCSK9 inhibitor or another lipid-lowering medication, with retinal artery and retinal vein occlusions as outcomes [324]. The study addressed treatment-associated vascular outcomes and does not establish that retinal occlusion is a presenting symptom of hyperlipidemia [324].
Triglyceride-related presentation
Severe triglyceride-predominant dyslipidemia may present with acute pancreatitis. In 113 consecutive patients with hyperlipidemic acute pancreatitis, a C-reactive-protein–triglyceride–glucose index was evaluated against severity defined by the Revised Atlanta Classification; the study linked the index to inflammatory and insulin-resistance features, but it did not provide a universal triglyceride diagnostic threshold [294]. Clinical evaluation should therefore distinguish pancreatitis associated with hyperlipidemia from nonspecific metabolic risk and should document the triglyceride level, abdominal symptoms, and systemic severity [294].
Interpretation and associated findings
The supplied evidence does not provide validated findings for classic lipid-storage manifestations, nor does it establish a characteristic symptom pattern for uncomplicated hyperlipidemia. Studies of young stroke populations, carotid revascularization timing, anticoagulation, vascular tortuosity, diabetic nephropathy, bariatric surgery, gastrointestinal bleeding, cystoid macular edema, autism-associated illnesses, and other conditions provide contextual comorbidity or vascular data but do not define the clinical presentation of hyperlipidemia [341][339][167]C4[334][267][342]C[109]A1a[255][262]. Accordingly, clinical assessment should emphasize lipid measurement and evaluation for cardiometabolic disease, atherosclerotic disease, retinal vascular events, and triglyceride-associated pancreatitis rather than relying on symptoms alone [22]B2b[294][324][340]C[343].
| Clinical context | Evidence-supported interpretation |
|---|---|
| Abnormal lipid testing | A cited cohort used LDL cholesterol ≥130 mg/dL and total cholesterol ≥220 mg/dL to identify treated patients [324]. |
| Metabolic dysfunction | Consider obesity, visceral adiposity, diabetes, hypertension, abnormal liver tests, or fatty liver disease [22]B2b[275][340]C. |
| Atherosclerotic disease | Peripheral artery disease, cerebrovascular disease, and retinal vascular occlusion may prompt lipid assessment [232][324][338][343]. |
| Acute pancreatitis | Hyperlipidemic acute pancreatitis is associated with inflammatory and insulin-resistance markers; severity was assessed by Revised Atlanta criteria [294]. |
| Post-revascularization risk | Conventional lipid measures may not fully capture residual lipid-related cardiovascular risk after peripheral revascularization [343]. |
Diagnosis and Workup
- ▸Confirm suspected hyperlipidemia with a lipid profile; the supplied evidence does not provide universal diagnostic cutoffs for LDL-cholesterol, triglycerides, HDL-cholesterol, or total cholesterol. [22] [220] [243]
- ▸Document secondary causes and associated disease, including diabetes, hypertension, obesity or visceral adiposity, depression-related risk, MASLD/NAFLD, sleep apnea, pregnancy-related risk, kidney disease, liver disease, thyroid disease, and medication exposure. [22] [125] [223] [234] [235] [236] [237]
- ▸For adults with prior stroke, the cited risk-control definition uses LDL-cholesterol **<70 mg/dL**. [245]
- ▸Coronary calcium scoring, angiography, carotid imaging, echocardiography, retinal imaging, and neurologic testing are adjunctive, risk-directed evaluations rather than diagnostic replacements for lipid testing. [232] [243] [269] [270] [276] [278]
- ▸Animal, cross-sectional, retrospective, and machine-learning studies should not be interpreted as validating new diagnostic criteria. [22] [121] [125] [220] [236] [237] [263] [269]
Diagnostic scope and confirmation
Hyperlipidemia should be confirmed with laboratory lipid assessment and interpreted in clinical context rather than inferred from a single cardiovascular or metabolic finding. In the available studies, lipid status was assessed using serum lipid profiles or LDL-cholesterol measurements, while some cohorts defined hyperlipidemia as an existing comorbidity or diagnosis. [220]C4 [22]B2b [236] [243] The supplied evidence does not establish a universal diagnostic cutoff for total cholesterol, LDL-cholesterol, triglycerides, or HDL-cholesterol; therefore, local laboratory reference ranges and the applicable professional guideline should be used when classifying an individual result. [22]B2b [220]C4 [243]
Obtain a complete fasting or nonfasting lipid profile according to local practice, including total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides. The evidence set specifically demonstrates clinical use of LDL-cholesterol for risk-control assessment, including a target of <70 mg/dL in adults with prior stroke. [245] HDL-cholesterol was examined as a vascular-metabolic exposure in adults with diabetes, and body roundness index was evaluated as a potential mediator of its association with diabetic retinopathy. [244] In children with familial dyslipidemia, lipid-profile assessment was paired with clinical examination and echocardiography. [243]
History and examination
The initial assessment should document age, sex, family history of premature atherosclerotic disease or markedly abnormal lipids, diet, alcohol exposure, weight trajectory, medications, pregnancy history, diabetes, hypertension, kidney disease, liver disease, thyroid disease, inflammatory disease, and other potential secondary causes. This broad clinical context is supported by studies examining secondary hyperlipidemia in depression, cardiometabolic disease in apparently healthy adults, metabolic liver disease, pregnancy-related risk, and chronic systemic disease. [236] [22]B2b [125]C4 [234] [235]
Record body-mass index, waist circumference, blood pressure, glycemic status, and relevant comorbidities. The UK Biobank study defined metabolically healthy non-obese individuals as having BMI <30 kg/m² and no diabetes, concurrent hypertension, or hyperlipidemia, illustrating that absence of obesity or a conventional diagnosis does not exclude unfavorable visceral adiposity. [22]B2b Whole-body MRI-derived visceral-to-subcutaneous adipose-tissue ratios identified additional cardiometabolic risk in this apparently low-risk group. [22]B2b In patients with sleep-apnea syndrome, anthropometric, biochemical, and comorbidity data were integrated into models for non-alcoholic fatty liver disease, supporting assessment for obesity-related hepatic disease when dyslipidemia coexists with sleep-disordered breathing. [237]
Evaluation for secondary causes and associated metabolic disease
Assess glycemia with appropriate glucose testing and HbA1c when clinically indicated. Hyperglycemia phenotypes defined by 75-g oral glucose-tolerance testing were associated with pregnancy outcomes in women with gestational diabetes, while hemoglobin glycation index was studied as a prognostic marker among critically ill patients diagnosed with hyperlipidemia. [234] [220]C4 These studies support documenting glycemic status, but they do not validate hemoglobin glycation index as a diagnostic test for hyperlipidemia. [220]C4
Review medications and psychiatric history in patients with depression, because a two-cohort machine-learning study specifically evaluated predictors of secondary hyperlipidemia in this population. [236] Evaluate hepatic steatosis and fibrosis risk when clinically appropriate. MASLD was investigated using fatty liver index criteria and serum Mac-2 binding protein glycan isomer in relation to cerebral small-vessel disease, and a separate multicenter model examined NAFLD risk in sleep-apnea syndrome. [125]C4 [237] These data support assessment of metabolic liver disease as a possible associated condition, not use of these biomarkers as lipid diagnostic substitutes. [125]C4 [237]
Pregnancy and reproductive history should be documented. Gestational weight gain and oral-glucose-tolerance-test hyperglycemia were independently and synergistically associated with adverse feto-maternal outcomes in women with gestational diabetes, and adverse pregnancy outcomes were associated with later peripheral artery disease in a nationwide Swedish cohort. [234] [235] These findings justify incorporating pregnancy history into long-term vascular-risk assessment, although they do not define hyperlipidemia.
Cardiovascular and end-organ assessment
Determine whether the patient has established atherosclerotic disease, including prior stroke, peripheral artery disease, coronary disease, or carotid disease, because treatment targets and urgency of evaluation may differ. In US adults with prior stroke, guideline-recommended LDL-cholesterol control was defined as <70 mg/dL; the study also assessed blood pressure, HbA1c, and smoking control. [245] Mobile health-unit screening identified uncontrolled cardiometabolic risk factors in socially disadvantaged urban communities and included medical history, blood pressure, LDL-cholesterol, and HbA1c testing. [246]
Additional testing should be symptom- and risk-directed rather than routine. Coronary artery calcium obtained from non-gated, noncontrast chest CT was evaluated for prediction of cardiovascular and transplant-related outcomes in lung-transplant recipients, and invasive coronary angiography was used to assess obstructive coronary disease. [276] Digital-subtraction angiography characterized carotid webs in patients with ischemic cerebrovascular events; a carotid web is an anatomic vascular lesion and should not be conflated with lipid-mediated atherosclerosis. [232] Carotid plaque burden assessed by head-and-neck CT angiography was associated with retinal vascular parameters, with diabetes modifying these relationships. [270]
Echocardiography is not a diagnostic test for hyperlipidemia but may evaluate suspected cardiac consequences or comorbidity. It was used to assess left-ventricular function and epicardial fat in children with familial dyslipidemia. [243] Experimental evidence in apolipoprotein-E-deficient mice indicates that high-fat diet and chronic pain can synergize through the JNK1/SIRT1 axis to promote cardiac injury, but this animal evidence cannot be used to diagnose human hyperlipidemia or determine clinical cardiac workup. [263]
Ocular and neurologic tests are likewise adjunctive. Serum and ocular studies investigated associations between lipid-related or metabolic measures and cataract, diabetic retinopathy, retinal microvasculopathy, and cerebral small-vessel disease. [121]C4 [244] [269] [278] These findings may inform evaluation of end-organ disease in selected patients but do not replace lipid measurement. [121]C4 [244] [269] [278]
Interpretation and limitations
Machine-learning models, imaging biomarkers, and observational associations in the cited studies may assist risk stratification, but they are not established stand-alone diagnostic criteria for hyperlipidemia. [22]B2b [236] [237] [269] The workup should therefore prioritize confirmed lipid measurements, identification of secondary causes, characterization of global cardiovascular risk, and targeted evaluation for established or suspected end-organ disease. [220]C4 [245] [246]
| Workup component | Evidence-based purpose |
|---|---|
| Lipid profile | Confirm and characterize the lipid abnormality; studies used serum lipid measures or LDL-cholesterol. [220]C4 [236] [243] |
| Glycemic assessment | Identify diabetes or hyperglycemia; OGTT and HbA1c-related measures were used in metabolic and pregnancy cohorts. [220]C4 [234] |
| Anthropometry and blood pressure | Detect cardiometabolic risk not captured by lipid values alone; visceral adiposity may be present despite BMI <30 kg/m². [22]B2b [246] |
| Liver assessment | Evaluate associated MASLD/NAFLD and fibrosis risk, particularly with metabolic disease or sleep apnea. [125]C4 [237] |
| Atherosclerotic disease assessment | Establish prior stroke, PAD, coronary disease, carotid plaque, or other disease that changes risk interpretation. [232] [245] [270] [276] |
| Targeted end-organ testing | Use echocardiography, retinal imaging, or neurologic evaluation when cardiac, ocular, or cerebrovascular disease is suspected. [243] [269] [278] |
Severity Staging and Risk Stratification
- ▸Hyperlipidemia severity should be assessed using lipid burden plus ASCVD history, metabolic comorbidity, organ dysfunction, treatment intensity, and acute clinical context.[132][279][282]
- ▸PCSK9 inhibitor exposure within 90 days before surgery was compared with statins in a 1:1 matched cohort using 30-day postoperative major adverse cardiovascular events as the primary endpoint; the supplied abstract does not provide comparative estimates.[132]
- ▸Established MI, stroke, or vascular disease places a patient in a high-risk clinical category independent of the apparent magnitude of the lipid abnormality.[279][284]
- ▸The ZJU index incorporates fasting glucose, BMI, ALT/AST ratio, triglycerides, and a **2-point female adjustment**, but is not a validated hyperlipidemia staging tool.[338]
- ▸A BMI below **30 kg/m²** and absence of diabetes, hypertension, and hyperlipidemia do not exclude unfavorable visceral adiposity.[22]
- ▸The cited references do not provide validated LDL-C or triglyceride thresholds for hyperlipidemia severity staging; guideline thresholds must be applied separately.[132][257][338]
Scope of severity assessment
Hyperlipidemia severity should not be determined by lipid concentration alone. The available updated evidence supports a multidimensional assessment incorporating lipid exposure, established or suspected atherosclerotic cardiovascular disease (ASCVD), metabolic comorbidity, organ dysfunction, treatment intensity, and short-term clinical context. Several cited studies identify hyperlipidemia as a covariate in broader prognostic models rather than defining lipid-specific severity thresholds; therefore, these studies should inform risk interpretation but should not be used to create unsupported LDL-C or triglyceride staging cutoffs.[279][282][287][288]C
Lipid-related treatment intensity and perioperative risk
Treatment intensity is a clinically relevant marker of disease burden and residual risk. In a nationwide, active-comparator cohort of adults with hyperlipidemia undergoing surgery, preoperative PCSK9 inhibitor use was compared with statin use after 1:1 propensity-score matching. Exposure was defined as treatment within 90 days before surgery, and the primary endpoint was 30-day postoperative major adverse cardiovascular events.[132]B2b The study was designed to evaluate perioperative effectiveness and safety, but the supplied abstract does not report the comparative outcome estimates; consequently, PCSK9 inhibitor therapy should not be interpreted from this reference as either superior or inferior to statins for perioperative risk reduction.[132]B2b
Established cardiovascular disease and secondary-risk stratification
Patients with previous myocardial infarction (MI), coronary disease, stroke, or other established vascular disease should be considered clinically high risk irrespective of whether the lipid abnormality is mild or severe. In a prospective cohort of 1,283 post-MI patients treated with percutaneous coronary intervention, circulating concentrations of 19 metals were evaluated for association with mortality, with adjustment including hyperlipidemia and conventional clinical variables; the investigators specifically examined whether metals added prognostic information beyond the GRACE score.[279] This supports consideration of additional exposures in selected post-MI patients, but it does not establish metals as routine components of hyperlipidemia staging.[279]
Coronary disease extent may further refine risk. In a prospective observational study of 269 patients with acute MI who underwent angiography, disease was categorized as single-, double-, or triple-vessel CAD, while habitual physical activity during the preceding 4 weeks was assessed as a potential correlate of angiographic extent.[284] These findings are relevant to global ASCVD-risk characterization, although the supplied evidence does not provide a lipid-specific threshold or validated hyperlipidemia score.[284]
Metabolic phenotype and comorbidity burden
Hyperlipidemia should be interpreted alongside obesity, glycemia, liver enzymes, triglycerides, and visceral adiposity. The ZJU index combines fasting plasma glucose, BMI, the ALT/AST ratio, and triglycerides, with a sex-related adjustment of 2 points for women; in a prospective registry of 1,897 patients with acute ischemic stroke, it was evaluated as a predictor of short-term functional outcome.[338] The index is a prognostic metabolic marker, not a validated severity classification for hyperlipidemia.[338]
In 22,040 UK Biobank participants initially characterized as metabolically healthy and non-obese—defined using BMI <30 kg/m² and absence of diabetes, hypertension, and hyperlipidemia—MRI-derived visceral and subcutaneous adipose tissue measures were used to identify unfavorable adiposity profiles.[22]B2b Thus, apparently low-risk anthropometric status does not necessarily exclude adverse visceral adiposity, and risk assessment should remain attentive to metabolic phenotype.[22]B2b
Metabolic dysfunction-associated fatty liver disease (MAFLD) is another risk-enhancing context. In 1,515 patients with MAFLD, an AI-assisted model integrated deep-learning segmentation, radiomics, and clinical variables to identify coronary heart disease risk.[340]C This model is investigational and should not replace validated clinical assessment, but it illustrates the potential value of integrating hepatic, imaging, and metabolic information when conventional lipid measurements inadequately describe risk.[340]C
Acute illness and competing clinical context
The prognostic meaning of hyperlipidemia may vary during acute illness. In a multicenter cohort of 2,973 adults with sepsis, metabolic syndrome was present in 44.0%; analyses examined whether associations with in-hospital mortality varied by disease severity and individual components, including overweight and hyperlipidemia.[282] These results should not be used to infer that hyperlipidemia is protective or harmful in every septic patient, because acute-illness associations may reflect severity-dependent confounding and do not define chronic ASCVD risk.[282]
Additional studies demonstrate that lipid status frequently appears within broader risk frameworks. Hyperlipidemia was included among adjustment or matching variables in studies of intracranial aneurysm device outcomes, non-arteritic anterior ischemic optic neuropathy, and other clinical populations.[345][281] It was also considered in studies of hydroxychloroquine-associated cardiometabolic outcomes in discoid lupus, cardiac risk among older adults receiving stereotactic body radiation therapy, and moderate aortic stenosis outcomes.[286][287][288]C These references support documenting hyperlipidemia as part of comorbidity burden, but they do not establish disease-specific lipid staging thresholds.[281][286][287][288]C
Emerging prediction tools and limitations
Machine-learning models may improve individualized cardiovascular prediction when they incorporate medications, laboratory results, blood pressure, and comorbidities. A Jordanian electronic-health-record study used approximately 600,000 individuals and evaluated pharmacotherapy-informed models, specifically addressing calibration and generalizability limitations of conventional risk tools.[257] Other prediction studies developed models for NAFLD in 595 training and 372 external-validation patients with sleep apnea, reproductive cancer outcomes in women with PCOS, and prognosis in urothelial cancer treated with disitamab vedotin plus PD-1 inhibition.[237][346][285] These models are disease-specific and should not be repurposed for hyperlipidemia staging.[237][285][346]
Practical staging framework
A defensible clinical classification is therefore: (1) biochemical abnormality without documented ASCVD; (2) hyperlipidemia with major metabolic or organ comorbidity; (3) hyperlipidemia with established ASCVD or prior MI/stroke; and (4) very high-risk disease requiring specialist-level assessment when recurrent events, extensive vascular disease, severe metabolic burden, or intensive therapy such as PCSK9 inhibition is present.[132]B2b[279][284] The cited evidence does not supply validated LDL-C, non-HDL-C, or triglyceride cut points for these categories; clinicians should therefore apply current guideline thresholds separately and use the studies above to refine—not replace—clinical risk assessment.[132]B2b[257][279][338][340]C
| Domain | Evidence-informed interpretation | Limitation |
|---|---|---|
| Lipid abnormality without ASCVD | Biochemical hyperlipidemia requiring baseline and treatment-response assessment | No lipid cutoffs supplied in the cited studies.[132]B2b[257] |
| Established ASCVD or prior MI/stroke | High clinical risk; integrate vascular extent and recurrent-event context | Metal exposure and activity findings are not lipid-specific staging tools.[279][284] |
| Metabolic comorbidity | Consider glucose, BMI, triglycerides, liver indices, MAFLD, and visceral adiposity | ZJU, VAT/SAT, and AI models require validation for routine lipid staging.[22]B2b[338][340]C |
| Intensive therapy or perioperative setting | Treatment intensity and timing may identify complex or high-risk patients | Comparative PCSK9-versus-statin outcome estimates were not provided.[132]B2b |
| Acute illness | Interpret lipid associations within disease severity and competing risks | Sepsis findings cannot be generalized to chronic ASCVD prevention.[282] |
Acute and Initial Management
- ▸Treat severe hypertriglyceridemia with DKA as a hospital-based metabolic emergency; the cited pediatric evidence defines severe HTG as **>11.3 mmol/L (approximately 1,000 mg/dL)** [355].
- ▸In DKA-associated severe HTG, insulin is described as central therapy and plasmapheresis as salvage therapy [355].
- ▸Tamoxifen-associated HTG can be profound and was associated with acute pancreatitis in 63.3% of reported cases [349].
- ▸Review tamoxifen and asparaginase promptly when severe or rapidly worsening HTG occurs; treatment modification may be necessary in asparaginase-associated toxicity [349,356].
- ▸The supplied evidence does not establish universal insulin doses, plasmapheresis criteria, or acute LDL-C treatment thresholds [349,355].
Immediate assessment and triage
Initial management should first identify whether dyslipidemia is causing an acute complication, particularly pancreatitis, diabetic ketoacidosis (DKA), or another severe metabolic disturbance. The supplied evidence is concentrated on severe hypertriglyceridemia (HTG), rather than isolated elevation of low-density lipoprotein cholesterol (LDL-C). In children with DKA, severe HTG was defined as triglycerides (TG) >11.3 mmol/L (approximately 1,000 mg/dL) and was described as a rare but serious complication requiring hospital-based management [355]C. In a systematic review of tamoxifen-associated HTG, acute pancreatitis occurred in 31 of 49 patients (63.3%), while median TG increased from 274 mg/dL before treatment to 2,534 mg/dL after treatment [349]C. Therefore, marked TG elevation, abdominal pain, vomiting, systemic inflammation, or biochemical evidence of DKA should prompt urgent evaluation for pancreatitis and metabolic decompensation [349]C[355]C.
The initial work-up should document the medication and disease context, including tamoxifen, asparaginase, uncontrolled diabetes, and other secondary contributors. Tamoxifen-associated HTG was reported predominantly in women, with 47 of 49 cases occurring in females; the included cases had a median age of 49 years, with a range of 34–74 years [349]C. Asparaginase-associated HTG can complicate treatment of childhood acute lymphoblastic leukemia and may coexist with pancreatitis, hepatic dysfunction, hypersensitivity, or thrombosis; severe cases may necessitate modification of antileukemic therapy [356]C. These reports support prompt review of causative therapy in severe or rapidly worsening HTG, in consultation with the relevant specialist, rather than treating the lipid result in isolation [349]C[356]C.
Severe hypertriglyceridemia with DKA or pancreatitis
For severe HTG occurring with DKA, insulin is the principal acute treatment strategy described in the available pediatric cohort, whereas plasmapheresis is reserved as salvage therapy [355]C. Management should therefore prioritize stabilization of DKA and supervised insulin-based treatment, with serial assessment of glucose, TG, electrolytes, acid–base status, renal function, and clinical evidence of pancreatitis [355]C. The supplied evidence does not establish a universal TG threshold, insulin dose, or plasmapheresis trigger beyond the study definition of severe HTG as >11.3 mmol/L [355]C. Plasmapheresis should not be treated as routine first-line therapy on the basis of this evidence; its role was characterized as salvage in children with DKA-associated severe HTG [355]C.
When tamoxifen is implicated, the systematic review supports immediate consideration of drug-related HTG, particularly when TG rises substantially or pancreatitis develops [349]C. The evidence consists of case reports and case series, so it establishes a clinically important pattern but cannot determine comparative efficacy of insulin, fibrates, omega-3 fatty acids, plasmapheresis, or other interventions [349]C. In patients receiving asparaginase, severe HTG may require temporary treatment modification because it can threaten continuation of essential antileukemic therapy and may be associated with life-threatening complications [356]C.
Initial cardiovascular and metabolic management
After acute instability is addressed, management should identify the patient’s overall atherosclerotic and metabolic risk rather than relying only on the label of hyperlipidemia. In patients with peripheral artery disease after lower-extremity revascularization, residual lipid-related proteomic and metabolomic signatures remained of interest despite widespread contemporary lipid-lowering therapy, indicating that conventionally measured lipids may not fully capture residual cardiovascular risk [343]. This finding supports continued secondary-prevention risk assessment and adherence review after revascularization, although the study did not establish a specific medication or treatment target [343].
Metabolic comorbidity is also clinically relevant. In a cohort of 1,897 patients with acute ischemic stroke, the ZJU index combined fasting plasma glucose, body mass index, the alanine aminotransferase/aspartate aminotransferase ratio, sex, and TG to study short-term prognosis [338]. This is prognostic evidence, not evidence for using the index to select lipid therapy [338]. Similarly, a post hoc randomized-trial analysis examined whether semaglutide or empagliflozin affected endothelial-function markers in people with type 2 diabetes, but the available abstract does not provide results sufficient to recommend either agent specifically for acute hyperlipidemia management [332].
Medication safety and follow-up
Bexarotene has a predictable and significant metabolic toxicity profile, but a propensity-matched real-world analysis of 2,242 exposed and 2,242 unexposed patients with mycosis fungoides found no significant increase in the composite adapted major adverse cardiovascular event endpoint over a median 4-year follow-up (hazard ratio 0.93, 95% confidence interval 0.78–1.11) [254]. This does not remove the need to monitor lipids during treatment, but it does not support stopping bexarotene solely because of demonstrated excess cardiovascular events in that analysis [254].
Care coordination may improve chronic disease follow-up: a Singapore teamlet model involving family physicians, a nurse, and a care coordinator was evaluated in patients with diabetes, hypertension, or hyperlipidemia using a matched difference-in-differences design [352]. However, the supplied abstract does not report enough outcome data to define an acute lipid-management protocol [352]. The remaining cited studies address unrelated conditions or outcomes and do not provide direct evidence for acute hyperlipidemia treatment [347][348][350][351]C[353][354][357]C.
| Scenario | Immediate priority | Evidence-based implication |
|---|---|---|
| Severe HTG with DKA | Stabilize DKA and initiate supervised insulin-based treatment | Insulin was characterized as central; plasmapheresis as salvage [355]C |
| Severe HTG with abdominal symptoms or pancreatitis | Urgently evaluate and manage pancreatitis and metabolic instability | Pancreatitis occurred in 63.3% of reported tamoxifen-associated cases [349]C |
| Tamoxifen-associated HTG | Review the drug as a probable secondary cause and coordinate treatment decisions | Median TG rose from 274 to 2,534 mg/dL in the reviewed cases [349]C |
| Asparaginase-associated HTG | Coordinate lipid, oncology, and complication management | Severe HTG may require therapy modification and can complicate further cancer treatment [356]C |
| Stable dyslipidemia without acute complication | Assess global cardiovascular and metabolic risk and arrange follow-up | Residual lipid-related risk may persist after revascularization despite lipid-lowering therapy [343] |
Long-term Guideline-Directed Therapy
- ▸The supplied evidence does not provide a new universal LDL-C target or treatment algorithm; established guideline-based risk assessment remains necessary. [343][363]
- ▸Shared decision-making should address LDL-C reduction, cardiovascular benefit, adverse effects, diabetes risk, musculoskeletal symptoms, and regimen burden. [363]
- ▸Residual lipid-related molecular risk may persist after PAD revascularization despite contemporary lipid-lowering therapy, but no replacement biomarker target can be derived from the supplied abstract. [343]
- ▸Tamoxifen-associated hypertriglyceridemia may be severe: acute pancreatitis occurred in 63.3% of reported cases, with median triglycerides rising from 274 to 2,534 mg/dL. [349]
- ▸Severe hypertriglyceridemia in the pediatric DKA series was defined as triglycerides >11.3 mmol/L; insulin was central and plasmapheresis was salvage therapy. [355]
- ▸Team-based chronic disease care and medication surveillance may support long-term treatment, but the supplied abstracts do not provide enough numerical data to quantify their effects. [352][364]
Scope of the available evidence
The supplied 2026 literature does not constitute a replacement for established lipid-management guidelines and does not provide a new universal LDL-C treatment algorithm. Instead, it adds evidence concerning treatment implementation, residual risk, medication-associated dyslipidemia, severe hypertriglyceridemia, and patient preferences. LDL-C remains described as a causal and modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD), while underuse of lipid-lowering therapy and failure to achieve LDL-C goals remain important clinical problems. [363]
Foundational long-term approach
Long-term therapy should be individualized according to ASCVD risk, baseline lipid profile, comorbidities, secondary causes, drug interactions, treatment preferences, and achieved lipid response. The contemporary evidence base supports maintaining attention to residual risk even when conventional lipid parameters and the clinical label of hyperlipidemia appear controlled, because residual lipid-related proteomic and metabolomic signatures were investigated in patients with peripheral artery disease (PAD) after lower-extremity revascularization. [343] The supplied abstract does not provide sufficient numerical results to define a replacement biomarker or treatment target; therefore, conventional guideline-based risk assessment and lipid monitoring remain necessary. [343]
Patient-centered shared decision-making is an important component of durable therapy. In a U.S. survey of adults aged ≥40 years with elevated LDL-C and a recommendation for lipid-lowering therapy, treatment preferences were assessed across LDL-C reduction, stroke risk, myocardial infarction risk, revascularization risk, new-onset diabetes, musculoskeletal pain, and regimen-related attributes. [363] These findings support discussing expected benefit, adverse effects, administration burden, and patient priorities rather than relying solely on a prespecified medication choice. [363]
Statins and combination therapy
The supplied evidence does not establish a new statin intensity hierarchy or specify LDL-C thresholds for adding ezetimibe, PCSK9-directed therapy, or other agents. Statin use was nevertheless evaluated in a multicenter retrospective, propensity-score-matched cohort of patients with newly diagnosed primary immune thrombocytopenia (ITP) and pre-existing hyperlipidemia who received initial corticosteroid therapy. [359] Because this was an observational study in a specialized hematologic population, its findings should not be extrapolated into a universal cardiovascular treatment algorithm without considering bleeding status, liver disease, drug interactions, and the indication for corticosteroids. [359]
A coordinated-care model may improve chronic disease management: a Singapore matched difference-in-differences analysis evaluated a teamlet model comprising family physicians, a nurse, and a care coordinator among patients with diabetes, hypertension, or hyperlipidemia. [352] The study assessed clinical parameters, adherence, healthcare utilization, and economic outcomes over 5 years, but the supplied abstract does not report the numerical effect estimates. [352] Accordingly, team-based follow-up is a reasonable implementation strategy, but the magnitude of benefit cannot be quantified from the available information. [352]
Diabetes and cardiometabolic risk
A post hoc analysis of a 32-week randomized trial examined semaglutide and empagliflozin in people with type 2 diabetes, focusing on reactive hyperemia index and endothelial-derived cell-adhesion molecules including E-selectin, ICAM-1, P-selectin, and VCAM-1. [332] The study was motivated by the vascular burden imposed by hyperglycemia, hypertension, and hyperlipidemia and by the established cardiovascular-risk reduction associated with these agents; however, the supplied abstract does not report the results needed to determine whether endothelial improvement mediated cardiovascular benefit or whether either drug should be selected specifically for lipid lowering. [332] These agents therefore should not be treated as substitutes for indicated lipid-lowering therapy on the basis of this analysis alone. [332]
A prospective cohort of 7,513,828 adults in northwestern China evaluated age-specific patterns of obesity, hepatic steatosis, hypertension, hyperlipidemia, diabetes, and renal dysfunction and their associations with incident CVD. [358] The study supports an integrated cardiometabolic approach across adulthood, but the supplied abstract does not provide the effect estimates or treatment comparisons needed to set lipid targets. [358]
Drug- and disease-associated dyslipidemia
Medication review is essential when triglycerides rise unexpectedly. A systematic review of 49 reported patients with tamoxifen-associated hypertriglyceridemia found acute pancreatitis in 31 patients (63.3%); median triglycerides increased from 274 mg/dL before tamoxifen to 2,534 mg/dL after initiation. [349]C These data are case-report-based and cannot establish incidence, but they support prompt triglyceride measurement and evaluation for tamoxifen-related dyslipidemia in symptomatic or high-risk patients. [349]C
Isotretinoin is another medication requiring metabolic surveillance. A Saudi Arabian retrospective cohort evaluated clinically significant adverse effects, laboratory abnormalities, management, and treatment outcomes in patients treated for acne; the supplied abstract does not provide the frequency or magnitude of lipid abnormalities. [364] Consequently, no isotretinoin-specific monitoring interval or discontinuation threshold can be derived from this study. [364]
Severe hypertriglyceridemia
Severe hypertriglyceridemia requires a separate safety pathway rather than routine long-term lipid follow-up. In the pediatric DKA series, severe hypertriglyceridemia was defined as triglycerides >11.3 mmol/L, and the study described insulin as central therapy and plasmapheresis as salvage in 21 children. [355]C Because the evidence was retrospective and pediatric, these findings should not be generalized automatically to adults or to non-DKA hypertriglyceridemia. [355]C Tamoxifen-related cases also demonstrate the potential for pancreatitis at markedly elevated triglyceride concentrations. [349]C
Practical summary
Continue guideline-directed lipid-lowering therapy according to ASCVD risk and treatment response; reassess adherence, tolerability, secondary causes, and patient preferences; monitor for medication-associated triglyceride elevation; and escalate urgently when severe hypertriglyceridemia or pancreatitis risk is present. The supplied studies refine implementation and risk recognition but do not replace established LDL-C targets or evidence-based escalation pathways. [343][349]C[352][355]C[363]
| Clinical situation | Evidence-informed action | Evidence limitation |
|---|---|---|
| Elevated LDL-C or established ASCVD risk | Use guideline-directed lipid-lowering therapy and shared decision-making. [363] | No new LDL-C thresholds are supplied. [363] |
| Persistent risk after PAD revascularization | Continue conventional lipid monitoring while recognizing possible residual molecular risk. [343] | Proteomic/metabolomic markers are not validated treatment targets in the supplied evidence. [343] |
| Type 2 diabetes with cardiometabolic risk | Consider glucose-lowering therapies according to diabetes and cardiovascular indications; do not substitute them for indicated lipid-lowering therapy. [332] | Endothelial-marker results are not reported in the supplied abstract. [332] |
| Tamoxifen exposure with rising triglycerides | Check triglycerides promptly and assess pancreatitis risk and medication causality. [349]C | Evidence is derived mainly from case reports and case series. [349]C |
| Severe hypertriglyceridemia, especially with DKA | Urgent specialist management is required; insulin was central in the pediatric DKA series and plasmapheresis was salvage. [355]C | Pediatric retrospective evidence cannot be directly generalized to adults. [355]C |
| Long-term adherence or complex comorbidity | Consider coordinated team-based follow-up and preference-sensitive care. [352][363] | Numerical outcome estimates are not available in the supplied abstracts. [352] |
Interventional and Device Therapy
- ▸PCI and drug-eluting stents treat coronary obstruction or ACS, not the underlying hyperlipidemia; lipid-lowering therapy remains necessary for secondary prevention. [179][181][183]
- ▸The SHEAR-STENT randomized study used OCT and computational-fluid-dynamics WSS analysis to evaluate 12-month neointimal healing in 86 PCI patients. [179]
- ▸cQFR was investigated as a post-primary-PCI marker of abnormal microvascular perfusion in a diagnostic cohort of 186 STEMI patients. [300]
- ▸WMT was associated with restoration of ILC3-related immune and metabolic signals in hyperlipidemia, but remains investigational. [299]
- ▸Coronary calcium scoring may assist cardiovascular-risk assessment in lung-transplant recipients, but it is diagnostic rather than lipid-lowering. [276]
- ▸The supplied evidence does not support topical oxygen therapy, cardiac rehabilitation, CRT-D, AI-ECG, diabetic-macular-edema assessment, or transplant-diabetes studies as treatments for hyperlipidemia. [187][180][301][302][182]
Scope and role
Interventional and device-based treatment does not replace lipid-lowering therapy for hyperlipidemia; it is primarily used to treat established atherosclerotic disease or its complications. The supplied evidence is heterogeneous and includes coronary intervention, vascular-flow assessment, transplant-associated cardiovascular care, microbiota-based treatment, and experimental metabolic interventions. Accordingly, most findings should be interpreted as adjunctive or investigational rather than as established treatments for dyslipidemia.
Percutaneous coronary intervention and stent therapy
Percutaneous coronary intervention (PCI) is a revascularization procedure for selected coronary lesions and acute coronary syndromes, not a treatment that corrects the underlying lipid disorder. Drug-eluting stents remain a central PCI technology in acute coronary syndrome (ACS), and a prospective single-center cohort followed patients treated with rapamycin-eluting or everolimus-eluting stents for 5–7 years to compare long-term safety, effectiveness, and cost; the supplied abstract does not report the comparative outcome results. [183]B2b In patients with non-ST-elevation ACS undergoing PCI, the CHIP Score was evaluated in a retrospective cohort of 348 patients as a predictor of post-discharge major adverse cardiac or cerebrovascular events, but this was a risk-validation study rather than a lipid-treatment trial. [181]B2b
The SHEAR-STENT randomized prospective study enrolled 86 patients undergoing PCI in angulated coronary arteries and compared Xience Xpedition everolimus-eluting stents with Resolute Integrity/Onyx zotarolimus-eluting stents. Serial optical coherence tomography (OCT) and computational-fluid-dynamics modeling were used to relate post-stent wall shear stress (WSS) to strut-, frame-, and patient-level neointimal thickness at 12 months. [179]A1b This study addresses vascular-healing mechanisms and device performance; it does not establish a cholesterol-lowering effect or demonstrate superiority of either stent for prevention of hyperlipidemia-related events. [179]A1b
Quantitative flow assessment may help characterize residual ischemic physiology after intervention. In patients with ST-segment-elevation myocardial infarction treated with successful primary PCI, contrast-flow quantitative flow ratio (cQFR) was studied in relation to abnormal microvascular perfusion using myocardial contrast perfusion echocardiography; the diagnostic cohort included 186 patients. [300] cQFR is therefore a potential post-PCI assessment tool, but the available evidence does not show that it modifies lipid levels or substitutes for intensive secondary prevention. [300]
Cardiovascular risk assessment in transplant populations
Coronary artery calcium scoring from non-gated, non-contrast computed tomography was evaluated in lung-transplant recipients without prior coronary revascularization as a predictor of obstructive coronary disease and major adverse cardiovascular events, defined as myocardial infarction, ischemic stroke, or all-cause death. [276] This supports coronary-risk stratification before or around transplantation, but it is diagnostic rather than lipid-lowering therapy. [276] A national inpatient analysis of PCI hospitalizations compared liver-transplant recipients with non-transplant patients using propensity-score matching; it examined in-hospital mortality and reflects procedural outcomes, not treatment of hyperlipidemia itself. [305]
Metabolic and microbiota-directed interventions
Washed microbiota transplantation (WMT) is an investigational biological intervention rather than a device-based treatment. In a prospective cohort of hyperlipidemia patients not receiving lipid-lowering medication, WMT was associated with restoration of circulating group 3 innate lymphoid cells (ILC3s), integrin-α4-positive ILC3s, and plasma interleukin-22, which were reduced in hyperlipidemia; microbial and plasma-metabolite changes were also assessed. [299] A hyperlipidemic mouse model was used to investigate whether healthy microbiota promote hepatic ILC3 homing through integrin α4. [299] These findings are mechanistically promising but do not establish WMT as a standard clinical lipid-lowering intervention. [299]
GLP-1 agonists may be used for weight and metabolic management after liver transplantation. In a retrospective cohort of 368 liver-transplant recipients, 73 (19.8%) received a GLP-1 analogue after transplantation; the study compared weight trajectory, comorbidities, and post-transplant outcomes with nonusers. [306] The supplied evidence does not establish a specific LDL-cholesterol reduction, cardiovascular-event benefit, or indication for GLP-1 therapy solely because hyperlipidemia is present. [306]
Adjunctive risk-factor management and experimental therapies
Statin therapy remains relevant to cardiovascular prevention in chronic kidney disease (CKD). A retrospective Swedish cohort evaluated adults aged 50–89 years with repeated estimated glomerular filtration rate values below 60 mL/min/1.73 m², without prior cardiovascular disease, diabetes, dialysis, transplantation, or another statin indication, and examined the association between primary-prevention statin use and all-cause mortality. [303] This evidence concerns preventive pharmacotherapy, not an interventional device, and observational associations should not be interpreted as proof of causation. [303]
Several supplied studies are not applicable to interventional treatment of hyperlipidemia. Everolimus pharmacokinetic monitoring in kidney-transplant recipients examined exposure, proteinuria, and de novo hyperlipidemia under tacrolimus-based therapy, indicating that immunosuppressive management may intersect with lipid abnormalities. [304] Cardiometabolic risk factors, including hyperlipidemia, were studied as predictors of recompensation and survival in alcohol-associated liver disease evaluated for early transplantation. [189]B2b Hepatic steatosis after kidney transplantation was assessed in 127 recipients, with 44 (30.1%) developing de novo steatosis. [275] Epicardial adipose tissue was evaluated in 138 STEMI patients after PCI as a prognostic and disease-severity marker. [307] Muscle-derived ANXA2 was investigated in experimental models of hepatic steatosis, while cinnamaldehyde was studied in cell and high-fat-diet models through SIRT1/FOXO1-related autophagy and gut-microbiota mechanisms; neither study provides clinical device or interventional evidence for hyperlipidemia treatment. [185]D5[186]D5
Topical oxygen therapy was retrospectively evaluated for refractory venous leg ulcers in 31 patients with 32 extremities, and cardiac rehabilitation was retrospectively examined for atrial-fibrillation recurrence after pulmonary-vein isolation; neither intervention directly treats hyperlipidemia. [187]C4[180]B2b AI-ECG age was studied retrospectively as a predictor of survival after CRT-D implantation, and kidney function was studied in relation to diabetic macular edema; these findings likewise do not provide lipid-lowering or hyperlipidemia-device evidence. [301][302] Lung-transplant recipients were also studied for post-transplant diabetes risk, which is relevant to metabolic risk but not a treatment for dyslipidemia. [182]B2b
Practical interpretation
For patients with hyperlipidemia and established coronary disease, PCI and drug-eluting stents should be viewed as treatment for obstructive or acute coronary disease, followed by comprehensive secondary prevention and lipid-lowering medication. [179]A1b[181]B2b[183]B2b WSS/OCT and cQFR may refine assessment of stent healing or residual perfusion, whereas calcium scoring may support transplant-related coronary-risk stratification. [179]A1b[276][300] WMT, GLP-1 agonists for transplant-associated metabolic disease, and microbiota- or pathway-directed approaches remain investigational or context-specific on the supplied evidence. [299][306][185]D5[186]D5
| Intervention or technology | Evidence and application | Role in hyperlipidemia |
|---|---|---|
| PCI and drug-eluting stents | ACS treatment; rapamycin- versus everolimus-eluting stents studied over 5–7 years. [183]B2b | Treats coronary disease; does not lower lipids. |
| OCT and WSS modeling | Randomized study of 86 patients with 12-month neointimal-healing assessment. [179]A1b | Device-healing research. |
| cQFR | Evaluated against microvascular-perfusion abnormalities after primary PCI in 186 STEMI patients. [300] | Post-PCI diagnostic assessment. |
| Coronary calcium scoring | Non-gated CT calcium scores assessed in lung-transplant recipients. [276] | Risk stratification, not treatment. |
| WMT | Prospective, medication-free hyperlipidemia cohort with ILC3, IL-22, microbiome, and metabolite assessment. [299] | Investigational metabolic intervention. |
| GLP-1 agonists | Used in 73 of 368 liver-transplant recipients. [306] | Context-specific weight/metabolic therapy; not proven lipid therapy. |
History and Evolution of Treatment
- ▸Contemporary hyperlipidemia treatment increasingly combines statins with individualized nonstatin therapy, particularly for older adults and patients with statin intolerance.[164,312]
- ▸Bempedoic acid phase 3 evidence specifically evaluated patients aged ≥75 years across maximal-statin and statin-intolerant cohorts.[164]
- ▸Tamoxifen-associated hypertriglyceridemia may be severe: median triglycerides rose from 274 mg/dL to 2,534 mg/dL, and acute pancreatitis occurred in 63.3% of reported cases.[349]
- ▸Menopausal hormone therapy was studied by cardiometabolic status but should not be considered a lipid-lowering treatment.[308]
- ▸Semaglutide, empagliflozin, L-arginine, and composite metabolic indices represent broader vascular-risk research rather than replacements for established lipid-lowering therapy.[290,332,338]
From lipid lowering to risk-based treatment
The modern treatment of hyperlipidemia has progressively shifted from treating an isolated laboratory abnormality to reducing global atherosclerotic cardiovascular risk. The supplied updated evidence reflects this evolution through studies of statin intensity, nonstatin LDL-C lowering, cardiometabolic phenotyping, medication-induced dyslipidemia, and metabolic therapies.
Statins remain a central reference treatment in contemporary hyperlipidemia research. A 2026 propensity-score-matched cohort evaluated patients with hyperlipidemia who initiated high-, medium-, or low-intensity statins and compared them with proton-pump-inhibitor users and unexposed controls; patients with prior uveitis or fibrate exposure were excluded.[312] This study was designed to assess whether statin intensity was associated with 5-year incident noninfectious uveitis, illustrating the modern emphasis on evaluating both cardiovascular benefit and uncommon extrahepatic safety outcomes.[312]
Expansion of nonstatin therapy
Treatment has expanded beyond statins for patients requiring additional LDL-C reduction or those unable to tolerate adequate statin therapy. Bempedoic acid has been evaluated in phase 3 placebo-controlled studies among high-risk patients aged ≥75 years, including cohorts receiving maximal background statin therapy and a separate statin-intolerant cardiovascular-outcomes cohort.[164]A1b The analyses assessed LDL-C, non-high-density lipoprotein cholesterol, total cholesterol, high-sensitivity C-reactive protein, and safety, thereby extending nonstatin treatment evidence to very old adults and to patients with differing levels of statin exposure.[164]A1b This supports an increasingly individualized treatment pathway in which age and statin tolerance influence selection of adjunctive or alternative therapy, although the supplied abstract does not provide the numerical efficacy or safety estimates.[164]A1b
Recognition and management of secondary or drug-induced dyslipidemia
The treatment history of hyperlipidemia also includes increasing attention to reversible secondary causes. A 2026 systematic review of tamoxifen-associated hypertriglyceridemia identified 49 patients, including 47 women, from case reports and case series.[349]C Acute pancreatitis occurred in 31 patients (63.3%), while median triglyceride concentration increased from 274 mg/dL before tamoxifen to 2,534 mg/dL after initiation.[349]C These findings reinforce the need to review medications when severe hypertriglyceridemia develops, monitor triglycerides in susceptible patients receiving tamoxifen, and address pancreatitis risk; however, the evidence level was case-based and does not establish comparative treatment effectiveness.[349]C
Integration with cardiometabolic risk and hormonal therapy
Treatment decisions increasingly incorporate blood pressure, glycemia, lipid profile, and metabolic syndrome rather than cholesterol values alone. A secondary analysis of two double-blind randomized trials evaluated cardiovascular effects of oral menopausal hormone therapy using conjugated equine estrogens (CEE) 0.625 mg/day, with or without medroxyprogesterone acetate (MPA) 2.5 mg/day, versus placebo in postmenopausal women aged 50–79 years.[308] The CEE-alone trial included 10,739 women with prior hysterectomy, and the CEE-plus-MPA trial included 16,608 women with an intact uterus; coronary heart disease was defined as nonfatal myocardial infarction or coronary death.[308] This evidence places lipid status within broader cardiometabolic assessment and does not support using menopausal hormone therapy as a lipid-lowering strategy.[308]
Metabolic therapies are also being studied for vascular effects beyond conventional lipid measurements. In a post hoc analysis of a randomized trial in type 2 diabetes, semaglutide and empagliflozin were evaluated for effects on reactive hyperemia index and endothelial-derived adhesion molecules, including E-selectin, ICAM-1, P-selectin, and VCAM-1.[332] Because the study concerned endothelial markers in people exposed to the combined vascular burden of hyperglycemia, hypertension, and hyperlipidemia, it represents a broader cardiometabolic approach rather than direct evidence that either drug replaces lipid-lowering therapy.[332]
Movement toward vascular-risk prevention and precision assessment
Several newer studies emphasize that hyperlipidemia treatment is increasingly embedded in prevention of systemic vascular disease. In patients with atherosclerotic lower-limb ischemia, a randomized double-masked trial assigned 87 patients to oral L-arginine 6 g/day or placebo for 2 months and examined asymmetric dimethylarginine and homocysteine according to lipid-abnormality subtype.[290] This addresses endothelial and nitric-oxide-pathway biomarkers, but it is adjunctive vascular research rather than established lipid-lowering treatment.[290]
Observational research has further linked metabolic abnormalities with vascular disease and prognosis. A meta-analysis of 37 studies assessed carotid plaque detection and associated factors in obstructive sleep apnea.[310] A prospective registry analysis of 1,897 patients with acute ischemic stroke evaluated the ZJU index, incorporating fasting glucose, body mass index, ALT/AST ratio, sex, and triglycerides, as a predictor of short-term functional outcome.[338] These studies support comprehensive risk assessment but do not establish lipid-specific therapies.[310][338]
Other supplied studies provide contextual rather than treatment-changing evidence: carotid-web management was examined in 48 patients diagnosed by digital-subtraction angiography,[232] adverse pregnancy outcomes were associated with later peripheral artery disease in a Swedish cohort of 2,201,446 women,[235] and hyperlipidemia appeared among variables examined in cancer-risk research in myeloproliferative neoplasms.[260] Additional studies addressed unrelated outcomes, including Wallerian degeneration after stroke,[298] medication-related osteonecrosis of the jaw,[311] residual dizziness after benign positional vertigo,[169]B2b hypertension in Middle Eastern and North African adults,[170]B2b postoperative atrial fibrillation,[62]B3b laryngeal cancer and 5-alpha-reductase inhibitors,[365] herpes zoster vaccination,[366] pseudophakic macular edema,[255] and infertility-related social determinants.[367] These investigations do not alter lipid-lowering treatment but illustrate the expanding use of comorbidity, medication, and social-context data in individualized cardiovascular care.
| Treatment or strategy | Population and design | Contribution to treatment evolution |
|---|---|---|
| Statin intensity | Propensity-matched cohort of patients with hyperlipidemia; high-, medium-, and low-intensity statins compared with control cohorts | Continued assessment of intensity-specific safety and outcomes.[312] |
| Bempedoic acid | Phase 3 placebo-controlled studies, including patients aged ≥75 years with maximal statin therapy or statin intolerance | Expands nonstatin options for residual LDL-C risk and statin intolerance.[164]A1b |
| Tamoxifen monitoring | Systematic review of 49 case-based reports | Highlights secondary hypertriglyceridemia, pancreatitis risk, and the importance of medication review.[349]C |
| Cardiometabolic therapies | Randomized-trial analyses of menopausal hormone therapy, semaglutide, empagliflozin, and L-arginine | Moves management toward integrated vascular and metabolic-risk assessment.[290][308][332] |
Complications
- ▸Hyperlipidemia-related complications in the supplied evidence are dominated by cardiovascular, cerebrovascular, peripheral vascular, endothelial, and pancreatitis outcomes [308,332,340,349,370].
- ▸Tamoxifen-associated hypertriglyceridemia was followed by acute pancreatitis in 31 of 49 reported patients (63.3%), with median triglycerides rising to 2,534 mg/dL [349].
- ▸Chronic pain may amplify high-fat-diet-associated cardiac injury in apolipoprotein E-deficient mice, but this remains preclinical evidence [263].
- ▸Several supplied studies include hyperlipidemia as a comorbidity or risk marker without demonstrating a direct hyperlipidemia-specific complication [22,232,235,249,261,317,333,348,351,359,368,369,371,169].
Cardiovascular and vascular complications
Hyperlipidemia is associated with clinically important cardiovascular and vascular complications, particularly when it coexists with diabetes, hypertension, obesity, metabolic dysfunction, or chronic inflammation. In type 2 diabetes, hyperglycemia, hypertension, and hyperlipidemia impose endothelial stress that may contribute to atherosclerosis and cardiovascular disease; endothelial-derived adhesion molecules and reactive hyperemia are therefore relevant markers of vascular dysfunction [332]. A randomized-trial analysis evaluated whether semaglutide or empagliflozin improved endothelial-function markers in this setting, although the supplied abstract does not establish that endothelial improvement mediated cardiovascular benefit [332].
The principal clinical consequences include coronary heart disease, myocardial infarction, ischemic stroke, peripheral arterial disease, and other major adverse cardiovascular events. Cardiometabolic status—including lipid profile, blood pressure, blood glucose, and metabolic syndrome—modified the cardiovascular effects assessed in randomized trials of oral menopausal hormone therapy, emphasizing that lipid abnormalities may alter the background cardiovascular risk and treatment-related risk in postmenopausal women [308]. In patients with metabolic dysfunction-associated fatty liver disease, a deep-learning/radiomics study specifically evaluated concomitant coronary heart disease risk, supporting the importance of cardiovascular risk stratification in this metabolically high-risk population [340]C.
Hyperlipidemia may also compound cardiac injury in the presence of other stressors. In apolipoprotein E-deficient mice receiving a high-fat diet, experimentally induced chronic pain was investigated as a synergistic contributor to cardiac injury through the c-Jun N-terminal kinase 1/silent information regulator 1 signaling axis; the model included echocardiographic assessment of left ventricular function [263]. These findings are mechanistic and preclinical and should not be interpreted as proof that chronic pain causes cardiac injury in humans with hyperlipidemia [263].
Cerebrovascular, retinal, and peripheral arterial events
Atherosclerotic vascular disease can manifest as ischemic cerebrovascular or peripheral arterial disease. In patients with retinal artery occlusion, a cohort study assessed subsequent major adverse cardiovascular and cerebrovascular events, defined as ischemic stroke or myocardial infarction, and evaluated clinical predictors and long-term outcomes [370]. The study supports retinal artery occlusion as a clinically important vascular event requiring cardiovascular and cerebrovascular evaluation, but the supplied abstract does not quantify hyperlipidemia-specific risk [370].
Carotid web is a distinct potential embolic cause of ischemic stroke rather than a typical lipid-mediated lesion. A 48-patient angiographic series examined its relationship with ischemic stroke, transient ischemic attack, recurrent ipsilateral events, treatment, and follow-up, and therefore should not be used to attribute carotid-web complications to hyperlipidemia [232]. Similarly, periodic repolarization dynamics predicted newly detected atrial fibrillation after ischemic stroke in a prospective cohort, but this biomarker study addresses post-stroke arrhythmia risk rather than a direct hyperlipidemia complication [333].
Adverse pregnancy outcomes were associated with later peripheral artery disease in a large Swedish cohort, providing an additional long-term vascular-risk context; the supplied abstract does not establish hyperlipidemia as the causal pathway [235].
Severe hypertriglyceridemia and acute pancreatitis
The most clearly documented acute complication in the supplied evidence is acute pancreatitis associated with severe hypertriglyceridemia. In a systematic review of tamoxifen-induced hypertriglyceridemia, 31 of 49 patients (63.3%) developed acute pancreatitis; median triglyceride concentration increased from 274 mg/dL before treatment to 2,534 mg/dL after tamoxifen initiation [349]C. These data derive mainly from case reports and case series, so they describe a serious signal rather than an incidence estimate for all tamoxifen users or all patients with hyperlipidemia [349]C.
Associated organ and treatment-related considerations
Hyperlipidemia may coexist with disorders in which vascular, inflammatory, metabolic, or treatment-related complications are clinically relevant. In systemic lupus erythematosus, a meta-analysis examined factors associated with osteonecrosis, a severe complication, but the supplied abstract does not provide sufficient detail to conclude that hyperlipidemia independently causes osteonecrosis [249]. In primary immune thrombocytopenia, hyperlipidemia was described as prevalent and potentially associated with greater bleeding severity or poorer treatment response; a multicenter retrospective study evaluated whether adding statins to corticosteroids affected efficacy and safety [359]. These observations indicate clinical association, not proof that hyperlipidemia directly causes bleeding [359].
After metabolic and bariatric surgery, hyperlipidemia may remit but later recur; a retrospective study evaluated recurrence of previously resolved obesity-related conditions, including hyperlipidemia, after sleeve gastrectomy, Roux-en-Y gastric bypass, or duodenal switch [261]. This is an important longer-term management issue because recurrence may restore cardiometabolic risk [261].
Several supplied studies address conditions in which hyperlipidemia was a comorbidity, covariate, or part of cardiometabolic risk assessment rather than a demonstrated complication: opportunistic screening of metabolically healthy non-obese adults [22]B2b, outcomes of GLP-1 receptor agonists or tirzepatide in hidradenitis suppurativa with diabetes or obesity [369], and long-term outcomes after anti-HER2 therapy [368]. Other reports concern generalized pustular psoriasis treatment [348], pediatric Crohn disease maintenance therapy [351]C, alcohol-associated liver disease and neighborhood deprivation [371], prescription-interception patterns [317], and residual dizziness after benign paroxysmal positional vertigo [169]B2b; their abstracts do not establish hyperlipidemia-specific complications [348][351]C[371][317][169]B2b.
Clinical interpretation
Complication risk should therefore be assessed according to the lipid phenotype and accompanying risk factors. Particular attention is warranted for very high triglyceride concentrations, especially when triglycerides approach or exceed the 2,500 mg/dL range, because the tamoxifen-associated cases demonstrate a strong association with acute pancreatitis at such levels [349]C. Cardiovascular assessment should consider coexisting diabetes, hypertension, metabolic syndrome, obesity, fatty liver disease, chronic inflammatory stress, and established vascular events [22]B2b[263][308][332][340]C[370].
| Domain | Evidence and clinical relevance |
|---|---|
| Cardiovascular disease | Endothelial dysfunction, coronary heart disease, myocardial infarction, and broader cardiovascular risk are evaluated in cardiometabolic populations [308][332][340]C. |
| Cardiac injury | High-fat diet and chronic pain synergized in an apolipoprotein E-deficient mouse model [263]. |
| Cerebrovascular/peripheral vascular disease | Stroke, retinal artery occlusion-associated events, and peripheral artery disease are examined in vascular cohorts, although hyperlipidemia-specific causality is not established in each study [232][235][333][370]. |
| Acute pancreatitis | Frequently reported in tamoxifen-associated severe hypertriglyceridemia; 31/49 cases developed pancreatitis [349]C. |
| Recurrence after treatment | Hyperlipidemia may recur after initial remission following metabolic and bariatric surgery [261]. |
Prognosis and Natural History
- ▸Hyperlipidemia prognosis is driven by cumulative lipid exposure and coexisting cardiometabolic disease; BMI alone may underestimate risk when visceral or central adiposity is present. [22][322][373]
- ▸Severe triglyceride elevation can progress to acute pancreatitis; in tamoxifen-associated case reports, median triglycerides increased from 274 mg/dL to 2,534 mg/dL and pancreatitis occurred in 63.3% of reported patients. [349]
- ▸Hyperlipidemia-related metabolic burden is relevant to functional and vascular outcomes after ischemic stroke, although the cited studies do not establish untreated hyperlipidemia as the sole cause. [338][347]
- ▸Established arterial events, including carotid disease and retinal artery occlusion, identify patients requiring intensified systemic vascular-risk assessment. [339][370]
- ▸Most available evidence is observational, secondary, or disease-specific; associations should not automatically be interpreted as causal effects of hyperlipidemia. [22][349][372][369]
Overview
Hyperlipidemia is a chronic, heterogeneous cardiometabolic exposure rather than a single self-limited disorder. Its long-term prognosis is determined by the magnitude and duration of atherogenic lipid exposure, coexisting metabolic disease, adiposity distribution, vascular disease, treatment response, and social determinants of health; the supplied evidence base is predominantly observational and often evaluates downstream complications rather than isolated hyperlipidemia. [322][22]B2b[373][250]
Cardiovascular and cerebrovascular prognosis
The prognostic importance of hyperlipidemia is amplified when it occurs with obesity, abnormal glucose metabolism, hypertension, or metabolic syndrome. In the UK Biobank, MRI-derived adiposity traits were evaluated longitudinally in relation to hyperlipidemia, type 2 diabetes, hypertension, myocardial infarction, and cerebral infarction, supporting the use of body-composition measures beyond BMI when assessing future cardiometabolic risk. [322] Among individuals classified as metabolically healthy and non-obese, visceral adiposity not captured by BMI or waist circumference was specifically investigated as a marker of later cardiometabolic disease, indicating that apparently low-risk patients may still harbor clinically relevant risk. [22]B2b Population data further showed that body-composition phenotypes defined by BMI and waist-to-height ratio were associated with cardiovascular-kidney-metabolic multimorbidity and long-term mortality; central adiposity may therefore worsen prognosis even at a normal BMI. [373]
The clinical consequences of adverse metabolic profiles are especially evident after vascular events. In 1,897 patients with acute ischemic stroke, the ZJU index—which integrates fasting glucose, BMI, the ALT/AST ratio, sex, and triglycerides—was studied as a predictor of short-term functional outcome, suggesting that triglyceride-related metabolic burden contributes to post-stroke prognosis in combination with other metabolic abnormalities. [338] In patients undergoing mechanical thrombectomy, a separate cohort developed and prospectively evaluated models for 90-day mortality, emphasizing that early outcome is influenced by the aggregate clinical risk profile rather than lipid levels alone. [159]B2b Convalescent ischemic-stroke patients with chronic vascular-metabolic disease burden were also followed for 12 months to assess activities-of-daily-living recovery, with N-butylphthalide plus basic treatment compared with basic treatment alone; this study addresses functional recovery in a high-risk population, not the untreated natural history of hyperlipidemia itself. [347]
Established vascular disease marks a substantially higher-risk stage. A 10-year multicenter cohort of patients with symptomatic carotid artery disease compared urgent intervention at 0–2 days, early intervention at 3–14 days, and delayed intervention at ≥15 days, assessing perioperative and long-term outcomes. [339] A multicenter study of flow-diverter treatment for unruptured intracranial aneurysms incorporated hyperlipidemia among variables used for propensity matching, demonstrating that it is considered an important confounder in cerebrovascular outcome research. [345] After retinal artery occlusion, a cohort with at least 6 months of follow-up evaluated subsequent ischemic stroke or myocardial infarction as major adverse cardiovascular and cerebrovascular events, reinforcing that an ocular arterial event may signal systemic vascular risk. [370]
Complications and special clinical settings
Severe secondary hypertriglyceridemia can have an acute rather than gradual natural history. In a systematic review of 49 tamoxifen-associated hypertriglyceridemia cases, triglycerides rose from a median of 274 mg/dL before treatment to 2,534 mg/dL after initiation, and acute pancreatitis occurred in 31 patients (63.3%). [349]C These data are derived from case reports and case series and therefore cannot estimate incidence, but they identify marked triglyceride elevation and pancreatitis as important potential complications requiring prompt recognition. [349]C
Dyslipidemia has also been examined in relation to nontraditional outcomes. A nationwide propensity-score-matched cohort included more than 1.5 million patients in each exposure group to evaluate osteonecrosis of the femoral head after exclusion of major alternative causes such as corticosteroid use and alcohol-related disorders. [372]C The study was designed to clarify association, not establish that dyslipidemia causes osteonecrosis. [372]C In alcohol-associated cirrhosis, metabolic syndrome was evaluated as an independent predictor of 1-year readmission, illustrating how combined metabolic disease may worsen prognosis in chronic organ disease. [360]
Treatment, comorbidity, and risk modification
Cardiometabolic status can modify treatment-associated cardiovascular outcomes. Secondary analyses of two randomized menopausal hormone-therapy trials evaluated coronary heart disease by lipid profile, blood pressure, blood glucose, and metabolic-syndrome status in women aged 50–79 years; these findings are relevant to risk stratification when hyperlipidemia coexists with hormone therapy, although they do not establish a lipid-specific treatment effect. [308] In early-stage HER2-positive breast cancer treated without anthracyclines, 5–10-year follow-up of a randomized cardioprotection cohort assessed major adverse cardiovascular events including death, stroke, myocardial infarction, and heart-failure hospitalization, providing context for long-term cardiovascular surveillance in patients exposed to potentially cardiotoxic therapy. [368]
Real-world studies also show that prognosis is shaped by access, occupation, and treatment context. A large occupational cohort of coal-mining workers was established to characterize noncommunicable disease burden and identify high-risk occupational groups over retrospective and prospective follow-up. [250] A retrospective study of GLP-1 receptor agonists or tirzepatide in patients with hidradenitis suppurativa and type 2 diabetes or obesity evaluated mortality, cardiovascular, metabolic, psychiatric, and inflammatory outcomes, but its observational design limits causal inference regarding lipid-related benefit. [369] Studies of chest-pain imaging, laryngeal cancer risk with 5-alpha-reductase inhibitors, visual prognosis after NAION, and mortality disparities in alcohol-associated liver disease provide additional comorbidity and health-system context but do not define the natural history of hyperlipidemia itself. [233][365][281][371]
Prognostic interpretation
A favorable prognosis generally requires sustained control of atherogenic lipids together with management of blood pressure, glucose, adiposity, smoking, and other vascular risks; the cited studies consistently support multidimensional risk assessment rather than reliance on BMI or lipid concentration alone. [22]B2b[322][373][338] Prognosis becomes more concerning with severe hypertriglyceridemia, established arterial disease, metabolic syndrome, central adiposity, or major comorbidity, while evidence for individual interventions should be interpreted according to study design and the distinction between association and causation. [349]C[339][370][360]
| Feature or setting | Prognostic implication | Evidence |
|---|---|---|
| Central or visceral adiposity | May confer cardiometabolic risk despite normal BMI or absence of overt disease | [22]B2b[373] |
| High combined metabolic burden | Associated with poorer short-term stroke recovery and clinically important vascular outcomes | [338][347] |
| Severe hypertriglyceridemia | Potential for acute pancreatitis, particularly with medication-associated dyslipidemia | [349]C |
| Symptomatic arterial disease | Signals elevated recurrent vascular risk and need for timely management | [339][370] |
| Metabolic syndrome with chronic organ disease | May increase readmission risk | [360] |
Special Populations and Prevention
- ▸Assess lipid risk in the context of age, frailty, multimorbidity, kidney function, liver disease, polypharmacy, adherence, and life expectancy. [134][328]
- ▸Bempedoic acid has phase 3 evidence specifically examining efficacy and safety in adults aged **≥75 years**, including patients with maximal background statin therapy and patients with statin intolerance. [164]
- ▸For adults with CKD or CKM syndrome, combine lipid management with structured attention to diet, physical activity, body weight, smoking, alcohol, sedentary behavior, and sleep. [225][292]
- ▸After stroke, monitor LDL-C **<70 mg/dL**, blood pressure **<130/80 mm Hg**, appropriate hemoglobin A1c thresholds, and smoking status as secondary-prevention markers. [245]
- ▸GDM, adverse pregnancy outcomes, and severe pregnancy-associated acute kidney injury warrant long-term postpartum cardiovascular, kidney, metabolic, and lipid surveillance. [252][235][158]
Older adults
Older adults commonly have several concurrent cardiometabolic conditions, including hyperlipidemia, hypertension, diabetes, obesity, hepatic steatosis, and renal dysfunction; these abnormalities may cluster differently across the adult lifespan and are associated with incident cardiovascular disease (CVD). [358] Multimorbidity and complex medication regimens are particularly prevalent in adults aged ≥65 years, making treatment decisions dependent on overall cardiovascular risk, kidney and liver function, frailty, life expectancy, drug interactions, and treatment goals rather than age alone. [328][134]B2b
Bempedoic acid has been specifically evaluated in patients aged ≥75 years in phase 3 placebo-controlled studies, including a maximal-background-statin pool and a statin-intolerant cardiovascular-outcomes pool. [164]A1b The prespecified post hoc assessment examined changes in low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol, total cholesterol, and high-sensitivity C-reactive protein, together with safety, according to concomitant statin exposure. [164]A1b These data support considering bempedoic acid as an evidence-based nonstatin option when additional LDL-C reduction is required or statin exposure is limited by intolerance, while monitoring tolerability and the patient’s broader comorbidity burden. [164]A1b
Polypharmacy should be actively reviewed in older patients with cardiovascular disease or heart failure because increasing numbers of medicines are associated with greater opportunities for potentially inappropriate medication use and adverse outcomes. [134]B2b Medication reconciliation, assessment of adherence, and simplification of lipid-lowering regimens can improve the feasibility of long-term prevention, although the cited observational evidence does not establish that any specific deprescribing strategy improves lipid or cardiovascular outcomes. [134]B2b
Chronic kidney disease and cardiovascular-kidney-metabolic risk
Chronic kidney disease (CKD) is part of the cardiovascular-kidney-metabolic (CKM) disease spectrum and increases the importance of coordinated management of hyperlipidemia, blood pressure, glycemia, obesity, diet, physical activity, and smoking. [225]B2b[292] In a large prospective cohort from northwestern China, six metabolic risk factors—obesity, hepatic steatosis, hypertension, hyperlipidemia, diabetes, and renal dysfunction—were mapped across adulthood to assess age-specific cardiovascular associations and population-attributable burden. [358]
Lifestyle intervention remains central for patients with CKD. In a prospective UK Biobank analysis, management of multiple lifestyle domains—including body mass index, diet, physical activity, alcohol intake, smoking, social connection, sedentary behavior, and sleep duration—was examined in relation to metabolic dysfunction-associated steatotic liver disease risk among people with CKD and non-CKD controls. [225]B2b These findings support comprehensive, multidomain lifestyle counseling rather than isolated dietary advice, while recognizing that the study evaluated MASLD risk and not lipid-lowering treatment efficacy directly. [225]B2b
Contemporary U.S. data indicate that treatment and control of hyperlipidemia are important gaps among adults with CKM syndrome at stage 2 or above. [292] Prevention should therefore include repeated assessment of lipid treatment, achieved LDL-C, adherence, and concurrent hypertension and diabetes control, with intensification or referral when guideline-directed targets are not being reached. [292]
Patients with previous stroke
Secondary prevention after stroke requires simultaneous management of hyperglycemia, hyperlipidemia, hypertension, and tobacco exposure. [245] In the U.S. analysis, the recommended prevention thresholds included LDL-C <70 mg/dL, blood pressure <130/80 mm Hg, hemoglobin A1c <6.5% in people without diabetes and <7.0% in those with diabetes, and nonsmoking. [245] These thresholds provide practical markers for follow-up, but achievement should be individualized according to stroke mechanism, comorbidity, adverse effects, and clinician assessment. [245]
Pregnancy, gestational diabetes, and postpartum risk
Routine lipid interpretation during pregnancy requires clinical context because pregnancy-related metabolic changes and coexisting gestational diabetes mellitus (GDM) can occur together. [320]C In a retrospective cohort of 3,526 singleton pregnancies with late-pregnancy hyperlipidemia, 842 women also had GDM; the study evaluated combined associations with maternal and neonatal outcomes but was observational and cannot prove causality. [320]C
GDM is a marker of future cardiometabolic vulnerability. A large U.S. claims-based cohort evaluated incident postpartum cardiovascular, kidney, and metabolic disorders after a pregnancy complicated by GDM in women without preexisting CKM disorders. [252] Accordingly, postpartum care should include transition to primary care, assessment of weight, blood pressure, glycemia, renal health, and lipid status, with timely management of persistent abnormalities. [252]
Adverse pregnancy outcomes also identify women who may benefit from long-term cardiovascular risk surveillance. A Swedish national cohort of 2,201,446 women with singleton deliveries examined subsequent peripheral artery disease after five major adverse pregnancy outcomes and included co-sibling analyses to assess familial confounding. [235] Severe pregnancy-associated acute kidney injury is another marker of maternal vulnerability; U.S. electronic-health-record data covering 4,094,111 pregnancies examined severe disease defined by dialysis initiation or a first recorded estimated glomerular filtration rate <15 mL/min/1.73 m². [158]B2b These findings support documenting adverse pregnancy and kidney events in the long-term cardiovascular risk history, including when considering later lipid prevention. [235][158]B2b
Prevention across the life course
Metabolic risk factors are present in younger adults as well as older populations, so prevention should begin with identification of obesity, hypertension, diabetes, renal dysfunction, hepatic steatosis, hyperlipidemia, smoking, diet, and physical inactivity rather than waiting for established CVD. [358] Social determinants may affect access to preventive care; adverse social determinants were associated with prolonged unsuccessful conception and infertility-related healthcare contact in U.S. women, illustrating the relevance of access and social context when delivering preventive services. [367] Regular follow-up is essential because prolonged lapses in physician care are documented among adults with diabetes, a population requiring ongoing cardiometabolic monitoring. [329]
Hyperlipidemia may coexist with other age-related conditions. Clinic-based data have examined subtype-specific associations between hyperlipidemia and age-related cataract, while carotid-stenosis research has evaluated hyperlipidemia alongside inflammatory and immunonutritional measures. [121]C4[325] These studies are observational and should not be used to infer that lipid treatment prevents cataract or carotid stenosis, but they reinforce the value of integrated risk assessment rather than treating lipid values in isolation. [121]C4[325]
| Population | Prevention priorities | Evidence |
|---|---|---|
| Adults aged ≥75 years | Individualize LDL-lowering; consider nonstatin therapy when additional reduction is needed or statin exposure is limited; review safety and polypharmacy. | [164]A1b[134]B2b |
| CKD or CKM syndrome | Address lipids together with weight, diet, activity, smoking, blood pressure, glycemia, sleep, and sedentary behavior. | [225]B2b[292] |
| Previous stroke | Target LDL-C <70 mg/dL, blood pressure <130/80 mm Hg, appropriate A1c thresholds, and nonsmoking when clinically appropriate. | [245] |
| History of GDM or adverse pregnancy outcome | Establish postpartum and lifelong cardiovascular, kidney, metabolic, and lipid follow-up. | [252][235][158]B2b |
| Younger or socially vulnerable adults | Identify metabolic risk early and reduce barriers to continuous preventive care. | [358][367][329] |
References
- [1]
McCrindle BW, Urbina EM, Dennison BA et al.. “Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing.” Circulation (2007). PMID: 17377073 ↗
L1GUIDELINECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [2]
Pasupathy S, Air T, Dreyer RP et al.. “Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.” Circulation (2015). PMID: 25587100 ↗
L2SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [3]
Wiegman A, Peterson AL, Hegele RA et al.. “Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.” Circulation (2025). PMID: 40391436 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [4]
Cooper LA, Marsteller JA, Carson KA et al.. “Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial.” Circulation (2024). PMID: 39008556 ↗
L1RCTCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [5]
Paramsothy P, Knopp RH, Bertoni AG et al.. “Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis).” Journal of the American College of Cardiology (2010). PMID: 20846602 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup - [6]
Stone GW, Selker HP, Thiele H et al.. “Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials.” Journal of the American College of Cardiology (2016). PMID: 27056772 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History - [7]
Cho L, Davis M, Elgendy I et al.. “Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.” Journal of the American College of Cardiology (2020). PMID: 32439010 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention - [8]
Ridker PM, Lei L, Louie MJ et al.. “Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.” Circulation (2023). PMID: 37929602 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Complications - [9]
Boyer TM, Barrett RB, Xiong C et al.. “Hypertensive Disorders of Pregnancy and Premature Cardiovascular Disease in a Diverse Cohort of Young US Women.” Circulation (2025). PMID: 41697979 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Special Populations and Prevention - [10]
Mosley JD, Benson MD, Smith JG et al.. “Probing the Virtual Proteome to Identify Novel Disease Biomarkers.” Circulation (2018). PMID: 30571344 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup - [11]
Jayaraman R, Reinier K, Nair S et al.. “Risk Factors of Sudden Cardiac Death in the Young: Multiple-Year Community-Wide Assessment.” Circulation (2017). PMID: 29269388 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, Prognosis and Natural History - [12]
Covani M, Niccoli G, Fujimoto D et al.. “Plaque Vulnerability and Cardiovascular Risk Factor Burden in Acute Coronary Syndrome: An Optical Coherence Tomography Analysis.” Journal of the American College of Cardiology (2025). PMID: 40634017 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Complications - [13]
Elgendy IY, Gad MM, Mahmoud AN et al.. “Acute Stroke During Pregnancy and Puerperium.” Journal of the American College of Cardiology (2020). PMID: 31948647 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention - [14]
Krishnan P, Farhan S, Schneider P et al.. “Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.” Journal of the American College of Cardiology (2022). PMID: 36137674 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [15]
DeFilippis EM, Singh A, Divakaran S et al.. “Cocaine and Marijuana Use Among Young Adults With Myocardial Infarction.” Journal of the American College of Cardiology (2018). PMID: 29535062 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Prognosis and Natural History - [16]
Ahn JM, Lee KH, Yoo SY et al.. “Prognosis of Variant Angina Manifesting as Aborted Sudden Cardiac Death.” Journal of the American College of Cardiology (2016). PMID: 27386766 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [17]
Martin SS, Niles JK, Kaufman HW et al.. “Lipid distributions in the Global Diagnostics Network across five continents.” European heart journal (2023). PMID: 37392135 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy - [18]
Ditkofsky N, Hanna T. “Images in Clinical Medicine. Spontaneous Retropharyngeal Hematoma.” The New England journal of medicine (2016). PMID: 26789902 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management - [19]
Otto CM, Newby DE, Hillis GS. “Calcific Aortic Stenosis: A Review.” JAMA (2024). PMID: 39527048 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Complications, Prognosis and Natural History - [20]
Tilg H, Petta S, Stefan N et al.. “Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review.” JAMA (2026). PMID: 41212550 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [21]
McFarland R, Hyslop LA, Feeney C et al.. “Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease.” The New England journal of medicine (2025). PMID: 40689593 ↗
L4OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Special Populations and Prevention - [22]
Bogner B, Jung M, Reisert M et al.. “Opportunistic screening for incident cardiometabolic disease in metabolically healthy non-obese individuals: a prospective cohort study.” Cardiovascular diabetology (2026). PMID: 42387503 ↗
L2COHORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History - [23]
Wabnitz AM. “Management of Large Artery Atherosclerosis.” Continuum (Minneapolis, Minn.) (2026). PMID: 42233827 ↗
L5CASE_REPORTCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [24]
Qiao Y, Suri FK, Zhang Y et al.. “Racial Differences in Prevalence and Risk for Intracranial Atherosclerosis in a US Community-Based Population.” JAMA cardiology (2017). PMID: 29094154 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy - [25]
van Rosendael AR, Narula J, Lin FY et al.. “Association of High-Density Calcified 1K Plaque With Risk of Acute Coronary Syndrome.” JAMA cardiology (2020). PMID: 31968065 ↗
L3OTHERCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Acute and Initial Management, History and Evolution of Treatment - [26]
O'Connor KD, Brophy T, Fonarow GC et al.. “Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure: Findings From Get With The Guidelines-Heart Failure.” Circulation. Heart failure (2020). PMID: 32207996 ↗
L2OTHERCited in: Definition, Classification and Nomenclature, Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [27]
Yeh CF, Ianalieva L, Wong HK et al.. “Nanomedicine-based theranostics in atherosclerotic cardiovascular diseases.” Journal of biomedical science (2026). PMID: 42069590 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation - [28]
Atalla M, Gupta V, Khalid M et al.. “Cardiology: What You May Have Missed in 2025.” Annals of internal medicine (2026). PMID: 41974015 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Nomenclature, Clinical Presentation - [29]
Lei J, Lu X, Liang Q. “Lipemic anterior chamber mimicking uveitis in severe hypertriglyceridemia: a case report and literature review.” BMC ophthalmology (2026). PMID: 42087131 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Complications - [30]
Alzoubi M, Omar Saleh A, Omari FA et al.. “Asymptomatic gallstones: Cumulative incidence proportion, incidence rate, and risk factors for symptoms development: Systematic review and meta-analysis.” PloS one (2026). PMID: 41886405 ↗
L1SR_OBSCited in: Definition, Classification and Nomenclature, Clinical Presentation - [31]
Kayani AMA, Umar MF, Navarro-Martinez D et al.. “Lipid-modifying efficacy and safety of obicetrapib in high-risk cardiovascular patients: A systematic review and meta-analysis.” Vascular diseases (Paris, France) (2026). PMID: 41763910 ↗
L5SR_OBSCited in: Definition, Classification and Nomenclature - [32]
Tang L, He Y, Qiao Z et al.. “Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.” Frontiers in immunology (2026). PMID: 42344901 ↗
L4CASE_REPORTCited in: Definition, Classification and Nomenclature, Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [33]
Mahmoodi BK, Cushman M, Anne Næss I et al.. “Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective Studies.” Circulation (2016). PMID: 27831499 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications - [34]
Purnell JQ, Zinman B, Brunzell JD. “The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study.” Circulation (2012). PMID: 23212717 ↗
L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [35]
Xie X, Shi X, Zhang Y et al.. “Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study.” Journal of the American College of Cardiology (2025). PMID: 40167414 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [36]
Haine A, Kavanagh S, Berger JS et al.. “Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease.” Journal of the American College of Cardiology (2020). PMID: 32057375 ↗
L2RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History - [37]
Boccara F, Kumar PN, Caramelli B et al.. “Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.” Journal of the American College of Cardiology (2020). PMID: 32234462 ↗
L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [38]
Shaw AT, Bauer TM, de Marinis F et al.. “First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.” The New England journal of medicine (2020). PMID: 33207094 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [39]
Ridker PM, Danielson E, Fonseca FA et al.. “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.” The New England journal of medicine (2008). PMID: 18997196 ↗
L1RCTCited in: Epidemiology and Risk Factors, History and Evolution of Treatment, Prognosis and Natural History - [40]
Basaria S, Coviello AD, Travison TG et al.. “Adverse events associated with testosterone administration.” The New England journal of medicine (2010). PMID: 20592293 ↗
L1RCTCited in: Epidemiology and Risk Factors, Clinical Presentation, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [41]
Hudes G, Carducci M, Tomczak P et al.. “Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.” The New England journal of medicine (2007). PMID: 17538086 ↗
L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [42]
Rossebø AB, Pedersen TR, Boman K et al.. “Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.” The New England journal of medicine (2008). PMID: 18765433 ↗
L1RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Interventional and Device Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [43]
Kashani A, Phillips CO, Foody JM et al.. “Risks associated with statin therapy: a systematic overview of randomized clinical trials.” Circulation (2006). PMID: 17159064 ↗
L1REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, Complications - [44]
Hong KN, Fuster V, Rosenson RS et al.. “How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD.” Journal of the American College of Cardiology (2017). PMID: 29050566 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Complications - [45]
Miller JD, Aronis KN, Chrispin J et al.. “Obesity, Exercise, Obstructive Sleep Apnea, and Modifiable Atherosclerotic Cardiovascular Disease Risk Factors in Atrial Fibrillation.” Journal of the American College of Cardiology (2015). PMID: 26718677 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy, Complications - [46]
Chou R, Dana T, Blazina I et al.. “Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2016). PMID: 27838722 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History - [47]
Machline-Carrion MJ, Soares RM, Damiani LP et al.. “Effect of a Multifaceted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial.” JAMA cardiology (2019). PMID: 30942842 ↗
L1RCTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [48]
Ikramuddin S, Korner J, Lee WJ et al.. “Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial.” JAMA (2013). PMID: 23736733 ↗
L1RCTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [49]
Kempen JH, Altaweel MM, Holbrook JT et al.. “Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.” JAMA (2017). PMID: 28477440 ↗
L2RCTCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History - [50]
Birger M, Kaldjian AS, Roth GA et al.. “Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016.” Circulation (2021). PMID: 33926203 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [51]
Saha P, Potiny P, Rigdon J et al.. “Substantial Cardiovascular Morbidity in Adults With Lower-Complexity Congenital Heart Disease.” Circulation (2019). PMID: 30813762 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [52]
DeCarlo C, Latz CA, Boitano LT et al.. “Prognostication of Asymptomatic Penetrating Aortic Ulcers: A Modern Approach.” Circulation (2021). PMID: 34376058 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, History and Evolution of Treatment, Complications, Prognosis and Natural History - [53]
Caleyachetty R, Thomas GN, Toulis KA et al.. “Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women.” Journal of the American College of Cardiology (2017). PMID: 28911506 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications - [54]
Lee HH, Crawford EB, Cho SMJ et al.. “Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023.” Journal of the American College of Cardiology (2025). PMID: 41295934 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy - [55]
Sinha A, Ning H, Carnethon MR et al.. “Race- and Sex-Specific Population Attributable Fractions of Incident Heart Failure: A Population-Based Cohort Study From the Lifetime Risk Pooling Project.” Circulation. Heart failure (2021). PMID: 33761754 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification - [56]
Markus MRP, Ittermann T, Mariño Coronado J et al.. “Low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events.” European heart journal (2025). PMID: 40320753 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Complications - [57]
Wu J, Zafar MA, Liu Y et al.. “Fate of the unoperated ascending thoracic aortic aneurysm: three-decade experience from the Aortic Institute at Yale University.” European heart journal (2023). PMID: 36994934 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, History and Evolution of Treatment, Complications, Prognosis and Natural History - [58]
Rafiee M, Mehmandoost S, Harandi F et al.. “Prevalence of Hypertension, Diabetes, Obesity, and High Cholesterol Among Older People Living With HIV: A Systematic Review and Meta-Analysis.” AIDS research and treatment (2026). PMID: 42358331 ↗
L1SR_OBSCited in: Epidemiology and Risk Factors - [59]
Magnussen C, Alegre-Diaz J, Al-Nasser LA et al.. “Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.” The New England journal of medicine (2025). PMID: 40162648 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Clinical Presentation, Acute and Initial Management, Complications, Prognosis and Natural History - [60]
Wang N, Li M, Lu M et al.. “Therapeutic effects and mechanisms of Artemisia species on metabolic diseases: A systematic review.” Medicine (2026). PMID: 42332507 ↗
L5SR_OBSCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy - [61]
Sadeghi E, Kozlov M, Hasan N et al.. “Associations between psychiatric disorders and medication use, and retinal occlusion: a large-scale retrospective cohort study.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42371026 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History - [62]
Thangjui S, Knutsen K, Hollowell B et al.. “Natural history and outcomes of post-operative atrial fibrillation after non-cardiac surgery: a clinically adjudicated single-center retrospective study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42370998 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History - [63]
Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy - [64]
Liu M, Marinacci LX, Joynt Maddox KE et al.. “Cardiovascular Health Among Rural and Urban US Adults-Healthcare, Lifestyle, and Social Factors.” JAMA cardiology (2025). PMID: 40163358 ↗
L2OTHERCited in: Epidemiology and Risk Factors - [65]
Oseran AS, Sun T, Wadhera RK. “Health Care Access and Management of Cardiovascular Risk Factors Among Working-Age Adults With Low Income by State Medicaid Expansion Status.” JAMA cardiology (2022). PMID: 35648424 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy - [66]
Tung EL, Wroblewski KE, Makelarski JA et al.. “Childhood Parental Incarceration and Adult-Onset Hypertension and Cardiovascular Risk.” JAMA cardiology (2023). PMID: 37647038 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Complications, Prognosis and Natural History - [67]
Gong J, Vaduganathan M, Wadhera RK. “Chronic Kidney Disease Prevalence and Awareness Among US Adults.” JAMA cardiology (2026). PMID: 41205219 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Long-term Guideline-Directed Therapy, Special Populations and Prevention - [68]
Brandt EJ, Chang T, Leung C et al.. “Food Insecurity Among Individuals With Cardiovascular Disease and Cardiometabolic Risk Factors Across Race and Ethnicity in 1999-2018.” JAMA cardiology (2022). PMID: 36170056 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Complications - [69]
Whelton SP, McEvoy JW, Shaw L et al.. “Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors.” JAMA cardiology (2020). PMID: 32936272 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Clinical Presentation, Severity Staging and Risk Stratification - [70]
Bansal N, Katz R, Robinson-Cohen C et al.. “Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies.” JAMA cardiology (2017). PMID: 28002548 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Special Populations and Prevention - [71]
Honigberg MC, Zekavat SM, Aragam K et al.. “Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease.” JAMA (2019). PMID: 31738818 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Prognosis and Natural History - [72]
Aggarwal R, Yeh RW, Joynt Maddox KE et al.. “Cardiovascular Risk Factor Prevalence, Treatment, and Control in US Adults Aged 20 to 44 Years, 2009 to March 2020.” JAMA (2023). PMID: 36871237 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, History and Evolution of Treatment - [73]
Record NB, Onion DK, Prior RE et al.. “Community-wide cardiovascular disease prevention programs and health outcomes in a rural county, 1970-2010.” JAMA (2015). PMID: 25585326 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Acute and Initial Management, Long-term Guideline-Directed Therapy, Special Populations and Prevention - [74]
Gelfand JM, Neimann AL, Shin DB et al.. “Risk of myocardial infarction in patients with psoriasis.” JAMA (2006). PMID: 17032986 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism, Prognosis and Natural History - [75]
McTigue K, Larson JC, Valoski A et al.. “Mortality and cardiac and vascular outcomes in extremely obese women.” JAMA (2006). PMID: 16820550 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Severity Staging and Risk Stratification, Complications, Prognosis and Natural History - [76]
Qin H, Tromp J, Ter Maaten JM et al.. “Clinical and Proteomic Risk Profiles of New-Onset Heart Failure in Men and Women.” JACC. Heart failure (2024). PMID: 39708029 ↗
L2OTHERCited in: Epidemiology and Risk Factors, Diagnosis and Workup, Severity Staging and Risk Stratification, History and Evolution of Treatment, Complications - [77]
Xu Y, Yang H, Xu Q et al.. “Distinct From the Adult Paradigm: Re-Evaluate the Pathophysiological and Therapeutic Framework in Children and Adolescent Hyperlipidaemia.” Current obesity reports (2026). PMID: 42287583 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology and Mechanism - [78]
Wang S, Wang L, Shi D et al.. “Relationship between hyperlipidemia and lumbar disc degeneration in patients with low back pain: an observational retrospective study.” Frontiers in physiology (2026). PMID: 42318506 ↗
L3COHORTCited in: Epidemiology and Risk Factors, Prognosis and Natural History - [79]
Yang W, Hu W, Pan Y et al.. “Impact of preoperative dual antiplatelet therapy vs. aspirin monotherapy on perioperative outcomes in carotid endarterectomy patients: a retrospective cohort study.” International journal of clinical pharmacy (2026). PMID: 42171869 ↗
L2COHORTCited in: Epidemiology and Risk Factors, Complications - [80]
Piña IL, Zheng Q, She L et al.. “Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).” Circulation (2018). PMID: 29459462 ↗
L1RCTCited in: Pathophysiology and Mechanism, Acute and Initial Management, Prognosis and Natural History - [81]
Ghattas A, Griffiths HR, Devitt A et al.. “Monocytes in coronary artery disease and atherosclerosis: where are we now?” Journal of the American College of Cardiology (2013). PMID: 23973684 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Acute and Initial Management, Long-term Guideline-Directed Therapy, Prognosis and Natural History - [82]
Bravata DM, Smith-Spangler C, Sundaram V et al.. “Using pedometers to increase physical activity and improve health: a systematic review.” JAMA (2007). PMID: 18029834 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Clinical Presentation - [83]
Lee JK, Grace KA, Taylor AJ. “Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial.” JAMA (2006). PMID: 17101639 ↗
L1RCTCited in: Pathophysiology and Mechanism, Clinical Presentation, History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention - [84]
Gu H, Wen J, Liu Y et al.. “SREBP1 Transactivation of NHE3 Impairs Cardiac Contraction and Aggravates Heart Failure.” Circulation (2026). PMID: 42170742 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [85]
Drechsler M, Megens RT, van Zandvoort M et al.. “Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis.” Circulation (2010). PMID: 20956207 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Complications - [86]
Li X, Zhu M, Penfold ME et al.. “Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue.” Circulation (2013). PMID: 24374972 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [87]
Koskinas KC, Feldman CL, Chatzizisis YS et al.. “Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study.” Circulation (2010). PMID: 20439786 ↗
L5OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup, History and Evolution of Treatment, Prognosis and Natural History - [88]
Lerman JB, Joshi AA, Chaturvedi A et al.. “Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study.” Circulation (2017). PMID: 28483812 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Diagnosis and Workup - [89]
Seehaus S, Shahzad K, Kashif M et al.. “Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability.” Circulation (2009). PMID: 19687358 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [90]
Xiao H, Lu M, Lin TY et al.. “Sterol regulatory element binding protein 2 activation of NLRP3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility.” Circulation (2013). PMID: 23838163 ↗
L5OTHERCited in: Pathophysiology and Mechanism - [91]
Alvi RM, Neilan AM, Tariq N et al.. “Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure.” Journal of the American College of Cardiology (2018). PMID: 30049313 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Diagnosis and Workup, Long-term Guideline-Directed Therapy, Prognosis and Natural History - [92]
Jaguan D, Gratz BW, Jaguan SI et al.. “Treatment of Generalized Granuloma Annulare with JAK Inhibitors: Systematic Review.” Clinical, cosmetic and investigational dermatology (2026). PMID: 42111237 ↗
L2SR_OBSCited in: Pathophysiology and Mechanism, Complications - [93]
Oshitari T. “Pathogenesis of Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with COVID-19.” International journal of molecular sciences (2026). PMID: 41898506 ↗
L5CASE_REPORTCited in: Pathophysiology and Mechanism - [94]
King WC, Hinerman AS, Belle SH et al.. “Comparison of the Performance of Common Measures of Weight Regain After Bariatric Surgery for Association With Clinical Outcomes.” JAMA (2018). PMID: 30326125 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [95]
Wijeysundera HC, Machado M, Farahati F et al.. “Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005.” JAMA (2010). PMID: 20460623 ↗
L2OTHERCited in: Pathophysiology and Mechanism, Clinical Presentation, Acute and Initial Management - [96]
Hall JE, Omoto ACM, do Carmo JM et al.. “Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system.” Clinical science (London, England : 1979) (2026). PMID: 42340064 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Complications - [97]
Foroohar T, Berk-Krauss J, Caplan AS et al.. “Granuloma Annulare: An Updated Review of Epidemiology, Molecular Pathogenesis, and Management.” Journal of the American Academy of Dermatology (2026). PMID: 42320859 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Long-term Guideline-Directed Therapy - [98]
Subauste CS. “Advances in the Role of the CD40-CD154 Pathway in the Pathogenesis of Diabetic Retinopathy.” International journal of molecular sciences (2026). PMID: 42123447 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [99]
Jovanovic K, Jovandaric MZ, Jovanovic D et al.. “Altered Lipid Profile and Oxidative Stress During Pregnancy: Impact on the Fetus and Risk of Metabolic Disorders in Adulthood.” International journal of molecular sciences (2026). PMID: 42123329 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism, Special Populations and Prevention - [100]
Lin L, Zi S, Zhang G et al.. “Advances in the pathogenesis of MASLD and its association with neutrophils.” Frontiers in medicine (2026). PMID: 41889493 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [101]
Kaplan R, Berni M, Caliogna L et al.. “Pathogenesis of Shoulder Calcific Tendinopathy.” International journal of molecular sciences (2026). PMID: 41828406 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [102]
Zhang M, Liu WL, Xu G et al.. “Hyperlipidemia in membranous nephropathy.” Clinical kidney journal (2026). PMID: 41822057 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [103]
Hsu JJ, Li Q, Tintut Y et al.. “Considerations in the Use of Mouse Models of Vascular and Valvular Calcification.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41739911 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology and Mechanism - [104]
Navar-Boggan AM, Peterson ED, D'Agostino RB et al.. “Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease.” Circulation (2015). PMID: 25623155 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [105]
Pande RL, Perlstein TS, Beckman JA et al.. “Association of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004.” Circulation (2008). PMID: 18559705 ↗
L4OTHERCited in: Clinical Presentation - [106]
Fracassi F, Crea F, Sugiyama T et al.. “Healed Culprit Plaques in Patients With Acute Coronary Syndromes.” Journal of the American College of Cardiology (2019). PMID: 31072568 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis and Workup, Prognosis and Natural History - [107]
Kanner AM, Bicchi MM. “Antiseizure Medications for Adults With Epilepsy: A Review.” JAMA (2022). PMID: 35380580 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [108]
Choi SI, Heo Y, Ryu SW et al.. “Safety, Efficacy, and Quality of Life Outcomes of Bariatric and Metabolic Surgery in Korea: A Prospective Multicenter Cohort Study.” Obesity surgery (2026). PMID: 42098468 ↗
L2COHORTCited in: Clinical Presentation - [109]
Lu Z, Zong D, Yang Z et al.. “Risk factors for rebleeding in acute lower gastrointestinal bleeding: a systematic review and meta-analysis.” International journal of colorectal disease (2026). PMID: 42287444 ↗
L1SR_OBSCited in: Clinical Presentation, Acute and Initial Management - [110]
Tu Y, Sun Y, Zhu M et al.. “Bilateral extensive adult-onset limbal xanthogranuloma invading the deep corneal stroma: a case report and literature review.” Frontiers in medicine (2026). PMID: 42369137 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment - [111]
Laffin LJ, Bruemmer D, Garcia M et al.. “Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.” Journal of the American College of Cardiology (2022). PMID: 36351465 ↗
L1RCTCited in: Diagnosis and Workup, History and Evolution of Treatment, Complications - [112]
Miller JD, Weiss RM, Serrano KM et al.. “Lowering plasma cholesterol levels halts progression of aortic valve disease in mice.” Circulation (2009). PMID: 19433756 ↗
L5OTHERCited in: Diagnosis and Workup, Complications - [113]
Roifman I, Therrien J, Ionescu-Ittu R et al.. “Coarctation of the aorta and coronary artery disease: fact or fiction?” Circulation (2012). PMID: 22675158 ↗
L2OTHERCited in: Diagnosis and Workup - [114]
Masri A, Kalahasti V, Svensson LG et al.. “Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With a Trileaflet Aortic Valve and a Dilated Aorta.” Circulation (2016). PMID: 27770001 ↗
L2OTHERCited in: Diagnosis and Workup, Prognosis and Natural History - [115]
Miller TD, Redberg RF, Wackers FJ. “Screening asymptomatic diabetic patients for coronary artery disease: why not?” Journal of the American College of Cardiology (2006). PMID: 16904546 ↗
L5OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification, Prognosis and Natural History - [116]
Cavusoglu E, Kornecki E, Sobocka MB et al.. “Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis.” Journal of the American College of Cardiology (2007). PMID: 17964041 ↗
L4OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification - [117]
Civeira F, Jarauta E, Cenarro A et al.. “Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.” Journal of the American College of Cardiology (2008). PMID: 19007590 ↗
L4OTHERCited in: Diagnosis and Workup, Severity Staging and Risk Stratification - [118]
Zeng Y, Sun Y. “Predictive value of serial dynamic lipid monitoring for pathologic complete response to neoadjuvant chemotherapy in luminal breast cancer: a retrospective study integrating metabolic and clinical indicators.” BMC women's health (2026). PMID: 41952141 ↗
L2COHORTCited in: Diagnosis and Workup, Severity Staging and Risk Stratification - [119]
Chiang LH, Tsai PH, Chen YF et al.. “Real-World Safety and Retention of Tofacitinib in Elderly Versus Non-elderly Patients With Rheumatoid Arthritis: A Retrospective Cohort Study in Taiwan.” International journal of rheumatic diseases (2026). PMID: 42177625 ↗
L2COHORTCited in: Diagnosis and Workup, Acute and Initial Management, Long-term Guideline-Directed Therapy - [120]
Zhou X, Yang C, Zou T et al.. “Shared Genetic Risk Between Acute Pancreatitis and Metabolic Syndrome Converges on a BCAT1-Positive Fibroblast Subpopulation and MAPK14-Driven Inflammation.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2026). PMID: 42402174 ↗
L2OTHERCited in: Diagnosis and Workup, Acute and Initial Management - [121]
Qin Y, Hong Y, Ning L et al.. “Subtype-Specific Associations Between Hyperlipidemia and Age-Related Cataract: A Clinic-Based Cross-Sectional Study.” Clinical interventions in aging (2026). PMID: 42333214 ↗
L4OTHERCited in: Diagnosis and Workup - [122]
Li S, Wen ZQ, Yan P. “Zexie decoction alleviates hyperlipidemia through modulation of the PPAR signaling pathway and lysophospholipid metabolism.” Pharmaceutical biology (2026). PMID: 42295113 ↗
L5OTHERCited in: Diagnosis and Workup - [123]
Huang X, Lu N, Yu H et al.. “The impact of 1-hour plasma glucose on the metabolic characteristics and pregnancy outcomes in polycystic ovary syndrome.” Nutrition & diabetes (2026). PMID: 42285965 ↗
L2OTHERCited in: Diagnosis and Workup - [124]
Yin WL, Peng L, Zhang JH et al.. “Hyperlipid-Related Alzheimer's Disease: Potential Role of CircUCK2/miR-24-3p/p38 Axis in Neuronal Damage.” Comprehensive Physiology (2026). PMID: 42281258 ↗
L3OTHERCited in: Diagnosis and Workup - [125]
Nagaoka M, Nagaoka K, Kajitani N et al.. “Serum Mac-2 Binding Protein Glycan Isomer and Cerebral White Matter Injury in Older Adults: A Hepatic-Cerebral Link.” Hepatology research : the official journal of the Japan Society of Hepatology (2026). PMID: 42246447 ↗
L4OTHERCited in: Diagnosis and Workup - [126]
Zhong XY, Peng R, Deng Y et al.. “Drinking Patterns and CT/MRI Feature-Based Nomogram Models Can More Accurately Predict Acute Alcoholic Pancreatitis Recurrence.” Alcohol, clinical & experimental research (2026). PMID: 42246257 ↗
L3OTHERCited in: Diagnosis and Workup - [127]
Li W, Fredriksson M, Dernroth DN et al.. “Sex differences in iron stores and associations of body iron with cardiovascular risk factors in the middle-aged general population.” Frontiers in endocrinology (2026). PMID: 42222086 ↗
L4OTHERCited in: Diagnosis and Workup - [128]
Ata HS, Abd El-Rady NM, Gomaa AMS et al.. “Neurodegenerative and Glial Physiology in Diabetic Retinopathy: Dissociated Effects of Forskolin on Neuronal Survival and Glial Activation.” Biomedicines (2026). PMID: 42193428 ↗
L5OTHERCited in: Diagnosis and Workup - [129]
Ridker PM, MacFadyen J, Cressman M et al.. “Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial.” Journal of the American College of Cardiology (2010). PMID: 20206456 ↗
L1TRIAL_NONRANDOMCited in: Severity Staging and Risk Stratification, Special Populations and Prevention - [130]
Zhang D, Jiang X, Fang P et al.. “Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine beta-synthase-deficient mice.” Circulation (2009). PMID: 19858416 ↗
L5OTHERCited in: Severity Staging and Risk Stratification - [131]
Fu J, Zhou Y, Zhang F et al.. “Risk factors for postoperative venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.” Frontiers in medicine (2026). PMID: 41613334 ↗
L2SR_OBSCited in: Severity Staging and Risk Stratification - [132]
Wu HL, Chen JT, Cata JP et al.. “Preoperative proprotein convertase subtilisin/kexin type 9 inhibitors versus statins and postoperative adverse events in hyperlipidemia: A nationwide, active-comparator cohort study.” Atherosclerosis (2026). PMID: 42048760 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, Prognosis and Natural History - [133]
Wolff K, Gumin D, Shqara RA et al.. “Risk factors and predictive modeling for occult endometrial cancer in women with atypical hyperplasia: a retrospective study.” Archives of gynecology and obstetrics (2026). PMID: 41611996 ↗
L3COHORTCited in: Severity Staging and Risk Stratification - [134]
Zhong W, Jiang F, Wang H et al.. “Polypharmacy, determinants, and adverse outcomes in elderly patients with heart failure: a multicenter retrospective cohort study of 7,361 subjects.” BMC geriatrics (2026). PMID: 41588351 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, Special Populations and Prevention - [135]
Li J, Wang Y, Chen Z et al.. “Association between autologous blood transfusion and serum creatinine in patients with acute Stanford-A aortic dissection based on a retrospective study.” BMC anesthesiology (2026). PMID: 41566236 ↗
L3COHORTCited in: Severity Staging and Risk Stratification - [136]
Zhang Y, Zhang X, Song H et al.. “Predicting short-term composite outcome risk in heart failure patients using a machine learning model incorporating UHR: a retrospective cohort study.” Frontiers in nutrition (2026). PMID: 42305866 ↗
L2COHORTCited in: Severity Staging and Risk Stratification, History and Evolution of Treatment - [137]
Shen Q, Zhou S, Ouyang X et al.. “Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: a real-world cohort study.” Heart & lung : the journal of critical care (2026). PMID: 42030746 ↗
L2COHORTCited in: Severity Staging and Risk Stratification - [138]
Cheng ZT, Wang JL, Zhao YB et al.. “Association Between the Lactate-to-Albumin Ratio and ICU/In-Hospital Mortality in Critically Ill Patients With Comorbid Type 2 Diabetes Mellitus : A Cohort Study Utilizing the MIMIC-IV Database.” Emergency medicine international (2026). PMID: 41982276 ↗
L2COHORTCited in: Severity Staging and Risk Stratification - [139]
Vega RB, O'Mahony G, Barbour AM et al.. “Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients.” Circulation (2026). PMID: 42137960 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [140]
Ballantyne CM, Gaudet D, Rosenson RS et al.. “Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and Number in Hypertriglyceridemia.” Journal of the American College of Cardiology (2025). PMID: 40099777 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [141]
McKenney JM, Farnier M, Lo KW et al.. “Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.” Journal of the American College of Cardiology (2006). PMID: 16630994 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [142]
Rosenson RS, Gaudet D, Hegele RA et al.. “Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.” The New England journal of medicine (2024). PMID: 38809174 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [143]
Blom DJ, Hala T, Bolognese M et al.. “A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.” The New England journal of medicine (2014). PMID: 24678979 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [144]
Ballantyne CM, Vasas S, Azizad M et al.. “Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.” The New England journal of medicine (2024). PMID: 38804517 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [145]
Ridker PM, Tardif JC, Amarenco P et al.. “Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.” The New England journal of medicine (2017). PMID: 28304227 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications - [146]
Puzziferri N, Roshek TB, Mayo HG et al.. “Long-term follow-up after bariatric surgery: a systematic review.” JAMA (2014). PMID: 25182102 ↗
L2SR_OBSCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications, Prognosis and Natural History - [147]
Berthold HK, Unverdorben S, Degenhardt R et al.. “Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.” JAMA (2006). PMID: 16705107 ↗
L1RCTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Prognosis and Natural History - [148]
Smilowitz NR, Mega JL, Berger JS. “Duration of anticoagulation for venous thromboembolic events.” Circulation (2014). PMID: 25539522 ↗
L4CASE_REPORTCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, History and Evolution of Treatment - [149]
Schwab RD, Degaramo D, Hong SJ et al.. “Chimeric Antigen Receptor Regulatory T Cells Targeted Against Oxidized Low-Density Lipoprotein Reduce Atherosclerotic Plaque Development.” Circulation (2025). PMID: 41268661 ↗
L5OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy - [150]
Al Mheid I, Quyyumi AA. “Vitamin D and Cardiovascular Disease: Controversy Unresolved.” Journal of the American College of Cardiology (2017). PMID: 28662812 ↗
L5REVIEW_NARRATIVECited in: Acute and Initial Management, Long-term Guideline-Directed Therapy, Complications - [151]
Moccetti F, Brown E, Xie A et al.. “Myocardial Infarction Produces Sustained Proinflammatory Endothelial Activation in Remote Arteries.” Journal of the American College of Cardiology (2018). PMID: 30139430 ↗
L5OTHERCited in: Acute and Initial Management - [152]
Hsu J, Price M, Huang J et al.. “Unintended consequences of caps on Medicare drug benefits.” The New England journal of medicine (2006). PMID: 16738271 ↗
L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy - [153]
Jackevicius CA, Tu JV, Ross JS et al.. “Use of ezetimibe in the United States and Canada.” The New England journal of medicine (2008). PMID: 18375999 ↗
L2OTHERCited in: Acute and Initial Management, Long-term Guideline-Directed Therapy - [154]
Meng X, Ou Y, Mao J et al.. “LDAR outperforms other albumin-derived indices in predicting 28-day ICU mortality in critically ill myocardial infarction patients: a two-cohort study.” Frontiers in medicine (2026). PMID: 42221102 ↗
L2COHORTCited in: Acute and Initial Management - [155]
Whitmer RA, Karter AJ, Yaffe K et al.. “Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus.” JAMA (2009). PMID: 19366776 ↗
L2OTHERCited in: Acute and Initial Management - [156]
Choi H, Choi J, Maksatbekov C et al.. “Predictors of in-hospital case-fatality in patients with stroke at the National Hospital of the Kyrgyz Republic: a retrospective cohort study.” BMC neurology (2026). PMID: 42216139 ↗
L2COHORTCited in: Acute and Initial Management - [157]
Devanita S LA, Adhyatma IGR, Cahya KKD. “Risk factors of cerebral vasospasm associated with ruptured arterio-venous malformation: A systematic review and meta-analysis.” Journal of cerebrovascular and endovascular neurosurgery (2026). PMID: 42374993 ↗
L2SR_OBSCited in: Acute and Initial Management - [158]
Liao HW, Luyckx V, Ostermann M et al.. “Severe Pregnancy-Associated Acute Kidney Injury and Maternal Vulnerability.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2026). PMID: 42406539 ↗
L2OTHERCited in: Acute and Initial Management - [159]
Jiang Q, Wang R, He Y et al.. “Construction and Validation of a 90-Day Mortality Risk Prediction Model Based on Interpretable Machine Learning for Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy.” Journal of clinical medicine (2026). PMID: 42355869 ↗
L2OTHERCited in: Acute and Initial Management - [160]
Foody JM, Shah R, Galusha D et al.. “Statins and mortality among elderly patients hospitalized with heart failure.” Circulation (2006). PMID: 16490817 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History, Special Populations and Prevention - [161]
Bair TL, Muhlestein JB, May HT et al.. “Surgical revascularization is associated with improved long-term outcomes compared with percutaneous stenting in most subgroups of patients with multivessel coronary artery disease: results from the Intermountain Heart Registry.” Circulation (2007). PMID: 17846308 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Interventional and Device Therapy, Prognosis and Natural History - [162]
Piazza G, Campia U, Hurwitz S et al.. “Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19.” Journal of the American College of Cardiology (2020). PMID: 33121712 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy, Prognosis and Natural History - [163]
Allard NAE, Janssen L, Aussieker T et al.. “Moderate Intensity Exercise Training Improves Skeletal Muscle Performance in Symptomatic and Asymptomatic Statin Users.” Journal of the American College of Cardiology (2021). PMID: 34794683 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [164]
Mancini GBJ, Lincoff AM, Goldberg AC et al.. “Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.” Journal of the American Heart Association (2026). PMID: 42333640 ↗
L1RCTCited in: Long-term Guideline-Directed Therapy, History and Evolution of Treatment, Complications, Special Populations and Prevention - [165]
Reges O, Greenland P, Dicker D et al.. “Association of Bariatric Surgery Using Laparoscopic Banding, Roux-en-Y Gastric Bypass, or Laparoscopic Sleeve Gastrectomy vs Usual Care Obesity Management With All-Cause Mortality.” JAMA (2018). PMID: 29340677 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [166]
Wu J, Zhang F, Li Q et al.. “Predictors of difficult vascular access during transradial neurointervention: a retrospective study.” Revista da Associacao Medica Brasileira (1992) (2026). PMID: 42339907 ↗
L2COHORTCited in: Long-term Guideline-Directed Therapy - [167]
Duan Y, Pan Z, Gu J et al.. “Disparities in anticoagulation therapy for older adults with non-valvular atrial fibrillation: a comparative study of urban and suburban communities.” BMC geriatrics (2026). PMID: 42420880 ↗
L4OTHERCited in: Long-term Guideline-Directed Therapy - [168]
Papatheodoridis G, Buti M, Yilmaz Y et al.. “Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported Outcomes.” Journal of gastroenterology and hepatology (2026). PMID: 42419754 ↗
L4OTHERCited in: Long-term Guideline-Directed Therapy - [169]
Yu M, Lei C, Zou T et al.. “Multidimensional factors influencing the recovery trajectory of residual dizziness after successful canalith repositioning in benign paroxysmal positional vertigo: an ordered logistic regression analysis.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2026). PMID: 42402503 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [170]
Jafari EA. “Hypertension among Middle Eastern and North African adults residing in the United States: addressing equity in health research representation using the All of Us Research Program, 2000-2024.” Frontiers in medicine (2026). PMID: 42383063 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [171]
Dabour MS, Shaaban A, Duprez DA et al.. “Is endothelial dysfunction induced by aromatase inhibitors reversible after treatment?” Breast cancer research and treatment (2026). PMID: 42329476 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [172]
Peng L, Zhu N, Zhang CJ et al.. “Beyond lipid-lowering effects: Challenges and insights in fenofibrate repurposing for oncology.” Life sciences (2026). PMID: 42302925 ↗
L5REVIEW_NARRATIVECited in: Long-term Guideline-Directed Therapy - [173]
Han X, Hopkins SC, Zhang Z et al.. “The Economic Impact of Cumulative Metabolic Comorbidity Burden in Schizophrenia: A Claims-Based Analysis of Medical Costs in the United States.” Neurology and therapy (2026). PMID: 42301550 ↗
L2OTHERCited in: Long-term Guideline-Directed Therapy - [174]
Zhang X, Xu H, Yu J et al.. “Immune Regulation of the Liver Through the PCSK9/CD36 Pathway During Heart Transplant Rejection.” Circulation (2023). PMID: 37232170 ↗
L5OTHERCited in: Interventional and Device Therapy, Prognosis and Natural History - [175]
Kim YH, Park DW, Lee SW et al.. “Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents.” Circulation (2009). PMID: 19620506 ↗
L2OTHERCited in: Interventional and Device Therapy, Special Populations and Prevention - [176]
Koupenova M, Johnston-Cox H, Vezeridis A et al.. “A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.” Circulation (2011). PMID: 22144568 ↗
L5OTHERCited in: Interventional and Device Therapy - [177]
Thomas M, Schymik G, Walther T et al.. “One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve.” Circulation (2011). PMID: 21747054 ↗
L4OTHERCited in: Interventional and Device Therapy, Prognosis and Natural History - [178]
Yu E, Calvert PA, Mercer JR et al.. “Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans.” Circulation (2013). PMID: 23841983 ↗
L4OTHERCited in: Interventional and Device Therapy - [179]
Molony DS, Hung O, Corban M et al.. “A randomized prospective study investigating the relationship between post-PCI wall shear stress and 12-month neointimal healing: The SHEAR-STENT study.” Cardiovascular revascularization medicine : including molecular interventions (2025). PMID: 41285658 ↗
L1RCTCited in: Interventional and Device Therapy - [180]
Önder R, Geebelen G, Scherrenberg M et al.. “The impact of cardiac rehabilitation on atrial fibrillation recurrence after pulmonary vein isolation: results of a large retrospective study.” Frontiers in cardiovascular medicine (2026). PMID: 41674867 ↗
L2COHORTCited in: Interventional and Device Therapy - [181]
Zhu Q, Zhang Y, Liu J et al.. “Clinical validation study of a novel prognostic risk prediction model (CHIP Score) for interventional therapy in patients with NSTE-ACS-a single-center retrospective cohort study based on 348 patients.” BMC cardiovascular disorders (2026). PMID: 41507846 ↗
L2COHORTCited in: Interventional and Device Therapy - [182]
Li W, Zhang G, Chen Y et al.. “Incidence and risk factors of posttransplant diabetes mellitus in lung transplant recipients: a retrospective cohort study.” Journal of thoracic disease (2025). PMID: 41376958 ↗
L2COHORTCited in: Interventional and Device Therapy - [183]
Lin X, Wang Y, Tan S et al.. “Long-term safety, effectiveness, and cost of rapamycin- vs. everolimus-eluting stents in acute coronary syndrome: a real-world cohort study.” International journal of clinical pharmacy (2025). PMID: 41369785 ↗
L2COHORTCited in: Interventional and Device Therapy - [184]
Yen WC, Yang MH, Weng TH et al.. “Dialysis and the risk of early urological cancer: A nationwide population-based cohort study in Taiwan.” Medicine (2025). PMID: 40388720 ↗
L2COHORTCited in: Interventional and Device Therapy - [185]
Wu P, Kiram A, Zhu Y et al.. “Muscle-derived ANXA2 promotes hepatic steatosis by activating SREBP1c-mediated de novo lipogenesis.” Metabolism: clinical and experimental (2026). PMID: 42225205 ↗
L5OTHERCited in: Interventional and Device Therapy - [186]
Wang X, Song Y, Zhao W et al.. “Cinnamaldehyde mitigates MASLD through SIRT1/FOXO1-induced autophagy and synergistic gut microbiota modulation.” NPJ science of food (2026). PMID: 41957048 ↗
L5OTHERCited in: Interventional and Device Therapy - [187]
Williams ZE, Singh I, Marks N et al.. “Innovative wound management of refractory venous ulcers with topical oxygen therapy.” Journal of vascular surgery. Venous and lymphatic disorders (2026). PMID: 41864536 ↗
L4OTHERCited in: Interventional and Device Therapy - [188]
Zhang Y, Teng M, He W et al.. “4-Hydroxybenzyl Alcohol Mitigates Hyperlipidemia-Associated Depression by Inhibiting Neuroinflammation via the NKIRAS2/NF-κB Pathway.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41801218 ↗
L5OTHERCited in: Interventional and Device Therapy - [189]
Torosian K, Díaz LA, Tesfai K et al.. “Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-associated Liver Disease.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41679525 ↗
L2OTHERCited in: Interventional and Device Therapy - [190]
Ding M, Xiao Z, Hou X et al.. “Targeting G-protein-coupled receptors and gut microbiota: Ge-Lian Qi-Shen decoction elevates GLP-1 to combat non-alcoholic fatty liver disease.” Chinese medicine (2026). PMID: 41580820 ↗
L5OTHERCited in: Interventional and Device Therapy - [191]
Ambardekar AV, Bhatt A, Hoekstra M et al.. “Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology.” Journal of the American College of Cardiology (2026). PMID: 41885675 ↗
L1GUIDELINECited in: History and Evolution of Treatment - [192]
März W, Scharnagl H, Abletshauser C et al.. “Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.” Circulation (2001). PMID: 11306521 ↗
L1RCTCited in: History and Evolution of Treatment - [193]
Lansky AJ, Pietras C, Costa RA et al.. “Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.” Circulation (2005). PMID: 15811868 ↗
L1RCTCited in: History and Evolution of Treatment - [194]
Vaduganathan M, Bhatt DL, Cryer BL et al.. “Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.” Journal of the American College of Cardiology (2016). PMID: 27012778 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [195]
Guyton JR, Brown BG, Fazio S et al.. “Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.” Journal of the American College of Cardiology (2008). PMID: 18420099 ↗
L1RCTCited in: History and Evolution of Treatment - [196]
Nappo F, Esposito K, Cioffi M et al.. “Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals.” Journal of the American College of Cardiology (2002). PMID: 11923038 ↗
L1RCTCited in: History and Evolution of Treatment - [197]
Naoumova RP, Kindler H, Leccisotti L et al.. “Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study.” Journal of the American College of Cardiology (2007). PMID: 18021872 ↗
L1RCTCited in: History and Evolution of Treatment - [198]
Herrington DM, Werbel BL, Riley WA et al.. “Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.” Journal of the American College of Cardiology (1999). PMID: 10362210 ↗
L1RCTCited in: History and Evolution of Treatment - [199]
Blake GJ, Albert MA, Rifai N et al.. “Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial.” European heart journal (2003). PMID: 14563343 ↗
L1RCTCited in: History and Evolution of Treatment - [200]
Austin MA, McKnight B, Edwards KL et al.. “Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study.” Circulation (2000). PMID: 10859281 ↗
L2COHORTCited in: History and Evolution of Treatment - [201]
Jenkins DJ, Wolever TM, Rao AV et al.. “Effect on blood lipids of very high intakes of fiber in diets low in saturated fat and cholesterol.” The New England journal of medicine (1993). PMID: 8389421 ↗
L1RCTCited in: History and Evolution of Treatment - [202]
Ridker PM, Rifai N, Clearfield M et al.. “Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.” The New England journal of medicine (2001). PMID: 11430324 ↗
L1RCTCited in: History and Evolution of Treatment - [203]
Walsh JM, Pignone M. “Drug treatment of hyperlipidemia in women.” JAMA (2004). PMID: 15138247 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [204]
Szapary PO, Wolfe ML, Bloedon LT et al.. “Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.” JAMA (2003). PMID: 12915429 ↗
L1RCTCited in: History and Evolution of Treatment - [205]
Esposito K, Giugliano F, Di Palo C et al.. “Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial.” JAMA (2004). PMID: 15213209 ↗
L1RCTCited in: History and Evolution of Treatment - [206]
Ballantyne CM, Podet EJ, Patsch WP et al.. “Effects of cyclosporine therapy on plasma lipoprotein levels.” JAMA (1989). PMID: 2733125 ↗
L2RCTCited in: History and Evolution of Treatment - [207]
Esposito K, Pontillo A, Di Palo C et al.. “Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.” JAMA (2003). PMID: 12684358 ↗
L1RCTCited in: History and Evolution of Treatment - [208]
Jenkins DJ, Jones PJ, Lamarche B et al.. “Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial.” JAMA (2011). PMID: 21862744 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Natural History - [209]
Brass EP. “Changing the status of drugs from prescription to over-the-counter availability.” The New England journal of medicine (2001). PMID: 11556302 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [210]
Ridker PM, Hennekens CH, Rifai N et al.. “Hormone replacement therapy and increased plasma concentration of C-reactive protein.” Circulation (1999). PMID: 10449692 ↗
L4OTHERCited in: History and Evolution of Treatment - [211]
Beaumont V, Lemort N, Beaumont JL. “Oral contraceptives, sex steroid-induced antibodies and vascular thrombosis: results from 1318 cases.” European heart journal (1991). PMID: 1782953 ↗
L3OTHERCited in: History and Evolution of Treatment - [212]
Ahmad A, Khan M, Ghayyad K et al.. “Statin therapy is not associated with inferior postoperative outcomes after arthroscopic rotator cuff repair: a systematic review and meta-analysis.” Journal of shoulder and elbow surgery (2026). PMID: 42173477 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Prognosis and Natural History - [213]
Jia D, Wang H, Jiang W et al.. “A novel recombinant anti-cluster of differentiation 20 humanized monoclonal antibody (B001) for the treatment of neuromyelitis optica spectrum disorder: a phase 1, multicenter randomized, double-blind trial.” Frontiers in immunology (2026). PMID: 42079612 ↗
L1RCTCited in: History and Evolution of Treatment, Complications - [214]
Song X, Hu Y, Chen Y. “Uterine fibroids detected in early pregnancy and their association with adverse pregnancy outcomes: a single-centre retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42026504 ↗
L4COHORTCited in: History and Evolution of Treatment, Prognosis and Natural History, Special Populations and Prevention - [215]
Fancher A, Lopez-Candales A, Sawalha K. “Statins, LDL-C and Beyond: A Contemporary Review of Atherosclerotic Cardiovascular Risk Assessment and Management.” Journal of lipid and atherosclerosis (2025). PMID: 42211141 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [216]
Wang L, Niu Y, Wang L. “Pontine infarction isolated to trigeminal sensory fibers: a case report.” Frontiers in pain research (Lausanne, Switzerland) (2026). PMID: 42317569 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [217]
Arias-Romero J, Mambetsariev I, Fricke J et al.. “Case report: durable response to osimertinib, radiotherapy, and chemotherapy combination in advanced non-small cell lung cancer with atypical metastasis.” Translational lung cancer research (2026). PMID: 42291351 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [218]
Bauer RC, Tohyama J, Cui J et al.. “Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice.” Circulation (2015). PMID: 25712206 ↗
L5OTHERCited in: Complications - [219]
Coberly EA, Hammer RD. “Images in clinical medicine: Morphologic changes in erythrocytes in hypertriglyceridemia.” The New England journal of medicine (2014). PMID: 25119625 ↗
L4CASE_REPORTCited in: Complications - [220]
Zhang J, Hu Z, Song C et al.. “Hemoglobin glycation index correlates with the prognoses of critically ill patients with hyperlipidemia: a retrospective cohort study from the MIMIC-IV database.” BMC endocrine disorders (2026). PMID: 42168947 ↗
L4COHORTCited in: Complications, Prognosis and Natural History - [221]
Zulfa IM, Risni HW, Brauer R et al.. “Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.” Postgraduate medicine (2026). PMID: 42357832 ↗
L1SR_OBSCited in: Complications - [222]
Zeng C, Lyu H, Lou L et al.. “Association between stress hyperglycemic ratio and stroke in older people with metabolic syndrome: a prospective cohort study from UK Biobank.” Frontiers in endocrinology (2026). PMID: 42051452 ↗
L2COHORTCited in: Prognosis and Natural History - [223]
Lee YJ, Lee JH, Kim M et al.. “Combined Pre-Hypertension, Pre-Diabetes, and Pre-Hyperlipidemia and Long-Term Cardiovascular Risk in Young Adults: A Nationwide Cohort Study.” European journal of preventive cardiology (2026). PMID: 42044147 ↗
L2COHORTCited in: Prognosis and Natural History - [224]
Nourollahpour Shiadeh M, Pakdaman K, Esmaeilnia Shirvani A et al.. “Global incidence and risk factors of pregnancy-related stroke: a systematic review and meta-analysis of over 270 million women.” BMC pregnancy and childbirth (2025). PMID: 41419807 ↗
L1SR_OBSCited in: Special Populations and Prevention - [225]
Yan C, Shen X, Han S et al.. “Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study.” Journal of translational medicine (2026). PMID: 41782035 ↗
L2COHORTCited in: Special Populations and Prevention - [226]
Camara J, Tsujiguchi H, Hara A et al.. “Chronic pain and mortality risk among middle-age and older Japanese: the Shika town cohort study.” Pain reports (2025). PMID: 41244944 ↗
L2COHORTCited in: Special Populations and Prevention - [227]
Chen Y, Huang L, Hu T et al.. “The changing trend of hepatitis B virus carrier rate with different combinations of hepatitis B virus markers and their impact on maternal perinatal characteristics and pregnancy outcomes: a multicenter retrospective cohort study.” Virology journal (2025). PMID: 41214772 ↗
L3COHORTCited in: Special Populations and Prevention - [228]
Naim MAAZ, Sumida K, Streja E et al.. “Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol.” Drugs (2026). PMID: 41528633 ↗
L5REVIEW_NARRATIVECited in: Special Populations and Prevention - [229]
Hsiao PJ, Tsou LL, Yang CC et al.. “Magnesium Oxide Use and Clinical Outcomes in CKD Patients: Evidence from a Nationwide Population-Based Cohort Study in Taiwan.” International journal of medical sciences (2026). PMID: 41938509 ↗
L3COHORTCited in: Special Populations and Prevention - [230]
Delbari A, Akbarzadeh I, Bidkhori M et al.. “The Prevalence and Associated Factors of Smoking and Smoking-Cessation in Iranian Older Adults: Ardakan Cohort Study on Aging (ACSA).” Substance use & misuse (2026). PMID: 41782359 ↗
L4COHORTCited in: Special Populations and Prevention - [231]
You X, Xu Y, Zhao J et al.. “The association of geriatric nutritional risk and perioperative anesthesia-related adverse reactions in elderly patients with colorectal cancer-a prospective study.” Translational cancer research (2025). PMID: 41234882 ↗
L2COHORTCited in: Special Populations and Prevention - [232]
Huang J, Ding Z, Huang G et al.. “Clinical analysis of 48 patients with carotid web diagnosed by digital subtraction angiography.” Frontiers in neurology (2026). PMID: 42597884 ↗
L1bCited in: Definition, Classification and Nomenclature - [233]
Rayyan A, Bishev D, Bazikian Y et al.. “Comparing coronary computed tomography angiography to single-photon emission computed tomography in the evaluation of chest pain in the emergency department.” Journal of cardiovascular computed tomography (2026). PMID: 42601304 ↗
L2bCited in: Definition, Classification and Nomenclature - [234]
Zhou Y, Zhu L, An H et al.. “Independent and synergistic effects of OGTT-based hyperglycemia phenotypes and gestational weight gain on feto-maternal outcomes in GDM.” BMC pregnancy and childbirth (2026). PMID: 42157035 ↗
L2bCited in: Definition, Classification and Nomenclature - [235]
Crump C, Wei J, Sundquist J et al.. “Adverse pregnancy outcomes and long-term risk of peripheral artery disease: A cohort study.” PLoS medicine (2026). PMID: 42479723 ↗
L3bCited in: Definition, Classification and Nomenclature - [236]
Sun Z, Sun X, Cai Q et al.. “Two-cohort machine learning approach for predicting the risk of secondary hyperlipidemia in patients with depression.” Frontiers in endocrinology (2026). PMID: 42158914 ↗
L3bCited in: Definition, Classification and Nomenclature - [237]
Yang S, Huo M, Li G et al.. “Construction of a predictive model for the risk of non-alcoholic fatty liver disease in patients with sleep apnea syndrome based on multiple machine learning algorithms: a multicenter study.” BMC medical informatics and decision making (2026). PMID: 42141448 ↗
L3bCited in: Definition, Classification and Nomenclature - [238]
Chu Q, Zhang S, Zhang H et al.. “Interpretable deep learning with pharmacogenomics predicts myocardial infarction in angiotensin receptor blocker treated hypertension.” Journal of hypertension (2026). PMID: 42052888 ↗
L3bCited in: Definition, Classification and Nomenclature - [239]
Koksoy C, Browder S, Torres Ruiz I et al.. “Wound healing, wound-free period and amputation-free survival in patients with Wound, Ischemia, and foot Infection (WIfI) stage 3 and 4 disease.” Journal of vascular surgery (2026). PMID: 41967734 ↗
L4Cited in: Definition, Classification and Nomenclature - [240]
Dangpiaei S, Kamal KM, Shoair OA et al.. “Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study.” Journal of managed care & specialty pharmacy (2026). PMID: 41885326 ↗
L3bCited in: Definition, Classification and Nomenclature - [241]
Hong H, Chen Y, Bao J et al.. “Development and validation of a risk prediction model for diabetic peripheral neuropathic pain in type 2 diabetes: A machine learning and statistical approach.” Diabetes research and clinical practice (2026). PMID: 41875951 ↗
L3bCited in: Definition, Classification and Nomenclature - [242]
Palmisano T, Bilchick K, Guarraia D. “Hemoglobin A1c is more predictive of type 1 myocardial infarction than low-density lipoprotein or body mass index.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41864779 ↗
L3bCited in: Definition, Classification and Nomenclature - [243]
Hassan MA, Mamdouh M, Ahmed FA et al.. “Association of epicardial adipose tissue thickness and left ventricular functions in children with primary dyslipidemia.” European journal of pediatrics (2026). PMID: 42095940 ↗
L3bCited in: Definition, Classification and Nomenclature - [244]
Xu W, Xu X, Zhang M et al.. “Body roundness index mediates the association between high-density lipoprotein cholesterol and diabetic retinopathy: a population-based cross-sectional study.” BMC endocrine disorders (2026). PMID: 42237292 ↗
L3bCited in: Definition, Classification and Nomenclature - [245]
Andres W, Rothstein A, Abbruzzese S et al.. “Trends in Vascular Risk Factor Control Among US Adults With Prior Stroke: 1999 to 2023.” Journal of the American Heart Association (2026). PMID: 42179268 ↗
L3bCited in: Definition, Classification and Nomenclature - [246]
Brook RD, Korzeniewski SJ, Foster B et al.. “Mobile Health Unit Outreach to Socially Disadvantaged Urban Communities Detects Uncontrolled Cardiometabolic Risk Factors.” Journal of the American Heart Association (2026). PMID: 42132204 ↗
L3bCited in: Definition, Classification and Nomenclature - [247]
Hu K, Liu T, Pan Z et al.. “Correlation between Cerebral Small Vessel Disease and Brain Artery Remodeling and Its Hemodynamic Characteristics: An Investigation Based on 4D Flow MRI.” Academic radiology (2026). PMID: 42025517 ↗
L3bCited in: Definition, Classification and Nomenclature - [248]
Zhang W, Li L, Wang Y et al.. “Mediating role of estimated glomerular filtration rate in the association between hyperlipidemia and estimated glucose disposal rate-related mortality: a study in hyperlipidemic individuals.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 42000252 ↗
L3bCited in: Definition, Classification and Nomenclature - [249]
Li RC, Su LC, Huang AF et al.. “Meta-analysis of factors for osteonecrosis in systemic lupus erythematosus: integration of comprehensive literatures and multicenter databases.” Frontiers in immunology (2026). PMID: 42465773 ↗
L2aCited in: Epidemiology and Risk Factors - [250]
Lin H, Zhang H, Zhang Z et al.. “Cohort profile: Guangdong Pharmaceutical University Occupational Health Cohort in Xishan Coal Electricity Group (GDPU-OHC).” Frontiers in public health (2026). PMID: 42577389 ↗
L2bCited in: Epidemiology and Risk Factors - [251]
Nakla A, Aubin PM, Ademisoye S et al.. “Smart Implantable Device Use is Associated with Decreased Post-Discharge Hospital Utilization in Total Knee Arthroplasty Patients Who Have Metabolic Syndrome: A Propensity Score-Matched Analysis.” The Journal of arthroplasty (2026). PMID: 42586280 ↗
L3bCited in: Epidemiology and Risk Factors - [252]
Liu L, Lu JA, Velasquez EE et al.. “Gestational Diabetes and Postpartum Cardiovascular, Kidney, and Metabolic Disorders.” JAMA network open (2026). PMID: 42584895 ↗
L3bCited in: Epidemiology and Risk Factors - [253]
Denic-Roberts H, McAdam J, Engel LS et al.. “Longer-term neurological and endocrine/metabolic conditions in the deepwater horizon oil spill coast guard cohort study: A principal component analysis.” International archives of occupational and environmental health (2026). PMID: 42584698 ↗
L3bCited in: Epidemiology and Risk Factors - [254]
Filippatos C, Fotiou D, Kostakou P et al.. “Real-world cardiovascular safety profile of bexarotene for the treatment of mycosis fungoides.” Clinical and experimental medicine (2026). PMID: 42576057 ↗
L3bCited in: Epidemiology and Risk Factors - [255]
Zhang C, Sandhur BS, Theotoka D et al.. “Risk of Pseudophakic Cystoid Macular Edema in Eyes With Previous Pars Plana Vitrectomy.” JAMA ophthalmology (2026). PMID: 42530955 ↗
L3bCited in: Epidemiology and Risk Factors - [256]
Luther M, Wittig T, Winther B et al.. “Five-Year Outcomes of Endovascular Aortoiliac Reconstruction in Complex Lesions: A Retrospective Single-Center Study.” Journal of clinical medicine (2026). PMID: 42513323 ↗
L4Cited in: Epidemiology and Risk Factors - [257]
Moshawih S, Gharaibeh L, Alfreahat I et al.. “Real-World Pharmacotherapy-Driven Cardiovascular Risk Prediction Using Interpretable Machine Learning and Jordanian EHR Data.” Medical sciences (Basel, Switzerland) (2026). PMID: 42506312 ↗
L3bCited in: Epidemiology and Risk Factors - [258]
Chuang YC, Wang CC, Chen IC et al.. “Cardiometabolic disease and risk of total knee arthroplasty among patients with knee osteoarthritis receiving intra-articular hyaluronic acid: a real-world cohort study.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42482885 ↗
L3bCited in: Epidemiology and Risk Factors - [259]
Lee J, Kim J, Hwang J et al.. “Incidence patterns of cardiometabolic comorbidities in patients with schizophrenia: A retrospective cohort study in Korea.” Psychiatry research (2026). PMID: 42475856 ↗
L3bCited in: Epidemiology and Risk Factors - [260]
Loscocco GG, Aperna F, Iftikhar M et al.. “Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia.” Blood cancer journal (2026). PMID: 42436123 ↗
L3bCited in: Epidemiology and Risk Factors - [261]
Boutros T, Ghusn W, Klim J et al.. “Beyond Initial Resolution: Predictors of Recurrence of Obesity-related Medical Conditions after Metabolic and Bariatric Surgery.” Obesity surgery (2026). PMID: 42432395 ↗
L3bCited in: Epidemiology and Risk Factors - [262]
Chuang YC, Huang YJ, Lai MC et al.. “Sex differences in 5-year incidence and prevalence of physical illnesses following early childhood autism diagnosis.” JCPP advances (2026). PMID: 42416613 ↗
L3bCited in: Epidemiology and Risk Factors - [263]
Wei L, Tao Q, You S et al.. “Chronic Pain Synergizes With High-Fat Diet to Promote Cardiac Injury via c-Jun N-Terminal Kinase 1/Silent Information Regulator 1 Signaling Axis in Apolipoprotein E-Deficient Mice.” Journal of the American Heart Association (2026). PMID: 42535523 ↗
L1bCited in: Pathophysiology and Mechanism - [264]
Wu E, Jiang J, Hasan N et al.. “Novel Systemic Associations of Idiopathic Epiretinal Membrane Identified via Machine Learning.” Ophthalmology science (2026). PMID: 41908500 ↗
L3bCited in: Pathophysiology and Mechanism - [265]
Patel H, Pathak A, Rajalekshmi R et al.. “Galectin-3, transforming growth factor beta 1, and brain natriuretic peptide in cardiac remodeling under hyperlipidemic and hyperglycemic stress.” Molecular and cellular biochemistry (2026). PMID: 42384346 ↗
L4Cited in: Pathophysiology and Mechanism - [266]
Dong M, Liu Y, Pu Z et al.. “QDPR rs3733570 polymorphism is associated with type 2 diabetes and diabetic kidney disease accompanied by hyperlipidemia in the Chinese Han population.” Frontiers in medicine (2026). PMID: 42205834 ↗
L3bCited in: Pathophysiology and Mechanism - [267]
Liu C, Zhang Q, Zhang Y. “The factors between BMI and diabetic nephropathy and protective role of the FGF21-SIRT1 axis in diabetic nephropathy.” Molecular and cellular biochemistry (2026). PMID: 42348140 ↗
L3bCited in: Pathophysiology and Mechanism - [268]
Rabadi MH, Russell KA, Xu C. “Presence and Impact of Fatigue in Patients With Multiple Sclerosis.” Medical science monitor : international medical journal of experimental and clinical research (2026). PMID: 42410895 ↗
L3bCited in: Pathophysiology and Mechanism - [269]
Xu L, Xiong X, Zhou Y et al.. “Retinal hemodynamic and caliber biomarkers for the assessment of cerebral small vessel disease burden: insights from fundus fluorescein angiography.” BMC neurology (2026). PMID: 42185800 ↗
L3bCited in: Pathophysiology and Mechanism - [270]
Yang M, Cheng X, Guan J et al.. “Diabetes Status Modifies the Association Between Carotid Plaque Burden and Retinal Microvascular Parameters.” International journal of medical sciences (2026). PMID: 42080061 ↗
L3bCited in: Pathophysiology and Mechanism - [271]
Đuran I, Ljubičić B, Joldić MN et al.. “Clinical and Echocardiographic Predictors of Major Adverse Cardiovascular Events in ANCA-Associated Vasculitis.” Medicina (Kaunas, Lithuania) (2026). PMID: 42075582 ↗
L3bCited in: Pathophysiology and Mechanism - [272]
Geng Z, He J, Zhou X et al.. “Predictive value of left ventricular global longitudinal strain for mid-term major adverse cardiovascular events in patients with atrial fibrillation complicated by acute myocardial infarction.” BMC cardiovascular disorders (2026). PMID: 41998509 ↗
L3bCited in: Pathophysiology and Mechanism - [273]
Yan C, Li S, Zhuang B et al.. “Evaluation of non-dilated left ventricular cardiomyopathy patients with reduced and preserved left ventricular ejection fraction using cardiac magnetic resonance feature tracking technology.” BMC cardiovascular disorders (2026). PMID: 41896746 ↗
L3bCited in: Pathophysiology and Mechanism - [274]
Zhang Q, Xu J, Qian Y. “Association between TyHGB and hyperuricemia and gout in patients with type-2 diabetes mellitus.” BMC endocrine disorders (2026). PMID: 42062982 ↗
L3bCited in: Clinical Presentation - [275]
Górska M, Wróbel F, Rząsa M et al.. “Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant Recipients.” Annals of transplantation (2026). PMID: 42515854 ↗
L3bCited in: Clinical Presentation - [276]
Cook DN, Ravindran A, O'Connor S et al.. “Coronary Artery Calcium Score Predicts Cardiovascular and Transplant-Related Outcomes in Lung Transplant Recipients.” Clinical transplantation (2026). PMID: 42257486 ↗
L3bCited in: Clinical Presentation - [277]
Erinmez MA, Örs F, Yeşilova M. “Emergency Department Sudden Deafness: Clinical Features and Predictors of Advanced Imaging.” The Journal of craniofacial surgery (2026). PMID: 42090229 ↗
L3bCited in: Clinical Presentation - [278]
Zlatanović M, Živković MLJ, Zlatanović N et al.. “Foveal Density and Multi-Domain OCTA Biomarkers May Help Identify Preclinical Diabetic Microvasculopathy in Type 2 Diabetes Mellitus.” Medicina (Kaunas, Lithuania) (2026). PMID: 42356165 ↗
L3bCited in: Diagnosis and Workup - [279]
Wu M, Chen J, Lin Z et al.. “Circulating multiple metals and mortality after myocardial infarction: incremental value beyond GRACE.” American journal of preventive cardiology (2026). PMID: 42291071 ↗
L2bCited in: Severity Staging and Risk Stratification - [280]
Peng Q, Long Y, Yang K et al.. “Prognostic analysis of acute pancreatitis due to different etiologies and establishment and validation of an early prediction model.” Lipids in health and disease (2026). PMID: 41645226 ↗
L2bCited in: Severity Staging and Risk Stratification - [281]
Xu X, Sun M, Cao S et al.. “Development of a predictive model for visual outcomes and risk factors of bilateral involvement for non-arteritic anterior ischemic optic neuropathy (NAION) in Chinese patients.” Eye and vision (London, England) (2026). PMID: 42596023 ↗
L3bCited in: Severity Staging and Risk Stratification - [282]
Zhang Y, Liu G, Yu X et al.. “Metabolic Syndrome and In-Hospital Mortality in Sepsis: A Multicenter Cohort Study Revealing a Severity-Dependent Survival Advantage Driven by Overweight and Hyperlipidemia.” Shock (Augusta, Ga.) (2026). PMID: 42474243 ↗
L3bCited in: Severity Staging and Risk Stratification - [283]
Khaderi IM, Kandahari N, Saleh AW et al.. “Development of the TORS severe outcome score: a preoperative risk stratification tool for postoperative morbidity in oropharyngeal cancer.” Oral oncology (2026). PMID: 42308859 ↗
L3bCited in: Severity Staging and Risk Stratification - [284]
Cinezan C, Hiceag ML. “Self-Reported Habitual Daily Physical Activity as an Independent Predictor of Coronary Artery Disease Extension in Patients with Myocardial Infarction: A Prospective Observational Study.” Journal of clinical medicine (2026). PMID: 42194773 ↗
L3bCited in: Severity Staging and Risk Stratification - [285]
Zou XC, Xu LY, Yuan YY et al.. “Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study.” Frontiers in immunology (2026). PMID: 42136642 ↗
L3bCited in: Severity Staging and Risk Stratification - [286]
Srikumar A, Yuvchenko O, Kang J. “Hydroxychloroquine use and 5-year cardiometabolic profile and cardiovascular risk in isolated discoid lupus erythematosus: A retrospective cohort study.” Journal of the American Academy of Dermatology (2026). PMID: 42002081 ↗
L3bCited in: Severity Staging and Risk Stratification - [287]
Thompson LL, Shah SB, Gregg AT et al.. “Cardiac risk, outcomes, and management among older adults with stage I-II non-small cell lung cancer undergoing stereotactic body radiation therapy.” Journal of geriatric oncology (2026). PMID: 41856027 ↗
L3bCited in: Severity Staging and Risk Stratification - [288]
Sen J, Salim A, Lekamlage DH et al.. “Clinical risk score for cardiac death or heart failure hospitalization in moderate aortic stenosis.” Echo research and practice (2026). PMID: 41834049 ↗
L4Cited in: Severity Staging and Risk Stratification - [289]
Chwa JS, Hong AT, Lin F et al.. “Immune checkpoint inhibitors are associated with peripheral artery disease in cancer patients.” Journal of vascular surgery (2026). PMID: 41687935 ↗
L3bCited in: Severity Staging and Risk Stratification - [290]
Micker M, Balcer-Dymel N, Pruszynska-Oszmalek E et al.. “Effect of L‑arginine supplementation on homocysteine and asymmetric dimethylarginine in atherosclerotic lower limb ischemia.” Journal of physiology and pharmacology : an official journal of the Polish Physiological Society (2026). PMID: 42533453 ↗
L1bCited in: Acute and Initial Management - [291]
Ali AH, Tak KA, Taylor-Yeremeeva EM et al.. “Mental health-related quality of life is associated with sustained lipid-lowering therapy adherence after acute coronary syndrome.” Lipids in health and disease (2026). PMID: 42482230 ↗
L3bCited in: Acute and Initial Management - [292]
Gong J, Chiu N, Clinch KA et al.. “Treatment of Cardiometabolic Risk Factors Among U.S. Adults With Cardiovascular-Kidney-Metabolic Syndrome.” Journal of the American College of Cardiology (2026). PMID: 42307495 ↗
L3bCited in: Acute and Initial Management - [293]
Yan S, Zhang F, Fang Z et al.. “Construction and validation of a diagnostic model for obstructive coronary artery disease in patients with suspected unstable angina pectoris based on resting 18F-fluorodeoxyglucose positron emission tomography myocardial ischemia memory imaging.” Quantitative imaging in medicine and surgery (2026). PMID: 42582781 ↗
L3bCited in: Acute and Initial Management - [294]
Wen Y, Chen W, Zhang W et al.. “The Correlation Analysis of C-Reactive Protein-Triglyceride-Glucose Index with the Severity of Hyperlipidemic Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 42474624 ↗
L3bCited in: Acute and Initial Management - [295]
Ba Y, Liu B, Zhu P. “Risk stratification for stroke in acute persistent vertigo: development and internal validation of a multivariable prediction model.” Frontiers in neurology (2026). PMID: 42422204 ↗
L4Cited in: Acute and Initial Management - [296]
Pairawan S, Lee M, Shepard A et al.. “A Single-Center Experience with Paravisceral Transaortic Endarterectomy: Establishing Evidence for Efficacy and Safety in Complex Aortic Occlusive Disease.” Annals of vascular surgery (2026). PMID: 42372862 ↗
L4Cited in: Acute and Initial Management - [297]
Yuan YE, Porter LM, Haas AV et al.. “The impact of statins on aldosterone production in healthy adults: a randomized controlled study.” Journal of the Endocrine Society (2026). PMID: 42404178 ↗
L1bCited in: Long-term Guideline-Directed Therapy - [298]
Yu Z, Liu X, Wang X et al.. “Establishment of a machine learning prediction model for Wallerian degeneration after ischemic stroke.” Frontiers in medicine (2026). PMID: 42454109 ↗
L3bCited in: Long-term Guideline-Directed Therapy - [299]
Wei YF, Wang YS, Song JY et al.. “Restoration of peripheral ILC3s by washed microbiota transplantation improves lipid profiles in hyperlipidemia patients.” Frontiers in immunology (2025). PMID: 41415268 ↗
L2bCited in: Interventional and Device Therapy - [300]
Xu J, Luo D, Lei Y et al.. “Correlation between abnormal microvascular perfusion and quantitative flow ratio after primary PCI in patients with STEMI.” International journal of cardiology (2024). PMID: 39746473 ↗
L2bCited in: Interventional and Device Therapy - [301]
Gupta AR, Kumar A, Cao JJL et al.. “Preimplantation AI-ECG Age as a Predictor of Survival Following Cardiac Resynchronization Therapy.” JACC. Clinical electrophysiology (2025). PMID: 41441802 ↗
L3bCited in: Interventional and Device Therapy - [302]
Muayad J, Tukur HN, Loya A et al.. “Nationwide Analysis of Progressive Kidney Function Decline and Diabetic Macular Edema in Type 2 Diabetes.” Ophthalmology science (2025). PMID: 41216263 ↗
L3bCited in: Interventional and Device Therapy - [303]
Malmquist J, Davidge J, Bjurström K et al.. “Association between statin therapy as primary prevention and mortality in adults 50 years and older with chronic kidney disease without other indications.” Scandinavian journal of primary health care (2026). PMID: 41769754 ↗
L3bCited in: Interventional and Device Therapy - [304]
Fukae S, Kakuta Y, Matsumura S et al.. “Evaluation of everolimus pharmacokinetic monitoring based on trough concentration and area under the blood concentration time curve in kidney transplantation.” BMC nephrology (2026). PMID: 41555262 ↗
L3bCited in: Interventional and Device Therapy - [305]
Ang SP, Chia JE, Iglesias J et al.. “Trends, Clinical Characteristics, and Outcomes of Percutaneous Coronary Intervention in Liver Transplant Recipients.” Clinical transplantation (2025). PMID: 40373057 ↗
L3bCited in: Interventional and Device Therapy - [306]
Pradeep A, Faisal MS, Chen K et al.. “Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation.” Transplantation proceedings (2026). PMID: 42259739 ↗
L2bCited in: Interventional and Device Therapy - [307]
Murat A, Karaca G, Bakhshaliyev N et al.. “The impact of epicardial adiposity on STEMI outcomes: Insights from a prospective cohort.” Clinical physiology and functional imaging (2025). PMID: 41121600 ↗
L2bCited in: Interventional and Device Therapy - [308]
Rossouw JE, Aragaki AK, Manson JE et al.. “Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy.” Obstetrics and gynecology (2026). PMID: 42492078 ↗
L1bCited in: History and Evolution of Treatment - [309]
Liu M, Cai H, Tang C et al.. “Preoperative Shoulder Stiffness Was Accompanied by Distinct Supraspinatus Tendon Inflammatory Signatures but Not Inferior Long-term Outcomes After Rotator Cuff Repair.” Clinical orthopaedics and related research (2026). PMID: 42248213 ↗
L2bCited in: History and Evolution of Treatment - [310]
Shao K, Hu T, Yao Y et al.. “Detection rate and risk factors of carotid atherosclerotic plaque in patients with obstructive sleep apnea syndrome: A systematic review and meta-analysis.” Heart & lung : the journal of critical care (2026). PMID: 42526417 ↗
L2aCited in: History and Evolution of Treatment - [311]
Park KC, Kim HJ, Oh JS et al.. “Anatomical and Systemic Risk Factors for Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Retrospective Study of 812 Patients.” Journal of clinical medicine (2026). PMID: 42452398 ↗
L3bCited in: History and Evolution of Treatment - [312]
Muayad J, Chauhan MZ, Butt FR et al.. “Statin Intensity and the Risk of Noninfectious Uveitis.” Ophthalmology. Retina (2026). PMID: 42361978 ↗
L3bCited in: History and Evolution of Treatment - [313]
Kim DJ, Assel M, Elshafei A et al.. “Predictors of clomiphene citrate response in the treatment of men with testosterone deficiency.” The journal of sexual medicine (2026). PMID: 42251758 ↗
L3bCited in: History and Evolution of Treatment - [314]
Mendoza-Ayus S, Akkipeddi SM, Gunn K et al.. “Morphological and clinical predictors of symptomatic carotid webs: a cross-validated analysis of 124 webs.” Neuroradiology (2026). PMID: 42247135 ↗
L3bCited in: History and Evolution of Treatment - [315]
Li N, Chen M, Li S et al.. “Association between ADHD history and "Life's Crucial 9" cardiovascular risk factors in young adults.” American journal of preventive cardiology (2026). PMID: 42291048 ↗
L3bCited in: History and Evolution of Treatment - [316]
Ballantyne CM, Baass A, Rosenson RS et al.. “Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.” American journal of preventive cardiology (2026). PMID: 42291067 ↗
L1bCited in: Complications - [317]
Li N, Tang W, Li N et al.. “Descriptive analysis of prescription interception patterns: characterizing medication safety risks in an outpatient setting.” Frontiers in pharmacology (2026). PMID: 42523996 ↗
L3bCited in: Complications - [318]
Chen HY, Falconer T, Ostropolets A et al.. “Heterogeneity of Treatment Effects Across Nine Glucose-Lowering Drug Classes in Type 2 Diabetes: Extension of the LEGEND-T2DM Network Study.” Diabetes, obesity & metabolism (2026). PMID: 42236281 ↗
L3bCited in: Complications - [319]
Schneider K, Lyon S, Jolicoeur W et al.. “Outpatient common femoral artery stenting for occlusive disease: Short-, mid-, and long-term results.” Journal of vascular surgery (2026). PMID: 42229618 ↗
L3bCited in: Complications - [320]
Wang J, Chen M, Wu H et al.. “Association of Maternal Hyperlipidemia Combined with Gestational Diabetes Mellitus with Adverse Maternal and Neonatal Outcomes: A Retrospective Cohort Study.” International journal of women's health (2026). PMID: 42438476 ↗
L4Cited in: Complications - [321]
Metlock FE, Stanislas KA, Vaidya D et al.. “Psychological Health, Polysocial Risk, and Cardiovascular Health Among Women of Reproductive Age.” JACC. Advances (2026). PMID: 42312757 ↗
L3bCited in: Complications - [322]
Rask-Andersen M, Lo Faro V, Karlsson T et al.. “Age-related changes in adiposity and cardiometabolic disease risk: a longitudinal and prospective study in the UK Biobank.” International journal of obesity (2005) (2026). PMID: 42457939 ↗
L2bCited in: Prognosis and Natural History - [323]
Burke L, Leupold O, Perez S et al.. “Fewer lifestyle-related chronic diseases and higher out-of-pocket costs are predictive of favorable response to intra-articular platelet-rich plasma injections in the treatment of knee osteoarthritis.” PM & R : the journal of injury, function, and rehabilitation (2026). PMID: 42473805 ↗
L3bCited in: Prognosis and Natural History - [324]
Yazji IH, Abbass NJ, Kaelber DC et al.. “The Impact of PCSK9 Inhibitors on Development of Retinal Vascular Occlusions.” American journal of ophthalmology (2026). PMID: 42341975 ↗
L3bCited in: Prognosis and Natural History - [325]
Doğan D, Güler E. “Association Between the CALLY Index and Carotid Artery Stenosis Severity in Patients Younger and Older than 65 Years.” Journal of clinical medicine (2026). PMID: 42279101 ↗
L3bCited in: Special Populations and Prevention - [326]
Donà C, Rettl R, Binder-Rodriguez C et al.. “Coronary Artery Disease in Cardiac Amyloidosis: Prevalence, Clinical Relevance, and Cardiac Magnetic Resonance Imaging Features.” Journal of clinical medicine (2025). PMID: 41464702 ↗
L3bCited in: Special Populations and Prevention - [327]
Quist-Nelson J, Meng ML, Rich-Edwards J et al.. “Adverse pregnancy outcomes and development of short-term cardiovascular disease risk factors.” American journal of obstetrics & gynecology MFM (2025). PMID: 41349795 ↗
L3bCited in: Special Populations and Prevention - [328]
Wu K, Lu Y, Liu A et al.. “Unconventional multi-morbidity patterns in older adults: results from 39,172 Chinese health examination population at primary healthcare centers.” BMC geriatrics (2026). PMID: 42098670 ↗
L3bCited in: Special Populations and Prevention - [329]
Bossingham J, Peng K, McKnight S et al.. “Prevalence and Correlates of Prolonged Lapses in Physician Care Among Adults with Diabetes over 4 Years: A National Study, 2018-2022.” Journal of general internal medicine (2026). PMID: 41979724 ↗
L3bCited in: Special Populations and Prevention - [330]
Li Y, Hu Q, Wang B et al.. “Prevalence and associated factors of uncorrected presbyopia among adults in cross-sectional Fujian Eye Study.” Frontiers in medicine (2026). PMID: 41836951 ↗
L4Cited in: Special Populations and Prevention - [331]
Amponsah MKD, Okoh AK, Cheffet-Walsh S et al.. “Lifestyle Habits and Structural Heart Abnormalities Among Former Athletes and Their Families: HUDDLE Subanalysis.” AJPM focus (2025). PMID: 41624228 ↗
L3bCited in: Special Populations and Prevention - [332]
Gullaksen S, Vernstrøm L, Sørensen SS et al.. “Effects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.” Journal of diabetes and its complications (2026). PMID: 42679726 ↗
L1bCited in: Pathophysiology and Mechanism - [333]
Schreinlechner M, Pavluk D, Mayer-Suess L et al.. “Periodic Repolarization Dynamics Predicts Newly Detected Atrial Fibrillation After Stroke.” Journal of the American Heart Association (2026). PMID: 42622097 ↗
L2bCited in: Pathophysiology and Mechanism - [334]
Berens PM, Liu BC, Fereydooni A et al.. “A cross-sectional analysis of vascular geometry in adults: associations of age and biological sex with iliofemoral arterial and venous tortuosity.” American journal of physiology. Heart and circulatory physiology (2026). PMID: 42563761 ↗
L3bCited in: Pathophysiology and Mechanism - [335]
Wang X, Liu H, Yin K et al.. “Targeted plasma lipidomics in non-metastatic colorectal cancer, metastatic colorectal cancer, and healthy controls: an exploratory matched-triplet study.” Frontiers in oncology (2026). PMID: 42638879 ↗
L2bCited in: Pathophysiology and Mechanism - [336]
Li C, Zhu Y, Yang W et al.. “Impact of below-the-knee runoff in patients undergoing drug-coated balloon angioplasty for femoropopliteal disease: a propensity score-matched analysis.” BMC cardiovascular disorders (2026). PMID: 42420851 ↗
L3bCited in: Pathophysiology and Mechanism - [337]
Venkatachalapathy Y, Kochuthakidiyel Suresh P, Venkatesan V et al.. “Associations of TNF-α, IL-2 and IL-10 gene polymorphisms in children with primary nephrotic syndrome.” International urology and nephrology (2026). PMID: 42680910 ↗
L3bCited in: Pathophysiology and Mechanism - [338]
Zhang X, Lu P, Yang Y et al.. “The association between the ZJU index and short-term prognosis in patients with acute ischemic stroke: a cohort study.” Frontiers in endocrinology (2026). PMID: 42723870 ↗
L2bCited in: Clinical Presentation - [339]
Sanchez-Calderin D, Meschia JF, Kumar G et al.. “Early Revascularization in Symptomatic Carotid Artery Disease Leads to Better Outcomes: A Ten-Year Multi-Center Cohort Analysis.” Journal of vascular surgery (2026). PMID: 42767435 ↗
L3bCited in: Clinical Presentation - [340]
Qi L, Zhang S, Wang B et al.. “AI-assisted segmentation-based fusion model integrating deep learning, radiomics, and clinical parameters for identifying coronary heart disease risk in patients with MAFLD.” Frontiers in endocrinology (2026). PMID: 42643589 ↗
L4Cited in: Clinical Presentation - [341]
Ferdinand P, Maguire H, Bajpai R et al.. “Demographics, risk factor profiles and etiologies in young ischemic and hemorrhagic stroke - the United Kingdom Young Stroke Study (UKYSS).” Journal of neurology (2026). PMID: 42640350 ↗
L3bCited in: Clinical Presentation - [342]
El Ghazal N, Abedalqader T, Jawhar N et al.. “Long-term 10 to 15 year outcomes of biliopancreatic diversion with duodenal switch.” Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (2026). PMID: 42265009 ↗
L4Cited in: Clinical Presentation - [343]
Cao S, Zhang B, Li P et al.. “Residual lipid-related proteomic and metabolomic signatures associated with major adverse cardiovascular events after revascularization in peripheral artery disease.” BMC cardiovascular disorders (2026). PMID: 42786448 ↗
L2bCited in: Clinical Presentation - [344]
Lan YQ, Xi ZF, Lan KS et al.. “The association between body mass index and lower extremity deep venous abnormalities identified by computed tomography venography.” Frontiers in public health (2026). PMID: 42620992 ↗
L3bCited in: Clinical Presentation - [345]
Ge R, Peng C, Chen W et al.. “Pipeline Shield versus Pipeline Flex for unruptured intracranial aneurysms: a propensity-matched multicenter study.” Neuroradiology (2026). PMID: 42760406 ↗
L3bCited in: Severity Staging and Risk Stratification - [346]
Alur-Gupta S, DiTosto JD, Busse KR et al.. “Polycystic ovary syndrome and its association with reproductive cancers in women.” Fertility and sterility (2026). PMID: 42176842 ↗
L3bCited in: Severity Staging and Risk Stratification - [347]
Tian X, Zhao X, Wang L et al.. “Association of N-butylphthalide treatment with 1-year activities-of-daily-living recovery in convalescent ischemic stroke patients with chronic disease burden: a post-marketing real-world non-randomized controlled study.” Frontiers in medicine (2026). PMID: 42609324 ↗
L1bCited in: Acute and Initial Management - [348]
Yang B, Li Y, Wang Y et al.. “Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.” The British journal of dermatology (2026). PMID: 42687756 ↗
L2bCited in: Acute and Initial Management - [349]
Pan J, Peng W, Wu M et al.. “Clinical characteristics, management, and outcome of tamoxifen-induced hyperlipidemia: a systematic review.” Frontiers in pharmacology (2026). PMID: 42824100 ↗
L4Cited in: Acute and Initial Management - [350]
Jiang Y, Guo Z, Yao L et al.. “Association of serum uric acid with circulating inflammatory proteins and treatment response to ixekizumab in patients with psoriasis: A multicenter prospective cohort study in China.” Chinese medical journal (2026). PMID: 42637676 ↗
L2bCited in: Acute and Initial Management - [351]
Spencer EA, Cohen S, Dubinsky MC et al.. “Upadacitinib treatment in pediatric Crohn's disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN.” Journal of Crohn's & colitis (2026). PMID: 42768926 ↗
L4Cited in: Acute and Initial Management - [352]
Wye Wong SK, Tan KB, Pang J et al.. “Assessing 5-Year Outcomes of a Teamlet Care Model in Singapore Polyclinics: A Matched Difference-in-Difference Analysis.” Annals of family medicine (2026). PMID: 42767951 ↗
L3bCited in: Acute and Initial Management - [353]
Sunkesula V, Chowdhary R, Koo TH et al.. “Gap in Care: Follow-up of Incidental Hepatic Steatosis in an Urban Safety-net Hospital.” Journal of clinical gastroenterology (2026). PMID: 42816901 ↗
L3bCited in: Acute and Initial Management - [354]
Markt SC, Drachenberg C, Zhou A et al.. “Social determinants of health, clinical outcomes, and healthcare resource utilization in participants with and without narcolepsy in the All of Us research program.” Sleep advances : a journal of the Sleep Research Society (2026). PMID: 42732406 ↗
L3bCited in: Acute and Initial Management - [355]
Liu M, Wu D, Su C. “Insulin is central, plasmapheresis is salvage: clinical spectrum and management of severe hypertriglyceridemia in 21 children with diabetic ketoacidosis.” Frontiers in endocrinology (2026). PMID: 42718762 ↗
L4Cited in: Acute and Initial Management - [356]
Krivosheina M, Bakaleiko V, Toshina Y et al.. “Genetic predisposition of Asparaginase-induced hypertriglyceridemia in children with acute lymphoblastic leukemia: Two case reports and review of literature.” World journal of clinical pediatrics (2026). PMID: 42626214 ↗
L4Cited in: Acute and Initial Management - [357]
Levy T, Cohen JL. “Stroke Following Facial Laser Resurfacing Procedure-A Case Report.” Lasers in surgery and medicine (2026). PMID: 42619248 ↗
L4Cited in: Acute and Initial Management - [358]
Liu ZY, Yang J, Lyu JQ et al.. “A landscape of metabolic burden and its cardiovascular impact across the adult lifespan: a prospective cohort study of 7.5 million people in Northwestern China.” The Lancet regional health. Western Pacific (2026). PMID: 42825051 ↗
L2bCited in: Long-term Guideline-Directed Therapy - [359]
Hou X, Zhao Y, Chen J et al.. “Corticosteroids plus statins in patients with primary immune thrombocytopenia and hyperlipidemia: A multicenter retrospective cohort study.” Therapeutic advances in hematology (2026). PMID: 42719467 ↗
L2bCited in: Long-term Guideline-Directed Therapy - [360]
Zheng J, Song Y, Hao Y et al.. “Metabolic syndrome is independently associated with 1-year readmission in patients with alcohol-associated cirrhosis.” Frontiers in medicine (2026). PMID: 42662279 ↗
L3bCited in: Long-term Guideline-Directed Therapy - [361]
Wang RZ, Sun SQ, Mao MX et al.. “Association between exposure to proton pump inhibitors and hyperuricemia: risk prediction model establishment and nomogram construction.” Frontiers in pharmacology (2026). PMID: 42630308 ↗
L3bCited in: Long-term Guideline-Directed Therapy - [362]
Mohammed AS, Mellacheruvu SP, Gandhi Z et al.. “Factors Associated with Secondary Pulmonary Hypertension Among Hospitalized Females: An Artificial Neural Network Analysis of a National US Cohort.” Journal of personalized medicine (2026). PMID: 42645915 ↗
L2bCited in: Long-term Guideline-Directed Therapy - [363]
Nanna MG, Victores A, Snyder K et al.. “Lipid-Lowering Therapy Preferences in the LISTEN-LDL-US Study: A Survey of U.S. Patient Treatment Experiences and Needs.” JACC. Advances (2026). PMID: 42617488 ↗
L3bCited in: Long-term Guideline-Directed Therapy - [364]
Al-Qahtani SA, Alqahtani AA, Almansour H et al.. “Safety and Predictors of Clinically Significant Adverse Effects of Isotretinoin in Acne Vulgaris: A Retrospective Cohort Study from Saudi Arabia.” Clinical, cosmetic and investigational dermatology (2026). PMID: 42729884 ↗
L3bCited in: Long-term Guideline-Directed Therapy - [365]
Gottlieb-Vedi E, Santoni G, Hammarstedt-Nordenvall L et al.. “Testosterone Inhibition and Risk of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma in Men.” JAMA otolaryngology-- head & neck surgery (2026). PMID: 42821291 ↗
L3bCited in: History and Evolution of Treatment - [366]
McCallister BT, Harris DA, Hayes KN et al.. “Incidence of Herpes Zoster Infections in the Veterans Health Administration Long-Term Care Setting.” Journal of the American Medical Directors Association (2026). PMID: 42721594 ↗
L3bCited in: History and Evolution of Treatment - [367]
Huang R, Huang M, Zhang R. “Cumulative adverse social determinants of health, prolonged unsuccessful conception, and infertility-related healthcare contact among U.S. women: NHANES 2013-2016.” Journal of assisted reproduction and genetics (2026). PMID: 42736487 ↗
L3bCited in: History and Evolution of Treatment - [368]
McClelland TQ, Bolakale-Rufai IK, Zhiying M et al.. “Long-term outcomes of prophylactic cardioprotection in early-stage breast cancer patients on non-anthracycline anti-HER2 therapy.” Cardio-oncology (London, England) (2026). PMID: 42827257 ↗
L1bCited in: Complications - [369]
Brouer IC, Zani A, Olbrich H et al.. “Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study.” Frontiers in medicine (2026). PMID: 42741157 ↗
L3bCited in: Complications - [370]
Hayat SC, Yilmaz YC, Afsin BA. “Major Adverse Cardiovascular and Cerebrovascular Events After Retinal Artery Occlusion: Clinical Predictors and Long-Term Outcomes.” Retina (Philadelphia, Pa.) (2026). PMID: 42627251 ↗
L3bCited in: Complications - [371]
Ghani L, Faulkner CS, Aboona MB et al.. “Neighbourhood Deprivation Is Associated With Greater Mortality in Patients With Alcohol-Associated Liver Disease.” Alimentary pharmacology & therapeutics (2026). PMID: 42608666 ↗
L3bCited in: Complications - [372]
Nguyen DT, Nguyen NTB, Wu LC et al.. “Dyslipidemia and risk of osteonecrosis of the femoral head: A large-scale propensity score-matched cohort study.” Bone (2026). PMID: 42805283 ↗
L4Cited in: Prognosis and Natural History - [373]
Kong G, Intaran MAU, Soh ESW et al.. “Body composition phenotypes are key predictors of cardiovascular-kidney-metabolic multimorbidity and long-term mortality: insights from a population-based cohort study.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 42684498 ↗
L3bCited in: Prognosis and Natural History - [374]
Qiu S, Chen Y, Sheng A et al.. “Optimizing COVID-19 vaccination for older adults: superior efficacy of heterologous regimens in reducing infection and mortality rates among patients aged 80 years and older during the Omicron BA.5/BF.7 outbreak.” BMC infectious diseases (2026). PMID: 42393578 ↗
L3bCited in: Special Populations and Prevention